Methods and compositions for modulating sebaceous glands

ABSTRACT

Methods and compositions for modulating sebaceous gland activity in a host are provided. In the subject methods, DGAT1 activity is modified, e.g., reduced or enhanced, to achieve the desired sebaceous gland activity modulation, e.g., reduction in sebum production and/or sebaceous gland size. Also provided are pharmaceutical preparations for use in practicing the subject methods. The subject methods and compositions find use in a variety of applications, including the treatment of hosts suffering from sebaceous gland related conditions, e.g., acne and related conditions.

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application is a continuation-in-part of application Ser. No. 10/040,315 filed Oct. 29, 2001; which application is: (a) a continuation-in-part of application Ser. No. 09/339,472 filed on Jun. 23, 1999, which application claims priority to the filing date of U.S. Provisional Patent Application Serial No. 60/107,771 filed Nov. 9, 1998; and (b) a continuation-in-part of PCT application Ser. No. PCT/US98/17883, filed Aug. 28, 1998, which application is a continuation in part of application Ser. No. 09/103,754, now U.S. Pat. No. 6,344,548, filed Jun. 24, 1998; the disclosures of which applications are herein incorporated by reference.

ACKNOWLEDGMENT OF GOVERNMENT SUPPORT

[0002] This invention was made with Government support under Grant Nos. R01 52069; R01 57170 and R01 DK56084 awarded by the National Institutes of Health. The Government has certain rights in this invention.

INTRODUCTION

[0003] 1. Field of the Invention

[0004] The invention relates generally to methods of treating a mammalian skin disorder associated with sebaceous glands.

[0005] 2. Background of the Invention

[0006] Sebaceous glands are associated with hair follicles and produce an oil called sebum, which is secreted into the hair follicle to keep the skin hair supple and waterproof. There are a variety of disorders associated with altered activity of sebaceous glands. Such disorders include acne, rosacea, perioral dermatitis, sebaceous cysts and seborrhea (greasy complexion or hair) and alopecia (baldness). In humans, sebaceous glands, although present over most of the body surface, usually are largest and most dense on the face, chest and upper back. Accordingly, sebaceous gland disorders predominantly affect these areas of the human body.

[0007] The most pervasive sebaceous follicle disorder in the United States is acne. Acne is characterized by inflammatory, follicular, papular and/or pustular eruptions involving sebaceous glands (Stedman's Medical Dictionary, 26th edition, (1995) Williams & Wilkins) and affects between 40 to 50 million individuals (White G M, (1998) J. Am. Acad. Dermatol. 39(2 Pt 3): S34-7). Although there are a variety of disorders that fall within the acne family, for example, acne conglobata, acne rosacea, and acne vulgaris, acne vulgaris is the most notable and commonly known form of acne. Acne vulgaris occurs with greatest frequency in individuals between the ages of 15 and 18 years, but may begin at virtually any age and can persist into adulthood. Because acne vulgaris can lead to permanent scarring, for example, facial scarring, this form of acne can have profound and long-lasting psychological effects on an afflicted individual. Furthermore, pustule formation and scarring can occur at an age when the potential impact on an individual is greatest, e.g., during adolescence.

[0008] Acne vulgaris typically results from a blockage of the opening of the sebaceous follicle. It is believed that both (i) the amount of sebum, (a lipid, keratin and cellular debris-containing fluid), produced and secreted by the sebaceous glands and (ii) bacteria, namely, Propionibacterium acnes (P. acnes) which metabolize lipids in the sebum, play a role in formation and development of acne vulgaris. The basic lesion of acne vulgaris is referred to as a comedo, a distension of the sebaceous follicle caused by sebum and keratinous debris. Formation of a comedo usually begins with defective keratinization of the follicular duct, resulting in abnormally adherent epithelial cells and plugging of the duct. When sebum production continues unabated, the plugged follicular duct distends. A blackhead (or open comedo) occurs when a plug comprising a melanin containing blackened mass of epithelial debris pushes up to opening of the follicular duct at the skin surface. A whitehead (or closed comedo) occurs when the follicle opening becomes very tightly closed and the material behind the closure ruptures the follicle causing a low-grade dermal inflammatory reaction. Accordingly, some comedos, for example, in acne vulgaris, evolve into inflammatory papules, pustules, nodules, or chronic granulomatous lesions. Proliferation of P. acnes can result in the production of inflammatory compounds, eventually resulting in neutrophil chemotaxis (Skyes and Webster (1994) Drugs 48: 59-70).

[0009] Typical short term treatments for sebaceous gland disorders include numerous cleansing methods that attempt to relieve the symptoms of the disorder. These treatments include special soaps, skin-peeling compositions, shampoos and the like, that may be used to, for example, remove comedos, prevent comedo formation and reduce the greasiness of hair. Many of the preparations attempt to reduce the tendency for acne by using drying, keratolytic, and antibacterial active ingredients. Skin cleansing degreases and extracts moisture from the skin and has the disadvantage that the water-insoluble calcium and magnesium salts of higher fatty acids, which form when the soaps are used in hard water, form slimy precipitates on the skin. Because they are difficult to rinse off, these precipitates remain for a relatively long period on the skin, block the follicle openings and can lead to the formation of more sebaceous gland problems. Syndets, i.e. surfactants without soap character, have been used to attempt to solve this problem, however, the use of most cleansing agents containing syndets often leads to a reduction in the water content in the upper layers of the skin, which in turn can induce inflammation.

[0010] For long-term treatment of sebaceous gland disorders, many acne patients may receive years of chronic topical or systemic treatments. Current treatment options include, for example, the use of topical anti-inflammatory agents, antibiotics and peeling agents, oral antibiotics, topical and oral retinoids, and hormonal agonists and antagonists. Topical agents include, for example, retinoic acid, benzoyl peroxide, and salicylic acid (Harrison's Principles of Internal Medicine, 14.sup.th edition, (1998) Fauci et al., eds. McGraw-Hill). Useful topical antibiotics include, for example, clindamycin, erythromycin, and tetracycline and useful systemic antibiotics include, for example, erythromycin, tetracycline, and sulphanilamides (see, for example, U.S. Pat. Nos. 5,910,493 and 5,674,539). Administration of the systemic retinoid, isotretinion, has demonstrated some success in the treatment of acne (Harrison's Principles of Internal Medicine, 14.sup.th edition, (1998) Fauci et al., eds. McGraw-Hill). Studies indicate that this drug decreases sebaceous gland size, decreases the rate of sebum production and/or secretion, and causes ductal epithelial cells to be less adherent, thereby preventing precursor lesions of acne vulgaris (Skyes and Webster (1994) supra). Side-effects, however, include dry mouth and skin, itching, small red spots in the skin, and eye irritation. A significant concern about oral retinoids is their possible teratogenicity (Turkington and Dover (1996) Skin Deep: An A-Z Of Skin Disorders, Treatment And Health Facts On File, Inc., New York, page 9). In addition, a variety of hormone-related therapies have been developed for the treatment of acne. These therapies can be expensive and most are associated with deleterious systemic or localized side-effects (Strauss (1982) Curr. Med. Res. Opin. 7(Suppl 2): 33-45).

[0011] As such, there is still not an optimal method for treating acne or other sebaceous gland disorders. Accordingly, there is an ongoing need for methods of effectively treating sebaceous gland disorders, particularly acne and seborrhea. This invention meets this, and other needs.

[0012] Relevant Literature

[0013] U.S. Patents and published patent applications of interest include: U.S. Pat. Nos. 6,100,077 and 6,344,548. Also of interest are Chen et al., J. Clin. Invest. (January, 2002) 109:175-181; Cases et al., Proc. Nat'l Acad. Sci. USA (1998) 95:13018-13023 and Cases et al., J. Biol. Chem. (2001) 276:38870-38876.

SUMMARY OF THE INVENTION

[0014] Methods and compositions for modulating sebaceous gland activity in a host are provided. In the subject methods, DGAT1 activity is modulated, e.g., inhibited or enhanced, to achieve the desired sebaceous gland modulation, e.g., reduction in sebum production and/or sebaceous gland size. Also provided are pharmaceutical preparations for use in practicing the subject methods. The subject methods and compositions find use in a variety of applications, including the treatment of hosts suffering from such conditions.

BRIEF DESCRIPTION OF THE FIGURES

[0015]FIGS. 1a to 1 d show photographs (FIGS. 1a and b) and line graphs (FIGS. 1c and d) showing the effects of DGAT1 deficiency on fur appearance, water repulsion, and thermoregulation in mice. FIG. 1a: Dry fur and hair loss in a 16-week-old male Dgat^(−/−) mouse. FIG. 1b: Male Dgat^(+/+) and Dgat^(−/−) mice 5 minutes after water immersion. FIGS. 1c and d: Impaired water repulsion and thermoregulation in Dgat^(−/−) mice after water immersion. Dgat^(−/−) mice retained more water in their fur than did Dgat^(+/+) mice, as reflected by a greater increase in mean relative body weight (FIG. 1 panel c). Dgat^(−/−) mice also developed hypothermia (FIG. 1d). n=4 per genotype. *P<0.05.

[0016]FIGS. 2a to 2 h provide a series of line graphs showing abnormalities of water repulsion and thermoregulation in DGAT1-deficient AY/a but not ob/ob mice. FIGS. 2a and b: Effect of DGAT1 deficiency on water repulsion (FIG. 2a) and thermoregulation (FIG. 2b) of AY/a mice after water immersion. FIGS. 2c-h: Effect of DGAT1 deficiency on water repulsion and thermoregulation of ob/ob mice after water immersion. FIGS. 2c and d: No leptin infusion. FIGS. 2e and f: After 2 weeks of subcutaneous leptin infusion (+Peripheral leptin). FIGS. 2g and h: Two weeks after the leptin infusion was stopped (After leptin). For each experiment, n=4 per genotype. *P<0.05.

[0017]FIGS. 3a and 3 b are two photographs showing DGAT mRNA expression in skin. An antisense probe detected DGAT1 mRNA expression in sebaceous glands (arrows, FIG. 3A) of skin from wild-type mice. Specific hybridization was not detected by the control sense probe (FIG. 3B).

[0018]FIGS. 4a-4 d are a series of photographs showing that age modulates the effect of DGAT1 deficiency on sebaceous gland morphology. (FIGS. 4a and b) In 6-week-old male mice, the sebaceous glands (SG) and hair follicles (HF) appeared to be normal, regardless of Dgat genotype. (FIGS. 4c and d) In 3-month-old male mice, DGAT1 deficiency was associated with atrophic sebaceous glands; for most hair follicles, sebaceous glands were not identifiable. Bar is 30 μm.

[0019]FIGS. 5a-5 j are a series of photographs showing sebaceous gland abnormalities in DGAT1-deficient AY/a but not ob/ob mice. FIGS. 5a and b: Skin section from Dgat^(+/+) AY/a mice (FIG. 5a) and Dgat^(−/−) AY/a mice (FIG. 5b). FIGS. 5c-j: skin sections from Dgat^(+/+) ob/ob and Dgat^(−/−) ob/ob mice. FIGS. 5c and d: No leptin infusion. FIGS. 5e and f: After 2 weeks of subcutaneous leptin infusion (+Peripheral leptin). FIGS. 5g and h: After 2 weeks of intracerebroventricular leptin infusion (+Central leptin). FIGS. 5i and j: Two weeks after the leptin infusion was stopped (After leptin). Representative samples from male mice are shown. SG, sebaceous gland. Bar, 30 μm.

[0020]FIGS. 6a and 6 b are two photographs showing abnormal fur lipid content in Dgat^(−/−) mice. FIG. 6a: Absence of specific lipids in the fur of Dgat^(−/−) mice (white and gray arrows). FIG. 6b: Effects of leptin on fur lipid content. The putative type II wax diester is indicated with a white arrow. Lipids were analyzed by TLC with hexane/ethyl ether/acetic acid (FIG. 6a) and hexane/benzene (FIG. 6b). Experiments were performed 3-4 times. Representative results are shown.

[0021]FIG. 7 is a photograph showing affects of androgens on fur lipids in Dgat^(−/−) mice. The putative type II wax diester is indicated with an open arrow. Lipids were analyzed by TLC with hexane/benzene. For lanes 3 and 4, testosterone propionate was injected subcutaneously for 2 weeks. For lanes 5 and 6, fur lipids were extracted 2 weeks after castration. Experiments were performed twice. Representative results are shown.

[0022]FIGS. 8a and 8 b are two bar graphs showing upregulation of DGAT2 in the skin of ob/ob mice. FIG. 8a: mRNA expression of DGAT2. n=3 per genotype. *P<0.05 vs. Dgat^(+/+). FIG. 8b: Increased upregulation of DGAT2 mRNA expression in ob/ob mice with DGAT1 deficiency. n=3 per genotype. *P<0.05.

DEFINITIONS

[0023] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Still, certain elements are defined below for the sake of clarity and ease of reference.

[0024] As used herein, the terms “sebaceous gland disorder” or “sebaceous gland condition” are used interchangeably to refer to any disorder that is caused by an alteration in the function of a sebaceous gland. Sebaceous gland disorders may be caused by overactive sebaceous glands, underactive sebaceous glands, mal-developed sebaceous glands, blocked sebaceous glands, infected sebaceous glands, inflamed sebaceous glands and the like. Examples of sebaceous gland disorders include, but are not limited to: acne, including open comedos (blackheads) and whiteheads, pimples, deep acne, acne conglobata, acne rosacea, comedos, cysts, microcomedos, papules, Propionibacterium acnes (P. acnes) infections, pustules, acne vulgaris, rosacea, perioral dermatitis, sebaceous cysts, primary seborrhea (seborrhea oleosa), secondary seborrhea (seborrhea sicca) and alopecia. Also within this definition are disorders treatable by altering the function of a sebaceous gland, such as dandruff and dry skin, and “cosmetic” sebaceous gland disorders, including dry hair, greasy hair, hair and skin sheen and other minor cosmetic disorders of the skin and/or complexion.

[0025] The term “phenomenon associated with sebaceous glands” as used herein refers to a structural, molecular, or functional characteristic associated with sebaceous gland function, particularly such a characteristic that is readily assessable in an animal model. Such characteristics include, but are not limited to, DGAT expression and/or activity, lipid production and/or secretion, water repulsion, hair sheen, thermoregulation, hair drying and the like.

[0026] As used herein, the terms “determining,” “measuring,” and “assessing,” and “assaying” are used interchangeably and include both quantitative and qualitative determinations.

[0027] The terms “polypeptide” and “protein”, used interchangeably herein, refer to a polymeric form of amino acids of any length, which can include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified peptide backbones. The term includes fusion proteins, including, but not limited to, fusion proteins with a heterologous amino acid sequence, fusions with heterologous and homologous leader sequences, with or without N-terminal methionine residues; immunologically tagged proteins; fusion proteins with detectable fusion partners, e.g., fusion proteins including as a fusion partner a fluorescent protein, β-galactosidase, luciferase, etc.; and the like.

[0028] The terms “polynucleotide” and “nucleic acid molecule” are used interchangeably herein to refer to polymeric forms of nucleotides of any length. The polynucleotides may contain deoxyribonucleotides, ribonucleotides, and/or their analogs. Nucleotides may have any three-dimensional structure, and may perform any function, known or unknown. The term “polynucleotide” includes single-, double-stranded and triple helical molecules. “Oligonucleotide” generally refers to polynucleotides of between about 5 and about 100 nucleotides of single- or double-stranded DNA. However, for the purposes of this disclosure, there is no upper limit to the length of an oligonucleotide. Oligonucleotides are also known as oligomers or oligos and may be isolated from genes, or chemically synthesized by methods known in the art.

[0029] As used herein the term “isolated,” when used in the context of an isolated compound, refers to a compound of interest that is in an environment different from that in which the compound naturally occurs. “Isolated” is meant to include compounds that are within samples that are substantially enriched for the compound of interest and/or in which the compound of interest is partially or substantially purified.

[0030] As used herein, the term “substantially pure” refers to a compound that is removed from its natural environment and is at least 60% free, preferably 75% free, and most preferably 90% free from other components with which it is naturally associated.

[0031] By “transgenic animal” is meant a non-human animal, usually a mammal, having a non-endogenous (i.e., heterologous) nucleic acid sequence present as an extrachromosomal element in a portion of its cells or stably integrated into its germ line DNA (i.e., in the genomic sequence of most or all of its cells). Heterologous nucleic acid is introduced into the germ line of such transgenic animals by genetic manipulation of, for example, embryos or embryonic stem cells of the host animal according to methods well known in the art. A “transgene” is meant to refer to such heterologous nucleic acid, e.g., heterologous nucleic acid in the form of an expression construct (e.g., for the production of a “knock-in” transgenic animal) or a heterologous nucleic acid that upon insertion within or adjacent a target gene results in a decrease in target gene expression (e.g., for production of a “knock-out” transgenic animal).

[0032] A “knock-out” of a gene means an alteration in the sequence of the gene that results in a decrease of function of the target gene, preferably such that target gene expression is undetectable or insignificant. Transgenic knock-out animals can be comprise a heterozygous knock-out of a target gene, or a homozygous knock-out of a target gene. “Knock-outs” as used herein also include conditional knock-outs, where alteration of the target gene can occur upon, for example, exposure of the animal to a substance that promotes target gene alteration, introduction of an enzyme that promotes recombination at the target gene site (e.g., Cre in the Cre-lox system), or other method for directing the target gene alteration postnatally.

[0033] A “knock-in” of a target gene means an alteration in a host cell genome that results in altered expression (e.g., increased (including ectopic) or decreased expression) of a target gene, e.g., by introduction of an additional copy of the target gene, or by operatively inserting a regulatory sequence that provides for enhanced expression of an endogenous copy of the target gene. “Knock-in” transgenics can comprise a heterozygous knock-in of the target gene or a homozygous knock-in of a target gene. “Knock-ins” also encompass conditional knock-ins.

[0034] By “operably linked” is meant that a DNA sequence and a regulatory sequence(s) are connected in such a way as to permit gene expression when the appropriate molecules (e.g., transcriptional activator proteins) are bound to the regulatory sequence(s).

[0035] By “operatively inserted” is meant that a nucleotide sequence of interest is positioned adjacent a nucleotide sequence that directs transcription and translation of the introduced nucleotide sequence of interest.

[0036] The term “therapeutic agent” as used herein refers to any molecule, e.g., protein or small molecule, pharmaceutical compound, antibody, antisense molecule, ribozyme, and the like, useful in the treatment of a disease or condition, e.g., a sebaceous gland condition. For example, therapeutic agents of the invention include molecules that inhibit, ameliorate, or relieve symptoms associated with a sebaceous gland condition.

[0037] The term “unit dosage form” as used herein refers to physically discrete units suitable as unitary dosages for subjects (e.g., animals, usually humans), each unit containing a predetermined quantity of agent(s) in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable diluent, carrier or vehicle. The specifications for the novel unit dosage forms of the present invention will depend on a variety of factors including, but not necessarily limited to, the particular agent employed and the effect to be achieved, and the pharmacodynamics associated with each compound in the host.

[0038] The terms “treatment”, “treating” and the like are used herein to generally mean obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease. “Treatment” as used herein covers any treatment of a disease in a mammal, particularly a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease; i.e., arresting its development; or (c) relieving the disease, i.e., causing regression of the disease.

[0039] The terms “subject,” “host,” “patient,” and “individual” are used interchangeably herein to refer to any mammalian subject for whom diagnosis or therapy is desired, particularly humans. Other subjects may include cattle, dogs, cats, guinea pigs, rabbits, rats, mice, horses, and so on.

DETAILED DESCRIPTION OF THE INVENTION

[0040] Methods and compositions for modulating sebaceous gland activity in a host are provided. In the subject methods, DGAT1 activity is modulated, e.g., inhibited or enhanced, to achieve the desired sebaceous gland modulation, e.g., reduction in sebum production and/or sebaceous gland size. Also provided are compositions for use in practicing the subject methods. The subject methods and compositions find use in a variety of applications, including the treatment of hosts suffering from conditions.

[0041] Before the subject invention is described further, it is to be understood that the invention is not limited to the particular embodiments of the invention described below, as variations of the particular embodiments may be made and still fall within the scope of the appended claims. It is also to be understood that the terminology employed is for the purpose of describing particular embodiments, and is not intended to be limiting. Instead, the scope of the present invention will be established by the appended claims.

[0042] In this specification and the appended claims, the singular forms “a,” “an” and “the” include plural reference unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs.

[0043] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range, and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

[0044] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this invention belongs. Although any methods, devices and materials similar or equivalent to those described herein can be used in the practice or testing of the invention, the preferred methods, devices and materials are now described.

[0045] All publications mentioned herein are incorporated herein by reference for the purpose of describing and disclosing the subject components of the invention that are described in the publications, which components might be used in connection with the presently described invention.

[0046] In further describing the invention, representative methods of modulating sebaceous glands in a host (as well as compositions for use in such methods) are reviewed first followed by a more detailed description of representative applications in which the subject methods find use. Next, representative kits that find use in practicing the subject methods are further described.

[0047] Methods of Modulating Sebaceous Glands

[0048] As summarized above, the subject invention provides methods of modulating sebaceous glands in a host. In many embodiments, the methods include administering to a host an effective, amount of one or more active agents that modulate DGAT1 activity in the host to modulate, sebaceous gland activity in the host.

[0049] By DGAT1 activity is meant the activity of a DGAT1 protein, where representative DGAT1 proteins are disclosed in Cases et al., Proc. Nat'l Acad. Sci. USA (1998) 95:13018-13023 and Genbank Accession Nos.: AAC63997, AF059202; as well as U.S. Pat. Nos. 6,100,077 and 6,344,548 and the priority applications to the present application (listed above); the disclosures of which are herein incorporated by reference.

[0050] As DGAT1 activity is modulated in certain embodiments of the invention, DGAT1 activity is increased or decreased in these embodiments. In many embodiments, DGAT1 activity is increased or decreased by at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 80%, at least about 90%, or more, as compared to a baseline DGAT1 activity level, e.g., that observed in the host prior to administration of the active agent.

[0051] In some embodiments where the desired sebaceous gland modulation is a reduction in a sebaceous gland parameter, e.g., a reduction in sebum production, a reduction in sebaceous gland size, etc., one or more agents that decreases DGAT1 activity is administered to the host. For example, in certain embodiments, one or more agents that decreases DGAT1 activity is administered to the host. In these embodiments, the agent is typically a DGAT1 inhibitor.

[0052] In some embodiments where an increase in sebaceous gland activity is desired, one or more agents that increase DGAT1 activity is administered. For example, in certain embodiments, one or more agents that increases DGAT1 activity is administered to the host.

[0053] For the modulation of DGAT1 activity in a host, an effective amount of active agent(s) that modulates the activity, e.g. reduces the activity of DGAT1 in vivo, is administered to the host. The active agent may be a variety of different compounds, including: polynucleotide compositions (e.g., coding sequences, antisense compositions, siRNA compositions, etc.), polypeptide, including antibody, compositions, naturally occurring or synthetic small molecule compounds, etc.

[0054] In certain embodiments, the active agents administered to the host are polynucleotide to nucleic acid compositions. The nucleic acids may be coding sequences, e.g., genes, gene fragments etc., which may be present in expression vectors, where such vectors generally have convenient restriction sites located near the promoter sequence to provide for the insertion of nucleic acid sequences. Transcription cassettes may be prepared that include a transcription initiation region, the target gene or fragment thereof, and a transcriptional termination region. The transcription cassettes may be introduced into a variety of vectors, e.g. plasmid; retrovirus, e.g. lentivirus; adenovirus; and the like, where the vectors are able to transiently or stably be maintained in the cells, usually for a period of at least about one day, more usually for a period of at least about several days to several weeks.

[0055] In yet other embodiments of the invention, the active agent is an agent that modulates, and generally decreases or down regulates, the expression of DGAT1 in the host. Antisense molecules can be used to down-regulate expression of a gene in cells. The anti-sense reagent may be antisense oligonucleotides (ODN), particularly synthetic ODN having chemical modifications from native nucleic acids, or nucleic acid constructs that express such anti-sense molecules as RNA. The antisense sequence is complementary to the mRNA of the targeted gene, and inhibits expression of the targeted gene products. Antisense molecules inhibit gene expression through various mechanisms, e.g. by reducing the amount of mRNA available for translation, through activation of RNAse H, or steric hindrance. One or a combination of antisense molecules may be administered, where a combination may comprise multiple different sequences.

[0056] Antisense molecules may be produced by expression of all or a part of the target gene sequence in an appropriate vector, where the transcriptional initiation is oriented such that an antisense strand is produced as an RNA molecule. Alternatively, the antisense molecule is a synthetic oligonucleotide. Antisense oligonucleotides will generally be at least about 7, usually at least about 12, more usually at least about 20 nucleotides in length, and not more than about 500, usually not more than about 50, more usually not more than about 35 nucleotides in length, where the length is governed by efficiency of inhibition, specificity, including absence of cross-reactivity, and the like. It has been found that short oligonucleotides, of from 7 to 8 bases in length, can be strong and selective inhibitors of gene expression (see Wagner et al. (1996), Nature Biotechnol. 14:840-844).

[0057] A specific region or regions of the endogenous sense strand mRNA sequence is chosen to be complemented by the antisense sequence. Selection of a specific sequence for the oligonucleotide may use an empirical method, where several candidate sequences are assayed for inhibition of expression of the target gene in an in vitro or animal model. A combination of sequences may also be used, where several regions of the mRNA sequence are selected for antisense complementation.

[0058] Antisense oligonucleotides may be chemically synthesized by methods known in the art (see Wagner et al. (1993), supra, and Milligan et al., supra.) Preferred oligonucleotides are chemically modified from the native phosphodiester structure, in order to increase their intracellular stability and binding affinity. A number of such modifications have been described in the literature, which alter the chemistry of the backbone, sugars or heterocyclic bases.

[0059] Among useful changes in the backbone chemistry are phosphorothioates; phosphorodithioates, where both of the non-bridging oxygens are substituted with sulfur; phosphoroamidites; alkyl phosphotriesters and boranophosphates. Achiral phosphate derivatives include 3′-O′-5′-S-phosphorothioate, 3′-S-5′-O-phosphorothioate, 3′-CH₂-5′-O-phosphonate and 3′-NH-5′-O-phosphoroamidate. Peptide nucleic acids replace the entire ribose phosphodiester backbone with a peptide linkage. Sugar modifications are also used to enhance stability and affinity. The α-anomer of deoxyribose may be used, where the base is inverted with respect to the natural β-anomer. The 2′-OH of the ribose sugar may be altered to form 2′-Q-methyl or 2′-O-allyl sugars, which provides resistance to degradation without comprising affinity. Modification of the heterocyclic bases must maintain proper base pairing. Some useful substitutions include deoxyuridine for deoxythymidine; 5-methyl-2′-deoxycytidine and 5-bromo-2′-deoxycytidine for deoxycytidine. 5-propynyl-2′-deoxyuridine and 5-propynyl-2′-deoxycytidine have been shown to increase affinity and biological activity when substituted for deoxythymidine and deoxycytidine, respectively.

[0060] As an alternative to anti-sense inhibitors, catalytic nucleic acid compounds, e.g. ribozymes, anti-sense conjugates, etc. may be used to inhibit gene,-expression. Ribozymes may be synthesized in vitro and administered to the patient or may be encoded on an expression vector, from which the ribozyme is synthesized in the targeted cell (for example, see International patent application WO 9523225, and Beigelman et al. (1995), Nucl. Acids Res. 23:4434-42). Examples of oligonucleotides with catalytic activity are described in WO 9506764. Conjugates of anti-sense ODN with a metal complex, e.g. terpyridylCu(II), capable of mediating mRNA hydrolysis are described in Bashkin et al. (1995), Appl. Biochem. Biotechnol. 54:43-56.

[0061] Alternatively, gene expression can be modified by gene silencing using double-strand RNA (Sharp (1999) Genes and Development 13: 139-141). RNAi, otherwise known as double-stranded RNA interference (dsRNAi) or small interfering RNA (siRNA), has been extensively documented in the nematode C. elegans (Fire, A., et al, Nature, 391, 806-811, 1998) and an identical phenomenon occurs in plants, in which it is usually referred to as post-transcriptional gene silencing (PTGS) (Van Blokland, R., et al., Plant J., 6: 861-877, 1994; deCarvalho-Niebel, F., et al., Plant Cell, 7: 347-358, 1995; Jacobs, J. J. M. R. et al., Plant J., 12: 885-893, 1997; reviewed in Vaucheret, H., et al., Plant J., 16: 651-659, 1998). The phenomenon also occurs in fungi (Romano, N. and Masino, G., Mol. Microbiol., 6: 3343-3353, 1992, Cogoni, C., et al., EMBO J., 15: 3153-3163; Cogoni, C. and Masino, G., Nature, 399: 166-169, 1999), in which it is often referred to as “quelling”. RNAi silencing can be induced many ways in plants, where a nucleic acid encoding an RNA that forms a “hairpin” structure is employed in most embodiments. Alternative strategies include expressing RNA from each end of the encoding nucleic acid, making two RNA molecules that will hybridize. Current strategies for RNAi induced silencing in plants are reviewed by Carthew et al (Curr Opin Cell Biol. 2001 13:244-8). RNAi is also described in WO 02/44321 and WO 01/68836; the priority documents of which are herein incorporated by reference.

[0062] Also of interest are polypeptide, e.g., proteinaceous, active agents. Specific polypeptide agents include proteins or active fragments thereof e.g., DGAT1 proteins, etc. A specific type of polypeptide active agent of interest is an antibody agent that modulates DGAT1 activity in the host. The antibodies may be monoclonal or polyclonal, and produced according to methods known in the art. Antibody fragments, such as Fv, F(ab′)₂ and Fab may be prepared by cleavage of the intact protein, e.g. by protease or chemical cleavage. Alternatively, a truncated gene is designed. For example, a chimeric gene encoding a portion of the F(ab′)₂ fragment would include DNA sequences encoding the CH1 domain and hinge region of the H chain, followed by a translational stop codon to yield the truncated molecule.Consensus sequences of H and L J regions may be used to design oligonucleotides for use as primers to introduce useful restriction sites into the J region for subsequent linkage of V region segments to human C region segments. C region cDNA can be modified by site directed mutagenesis to place a restriction site at the analogous position in the human sequence.

[0063] Expression vectors include plasmids, retroviruses, YACs, EBV derived episomes, and the like. A convenient vector is one that encodes a functionally complete human CH or CL immunoglobulin sequence, with appropriate restriction sites engineered so that any VH or VL sequence can be easily inserted and expressed. In such vectors, splicing usually occurs between the splice donor site in the inserted J region and the splice acceptor site preceding the human C region, and also at the splice regions that occur within the human CH exons. Polyadenylation and transcription termination occur at native chromosomal sites downstream of the coding regions. The resulting chimeric antibody may be joined to any strong promoter, including retroviral LTRs, e.g. SV-40 early promoter, (Okayama et al. (1983) Mol. Cell. Bio. 3:280), Rous sarcoma virus LTR (Gorman et al. (1982) P.N.A.S. 79:6777), and moloney murine leukemia virus LTR (Grosschedl et aL. (1985) Cell 41:885); native Ig promoters, etc.

[0064] Naturally occurring or synthetic small molecule compounds of interest as active agents include numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 50 and less than about 2,500 daltons. Candidate agents include functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Of particular interest are those agents identified by the screening assays of the subject invention, as described above.

[0065] In certain embodiments, in addition to (or in some embodiments instead of) the DGAT1 modulatory active agent, a leptin modulatory active agent, e.g., an agent that enhances or inhibits leptin activity, is administered. For example, in certain embodiments where a DGAT1 inhibitory agent is administered, a leptin activity enhancing agent may also be administered, such, that both a DGAT1 inhibitory agent and a leptin activity enhancing agent are administered to the host. Such embodiments include those embodiments where one wishes to modulate sebaceous glands in way that decreases a parameter thereof, e.g., reduces sebum production and/or reduces sebaceous gland size. In certain other embodiments, a leptin activity decreasing agent, e.g., a leptin activity inhibitor is administered to the host, either alone or in combination with a DGAT1 activity enhancing agent. Such embodiments include those embodiments where it is desired to increase a parameter of sebaceous glands, e.g., to increase sebum production and/or increase sebaceous gland size.

[0066] In practicing the subject methods, an effective amount of the active agent is administered to the host, where the term “effective amount” means a dosage sufficient to produce a desired result, where the desired result is the desired modulation, e.g., enhancement, reduction, of DGAT1 activity.

[0067] In practicing the subject methods, the active agent or agents are typically administered to the host in a physiologically acceptable delivery vehicle, e.g., as a pharmaceutical preparation. A variety of representative formulations, dosages, routes of administration for candidate agents, nucleic acid delivery vehicles and nucleic acid formulations for nucleic acid delivery are described below.

[0068] Formulations, Dosages, and Routes of Administration

[0069] The invention provides formulations, including pharmaceutical formulations, that include an agent which modulates sebaceous glands in a host. In general, a formulation comprises an effective amount of an agent that modulates DGAT1 (and/or leptin) activity in a host. An “effective amount” refers to an amount that is sufficient to produce a desired result, e.g., reduction or increase in a level of DGAT1 expression and/or activity, decrease in hair loss or hair sheen, an increase in thermotolerance, or skin drying etc. In many embodiments, the desired result is at least a reduction or increase in a phenotype as compared to a control such that the phenotype is more similar to normal.

[0070] Formulations

[0071] In the subject methods, the active agent(s) may be administered to the host using any convenient means capable of resulting in the desired reduction in of a sebaceous gland-related phenotype.

[0072] Thus, the agent can be incorporated into a variety of formulations for therapeutic administration. More particularly, the agents of the present invention can be formulated into pharmaceutical compositions by combination with appropriate, pharmaceutically acceptable carriers or diluents, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants and aerosols.

[0073] In pharmaceutical dosage forms, the agents may be administered in the form of their pharmaceutically acceptable salts, or they may also be used alone or in appropriate association, as well as in combination, with other pharmaceutically active compounds. The following methods and excipients are merely exemplary and are in no way limiting.

[0074] For oral preparations, the agents can be used alone or in combination with appropriate additives to make tablets, powders, granules or capsules, for example, with conventional additives, such as lactose, mannitol, corn starch or potato starch; with binders, such as crystalline cellulose, cellulose derivatives, acacia, corn starch or gelatins; with disintegrators, such as corn starch, potato starch or sodium carboxymethylcellulose; with lubricants, such as talc or magnesium stearate; and if desired, with diluents, buffering agents, moistening agents; preservatives and flavoring agents.

[0075] The agents can be formulated into preparations for injection by dissolving, suspending or emulsifying them in an aqueous or nonaqueous solvent, such as vegetable or other similar oils, synthetic aliphatic acid glycerides, esters of higher aliphatic acids or propylene glycol; and if desired, with conventional additives such as solubilizers, isotonic agents, suspending agents, emulsifying agents, stabilizers and preservatives.

[0076] The agents can be utilized in aerosol formulation to be administered via inhalation. The compounds of the present invention can be formulated into pressurized acceptable propellants such as dichlorodifluoromethane, propane, nitrogen and the like.

[0077] Furthermore, the agents can be made into suppositories by mixing with a variety of bases such as emulsifying bases or water-soluble bases. The compounds of the present invention can be administered rectally via a suppository. The suppository can include vehicles such as cocoa butter, carbowaxes and polyethylene glycols, which melt at body temperature, yet are solidified at room temperature.

[0078] Unit dosage forms for oral or rectal administration such as syrups, elixirs, and suspensions may be provided wherein each dosage unit, for example, teaspoonful, tablespoonful, tablet or suppository, contains a predetermined amount of the composition containing one or more inhibitors. Similarly, unit dosage forms for injection or intravenous administration may comprise the inhibitor(s) in a composition as a solution in sterile water, normal saline or another pharmaceutically acceptable carrier.

[0079] The term “unit dosage form,” as used herein, refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of compounds of the present invention calculated in an amount sufficient to produce the desired effect in association with a pharmaceutically acceptable diluent, carrier or vehicle. The specifications for the novel unit dosage forms of the present invention depend on the particular compound employed and the effect to be achieved, and the pharmacodynamics associated with each compound in the host.

[0080] Other modes of administration will also find use with the subject invention. For instance, an agent of the invention can be formulated in suppositories and, in some cases, aerosol and intranasal compositions. For suppositories, the vehicle composition will include traditional binders and carriers such as, polyalkylene glycols, or triglycerides. Such suppositories may be formed from mixtures containing the active ingredient in the range of about 0.5% to about 10% (w/w), preferably about 1% to about 2%.

[0081] Intranasal formulations will usually include vehicles that neither cause irritation to the nasal mucosa nor significantly disturb ciliary function. Diluents such as water, aqueous saline or other known substances can be employed with the subject invention. The nasal formulations may also contain preservatives such as, but not limited to, chlorobutanol and benzalkonium chloride. A surfactant may be present to enhance absorption of the subject proteins by the nasal mucosa.

[0082] An agent of the invention can be administered as injectables. Typically, injectable compositions are prepared as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid vehicles prior to injection may also be prepared. The preparation may also be emulsified or the active ingredient encapsulated in liposome vehicles.

[0083] Suitable excipient vehicles are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. In addition, if desired, the vehicle may contain minor amounts of auxiliary substances such as wetting or emulsifying agents or pH buffering agents. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in the art. See, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 17th edition, 1985; Remington: The Science and Practice of Pharmacy, A. R. Gennaro, (2000) Lippincott, Williams & Wilkins. The composition or formulation to be administered will, in any event, contain a quantity of the agent adequate to achieve the desired state in the subject being treated.

[0084] The pharmaceutically acceptable excipients, such as vehicles, adjuvants, carriers or diluents, are readily available to the public. Moreover, pharmaceutically acceptable auxiliary substances, such as pH adjusting and buffering agents, tonicity adjusting agents, stabilizers, wetting agents and the like, are readily available to the public.

[0085] Dosages

[0086] Although the dosage used will vary depending on the clinical goals to be achieved, a suitable dosage range is one which provides up to about 1 μg to about 1,000 μg or about 10,000 μg of an agent that reduces a symptom of a sebaceous gland disorder, or a sebaceous gland activity in a subject animal.

[0087] Those of skill will readily appreciate that dose levels can vary as a function of the specific compound, the severity of the symptoms and the susceptibility of the subject to side effects. Preferred dosages for a given compound are readily determinable by those of skill in the art by a variety of means.

[0088] Routes of Administration

[0089] Conventional and pharmaceutically acceptable routes of administration include intranasal, intramuscular, intratracheal, intratumoral, subcutaneous, intradermal, topical application, intravenous, rectal, nasal, oral and other parenteral routes of administration. Routes of administration may be combined, if desired, or adjusted depending upon the agent and/or the desired effect. The composition can be administered in a single dose or in multiple doses.

[0090] The agent can be administered to a host using any available conventional methods and routes suitable for delivery of conventional drugs, including systemic or localized routes. In general, routes of administration contemplated by the invention include, but are not necessarily limited to, enteral, parenteral, or inhalational routes.

[0091] Parenteral routes of administration other than inhalation administration include, but are not necessarily limited to, topical, transdermal, subcutaneous, intramuscular, intraorbital, intracapsular, intraspinal, intrasternal, and intravenous routes, i.e., any route of administration other than through the alimentary canal. Parenteral administration can be carried to effect systemic or local delivery of the agent. Where systemic delivery is desired, administration typically involves invasive or systemically absorbed topical or mucosal administration of pharmaceutical preparations.

[0092] The agent can also be delivered to the subject by enteral administration. Enteral routes of administration include, but are not necessarily limited to, oral and rectal (e.g., using a suppository) delivery.

[0093] Methods of administration of the agent through the skin or mucosa include, but are not necessarily limited to, topical application of a suitable pharmaceutical preparation, transdermal transmission, injection and epidermal administration. For transdermal transmission, absorption promoters or iontophoresis are suitable methods. Iontophoretic transmission may be accomplished using commercially available “patches” which deliver their product continuously via electric pulses through unbroken skin for periods of several days or more.

[0094] By treatment is meant at least an amelioration of the symptoms associated with the pathological condition afflicting the host, where amelioration is used in a broad sense to refer to at least a reduction in the magnitude of a parameter, e.g. symptom, associated with the pathological condition being treated, such as an sebaceous gland disorder and psychological trauma associated therewith. As such, treatment also includes situations where the pathological condition, or at least symptoms associated therewith, are completely inhibited, e.g. prevented from happening, or stopped, e.g. terminated, such that the host no longer suffers from the pathological condition, or at least the symptoms that characterize the pathological condition.

[0095] A subject polynucleotide can be delivered as a naked polynucleotide, or associated with (complexed with) a delivery vehicle. “Associated with”, or “complexed with”, encompasses both covalent and non-covalent interaction of a polynucleotide with a given delivery vehicle.

[0096] Nucleic Acid Delivery Vehicles

[0097] In certain embodiment, an agent is a nucleic acid. Nucleic acids may be delivered using several different vehicles, including viral and non-viral delivery vehicles.

[0098] Viral Delivery Vehicles

[0099] A subject polynucleotide can be associated with viral delivery vehicles. As used herein, a “viral delivery vehicle” intends that the polynucleotide to be delivered is encapsidated in a viral particle.

[0100] Numerous viral genomes useful in in vivo transformation and gene therapy are known in the art, or can be readily constructed given the skill and knowledge in the art. Included are replication competent, replication deficient, and replication conditional viruses. Viral vectors include adenovirus, mumps virus, a retrovirus, adeno-associated virus, herpes simplex virus (HSV), cytomegalovirus (CMV), vaccinia virus, and poliovirus, and non-replicative mutants/variants of the foregoing. In some embodiments, a replication-deficient virus is capable of infecting slowly replicating and/or terminally differentiated cells, since the respiratory tract is primarily composed of these cell types. For example, adenovirus efficiently infects slowly replicating and/or terminally differentiated cells. In some embodiments, the viral genome itself, or a protein on the viral surface, is specific or substantially specific for cells of the targeted cell. A viral genome can be designed to be target cell-specific by inclusion of cell type-specific promoters and/or enhancers operably linked to a gene(s) essential for viral replication.

[0101] Where a replication-deficient virus is used as the viral genome, the production of virus particles containing either DNA or RNA corresponding to the polynucleotide of interest can be produced by introducing the viral construct into a recombinant cell line which provides the missing components essential for viral replication and/or production. Preferably, transformation of the recombinant cell line with the recombinant viral genome will not result in production of replication-competent viruses, e.g., by homologous recombination of the viral sequences of the recombinant cell line into the introduced viral genome. Methods for production of replication-deficient viral particles containing a nucleic acid of interest are well known in the art and are described in, for example, Rosenfeld et al., Science 252:431-434, 1991 and Rosenfeld et al., Cell 68:143-155, 1992 (adenovirus); U.S. Pat. No. 5,139,941 (adeno-associated virus); U.S. Pat. No. 4,861,719 (retrovirus); and U.S. Pat. No. 5,356,806 (vaccinia virus). Methods and materials for manipulation of the mumps virus genome, characterization of mumps virus genes responsible for viral fusion and viral replication, and the structure and sequence of the mumps viral genome are described in Tanabayashi et al., J. Virol. 67:2928-2931, 1993; Takeuchi et al., Archiv. Virol., 128:177-183, 1993; Tanabayashi et al., Virol. 187:801-804, 1992;,Kawano et al., Virol., 179:857-861, 1990; Elango et al., J. Gen. Virol. 69:2893-28900, 1988.

[0102] Non-Viral Delivery Vehicles

[0103] A subject polynucleotide can be administered using a non-viral delivery vehicle. “Non-viral delivery vehicle” (also referred to herein as “non-viral vector”) as used herein is meant to include chemical formulations containing naked or condensed polynucleotides (e.g, a formulation of polynucleotides and cationic compounds (e.g., dextran sulfate)), and naked or condensed polynucleotides mixed with an adjuvant such as a viral particle (i.e., the polynucleotide of interest is not contained within the viral particle, but the transforming formulation is composed of both naked polynucleotides and viral particles (e.g., adenovirus particles) (see, e.g., Curiel et al. 1992 Am. J. Respir. Cell Mol. Biol. 6:247-52)). Thus “non-viral delivery vehicle” can include vectors composed of polynucleotides plus viral particles where the viral particles do not contain the polynucleotide of interest. “Non-viral delivery vehicles” include bacterial plasmids, viral genomes or portions thereof, wherein the polynucleotide to be delivered is not encapsidated or contained within a viral particle, and constructs comprising portions of viral genomes and portions of bacterial plasmids and/or bacteriophages. The term also encompasses natural and synthetic polymers and co-polymers. The term further encompasses lipid-based vehicles. Lipid-based vehicles include cationic liposomes such as disclosed by Felgner et al (U.S. Pat. Nos. 5,264,618 and 5,459,127; PNAS 84:7413-7417, 1987; Annals N.Y. Acad. Sci. 772:126-139, 1995); they may also consist of neutral or negatively charged phospholipids or mixtures thereof including artificial viral envelopes as disclosed by Schreier et al. (U.S. Pat. Nos. 5,252,348 and 5,766,625).

[0104] Non-viral delivery vehicles include polymer-based carriers. Polymer-based carriers may include natural and synthetic polymers and co-polymers. Preferably, the polymers are biodegradable, or can be readily eliminated from the subject. Naturally occurring polymers include polypeptides and polysaccharides. Synthetic polymers include, but are not limited to, polylysines, and polyethyleneimines (PEI; Boussif et al., PNAS 92:7297-7301, 1995) which molecules can also serve as condensing agents. These carriers may be dissolved, dispersed or suspended in a dispersion liquid such as water, ethanol, saline solutions and mixtures thereof. A wide variety of synthetic polymers are known in the art and can be used. “Non-viral delivery vehicles” further include bacteria. The use of various bacteria as delivery vehicles for polynucleotides has been described. Any known bacterium can be used as a delivery vehicle, including, but not limited to non-pathogenic strains of Staphylococcus, Salmonella, and the like.

[0105] Formulations for Nucleic Acid Delivery

[0106] The polynucleotide to be delivered can be formulated as a DNA- or RNA-liposome complex formulation. Such complexes comprise a mixture of lipids which bind to genetic material (DNA or RNA) by means of cationic charge (electrostatic interaction). Cationic liposomes which may be used in the present invention include 3β-[N-(N′, N′-dimethyl-aminoethane)-carbamoyl]-cholesterol (DC-Chol), 1,2-bis(oleoyloxy-3 -trimethylammonio-propane (DOTAP) (see, for example, WO 98/07408), lysinylphosphatidylethanolamine (L-PE), lipopolyamines such as lipospermine, N-(2-hydroxyethyl)-N,N-dimethyl-2,3-bis(dodecyloxy)-1-propanaminium bromide, dimethyl dioctadecyl ammonium bromide (DDAB), dioleoylphosphatidyl ethanolamine (DOPE), dioleoylphosphatidyl choline (DOPC), N(1,2,3-dioleyloxy) propyl-N,N,N-triethylammonium (DOTMA), DOSPA, DMRIE, GL-67, GL-89, Lipofectin, and Lipofectamine (Thiery et al. (1997) Gene Ther. 4:226-237; Felgner et al., Annals N.Y. Acad. Sci. 772:126-139, 1995; Eastman et al., Hum. Gene Ther. 8:765-773, 1997). Polynucleotide/lipid formulations described in U.S. Pat. No. 5,858,784 can also be used in the methods described herein. Many of these lipids are commercially available from, for example, Boehringer-Mannheim, and Avanti Polar Lipids (Birmingham, Ala.). Also encompassed are the cationic phospholipids found in U.S. Pat. Nos. 5,264,618, 5,223,263 and 5,459,127. Other suitable phospholipids which may be used include phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingomyelin, phosphatidylinositol, and the like. Cholesterol may also be included.

[0107] Utility

[0108] The subject compositions and methods of modulating the activity of a sebaceous gland find use in a variety of therapeutic protocols. In general, these protocols involve administering to a host suffering from a sebaceous gland condition an effective amount of one or more active agents that modulate DGAT1 (and/or leptin) function in the host to modulate sebaceous gland parameters (e.g., sebum production, size, etc.) in the host and treat the host for the condition.

[0109] By treatment is meant at least an amelioration of a symptom associated with the pathological condition afflicting the host, where amelioration is used in a broad sense to refer to at least a reduction in the magnitude of a parameter, e.g. symptom, associated with the pathological condition being treated, such as hair greasiness, number and size of comidones, etc. As such, treatment also includes outcomes where the pathological condition, or at least symptoms associated therewith, are completely inhibited, e.g. prevented from happening, or stopped, e.g. terminated, such that the host no longer suffers from the pathological condition, or at least the symptoms that characterize the pathological condition. For example, where the disease condition is marked by the presence of elevated hair greasiness, treatment includes at least a reduction in the observed hair greasiness, including a restoration of normal hair greasiness.

[0110] A variety of hosts are treatable according to the subject methods. Generally such hosts are mammals or mammalian, where these terms are used broadly to describe organisms which are within the class mammalia, including the orders carnivore (e.g., dogs and cats), rodentia (e.g., mice, guinea pigs, and rats), and primates (e.g., humans, chimpanzees, and monkeys). In many embodiments, the hosts will be humans.

[0111] Of particular interest is treatment and prevention of sebaceous gland disorders associated with undesirable sebaceous gland activity, including overactive sebaceous glands, underactive sebaceous glands, mal-developed sebaceous glands, blocked sebaceous glands, infected sebaceous glands, inflamed sebaceous glands and the like. Examples of sebaceous gland disorders include, but are not limited to: acne, including open comedos (blackheads) and whiteheads, pimples, deep acne, acne conglobata, comedos, cysts, microcomedos, papules, Propionibacterium acnes (P. acnes) infections, pustules and acne vulgaris, acne rosacea, acne conglobata, perioral dermatitis, sebaceous cysts, primary seborrhea (seborrhea oleosa), secondary seborrhea (seborrhea sicca) and alopecia. Also of interest are disorders treatable by altering the function of a sebaceous gland, such as dandruff and dry skin, and “cosmetic” sebaceous gland disorders, including dry hair, greasy hair, hair and skin sheen and other minor cosmetic disorders of the skin and/or complexion. The subject methods also find use in the modulation of sebaceous gland activity in hosts not suffering from a particular sebaceous gland condition but in which the modulation of sebaceous gland activity is nonetheless desired.

[0112] In some embodiments, where a reduction of sebaceous gland activity is desired, one or more agents that decreases DGAT1 activity (and/or increases leptin activity) may be administered, whereas when an increase in sebaceous gland activity is desired, one or more agents that increases DGAT1 activity (and/or decreases leptin activity) may be administered.

[0113] Subject treatment methods are typically performed on hosts with such disorders or on hosts with a desire to avoid contracting such disorders. Subjects of particular interest include those that are prone to sebaceous gland disorders, such as human teenagers or adolescents, typically aged between 12 and 17 years.

[0114] The invention also includes preventing or reducing the risk of a sebaceous gland disorder in a host by administering a pharmaceutical composition.

[0115] Kits

[0116] Also provided by the subject invention are kits for practicing the subject methods, as described above. The subject kits at least include one or more of a pharmaceutical preparation comprising at least one active agent that modulates DGAT1 activity (and/or leptin activity), as described above. Other optional components of the kit include: a syringe or another administration device. The various components of the kit may be present in separate containers or certain compatible components may be precombined into a single container, as desired. In many embodiments, kits with unit doses of the active agent, e.g. in oral or injectable doses, are provided. In many embodiments the subject composition is contained within a media, such as a hair shampoo, a hair conditioner, a soap bar, a facial scrub, a facial cream for topical administration and the like.

[0117] In addition to above-mentioned components, the subject kits typically further. include instructions for using the components of the kit to practice the subject methods treating a host suffering from a sebaceous gland condition by administering to said host an effective amount of one or more active agents that modulate DGAT1 (and/or leptin) activity in the host to modulate sebaceous gland activity in the host and treat the host for the condition. The instructions for practicing the subject methods are generally recorded on a suitable recording medium. For example, the instructions may be printed on a substrate, such as paper or plastic, etc. As such, the instructions may be present in the kits as a package insert, in the labeling of the container of the kit or components thereof (i.e., associated with the packaging or subpackaging) etc. In other embodiments, the instructions are present as an electronic storage data file present on a suitable computer readable storage medium, e.g. CD-ROM, diskette, etc. In yet other embodiments, the actual instructions are not present in the kit, but means for obtaining the instructions from a remote source, e.g. via the internet, are provided. An example of this embodiment is a kit that includes a web address where the instructions can be viewed and/or from which the instructions can be downloaded. As with the instructions, this means for obtaining the instructions is recorded on a suitable substrate.

[0118] Animal Models for Sebaceous Gland Disorders

[0119] The invention provides a non-human animal model for a sebaceous gland disorder. In general, the non-human animal model is characterized by having abnormal DGAT activity.

[0120] A non-human animal may be any animal, e.g., a mammal or avian species that can serve as an animal model for testing therapies for sebaceous gland conditions. In many embodiments the non-human animal is a laboratory animal, usually a rodent, e.g., mouse, rat, hamster, guinea pig or the like. Other suitable laboratory animals are rabbits, cats, dogs, small monkeys, and apes. In addition, certain farm animals are also often employed as laboratory animals, notably chickens, goats, sheep, and pigs. Mice suitable for use in the present invention can be produced from any of a variety of background strains including, but not necessarily limited to, the strains C.B-17, C3H, BALB/c, C57131/6, AKR, BA, B10, 129, etc. Non-human animals are readily available from researchers or commercial suppliers, such as Jackson Laboratories (Bar Harbor, Me.), Charles River Breeding Laboratories (Wilmington, Mass.), Taconic Farms (Germantown, N.Y.), to mention a few such suppliers.

[0121] DGAT activity, including DGAT1 and/or DGAT2 activity, may be modified in animals by a variety of methods. In many embodiments, these methods involve modifying the expression of DGAT, leptin or the leptin receptor in a transgenic animal. In many embodiments, the expression of a DGAT, leptin or the leptin receptor endogenous to the animal is reduced in an animal. This may be accomplished through knockout strategies, where an nucleic acid insertion into an endogenous gene inactivates the gene (described in U.S. Pat. Nos. 5,487,992; 5,627,059; 5,631,153; and 6,204,061), or by other methods e.g. antisense, inhibitory RNA (RNAi), ribozyme or co-supression technologies, as is known in the art (e.g. Hannon et al., Nature 418:244-51, 2002; Ueda, J Neurogenet. 15:193-204, 2001; Review. Lindenbach et al., Mol Cell. 9:925-7, 2002; Brantl, Biochim Biophys Acta. 1575:15-25, 2002; Zhang et al., Ann NY Acad Sci. 923:210-33, 2000). In other embodiments, an endogenous DGAT, leptin or the leptin receptor or an exogenous DGAT, leptin or the leptin receptor is over-expressed in an animal. In these embodiments, a DGAT, leptin or leptin receptor coding sequence (for example, a coding sequence provided by one of the following NCBI accession: NM_(—)010046 (SEQ ID NO: 1), XM_(—)035370 (SEQ ID NO:2), NM_(—)053437 (SEQ ID NO: 3), AJ318490 (SEQ ID NO: 4), AF221132 (SEQ ID NO:5), AF468649 (SEQ ID NO: 6), AY093657 (SEQ ID NO: 7), AF384161 (SEQ ID NO:8), NM_(—)012079 (SEQ ID NO: 9), AF384163 (SEQ ID NO: 10), AF384162 (SEQ ID NO:11), AF078752 (SEQ ID NO: 12), NM_(—)013076 (SEQ ID NO: 13), NM_(—)010704 (SEQ ID NO:14), NM_(—)008493 (SEQ ID NO: 15), BTU83512 (SEQ ID NO: 16), NM_(—)000230 (SEQ ID NO: 17), and NM_(—)012596 (SEQ ID NO: 18)) is cloned into an expression cassette in an appropriate vector, and transferred into the genome of an animal to make a transgenic animal. In many embodiments, the animal is homozygous for a defect in a gene selected from DGAT, obese (encoding leptin) or the leptin receptor. In many embodiments, the subject animal is homozygous for a knockout in one of these genes.

[0122] Cloning technology, cloning strategies, expression cassettes, and suitable vectors for performing animal transformation are well known in the art (Ausubel, et al, Short Protocols in Molecular Biology, 3rd ed., Wiley & Sons, 1995; Sambrook, et al., Molecular Cloning: A Laboratory Manual, Second Edition, (1989) Cold Spring Harbor, N.Y.). Methods of generating transgenic, non-human animals, particularly transgenic, non-human mammals, are also known in the art. See, e.g., U.S. Pat. Nos. 6,268,545; 6,255;554; 6,222,094; 5,387,742, 4,736,866 and 5,565,186 and 6,204,43; “Transgenic Animal Technology” C. A. Pinkert, ed. (1997) Acad. Press; “Gene Knockout Protocols” M. J. Tymms, et al., eds. (2001) Humana Press; and “Gene Targeting: A Practical Approach” A. L. Joyner, ed. (2000) Oxford Univ. Press.

[0123] One method for producing a transgenic animal employs embryonic stem (ES) cells obtained from an animal to be transformed, e.g. mouse, rat, guinea pig, etc. In these methods, ES cells are grown on an appropriate fibroblast-feeder layer or grown in the presence of appropriate growth factors, such as leukemia inhibiting factor (LIF). When ES cells have been transformed, they may be used to produce transgenic animals. After transformation, the cells are plated onto a feeder layer in an appropriate medium. Cells containing the construct may be detected by employing a selective medium. After sufficient time for colonies to grow, they are picked and analyzed for the occurrence of homologous recombination or integration of the construct. Those colonies that are positive may then be used for embryo manipulation and blastocyst injection. Blastocysts are obtained from 4 to 6 week old superovulated females. The ES cells are trypsinized, and the modified cells are injected into the blastocoel of the blastocyst. After injection, the blastocysts are returned to each uterine horn of pseudopregnant females. Females are then allowed to go to term and the resulting litters screened for mutant cells having the construct. By providing for a different phenotype of the blastocyst and the ES cells, chimeric progeny can be readily detected. Progeny of transgenic animals may be screened for the presence of the modified gene and males and females having appropriate modified genomes are mated to produce homozygous progeny.

[0124] In certain embodiments, transgenic animals may be inter-crossed or may contain more than one genetic modification in order to produce a subject animal model. For example, an animal overexpressing DGAT1 may be bred with an animal knockout of a leptin-encoding gene to produce an a subject animal model containing an increase in DGAT activity and a decrease in leptin activity and an animal overexpressing leptin may also be bred with an animal knockout of a DGAT-encoding gene to produce an a subject animal model containing a decrease in DGAT activity and an increase in leptin activity, etc. Subject animals may also be intercrossed with hairless “nude” strains of animals, e.g. nude mice.

[0125] In embodiments where DGAT, leptin or the leptin receptor is overexpressed in a subject animal, DGAT, leptin or the leptin receptor expression is increased more than about 1.5-fold, more than about 2-fold, more than about 3-fold, more than about 5-fold, more than about 10-fold or even more than about 100-fold in a subject animal, as compared to an animal in which DGAT, leptin or the leptin receptor expression is not increased.

[0126] In embodiments where DGAT, leptin or the leptin receptor expression is decreased in a subject animal, DGAT, leptin or the leptin receptor expression is decreased by more than about 30%, more than about 50%, more than about 70%, more than about 90%, more than about 95% or even more than about 98%, about 99% or 99.5% in a subject animal, as compared to an animal in which DGAT, leptin or the leptin receptor expression is not decreased.

[0127] The subject animals have abnormal sebaceous gland activity. In certain embodiments, the phenotypes exhibited by the subject animals include, but are not limited to, dry fur, fur with reduced sheen, fur loss, altered sebaceous gland development, atrophic sebaceous glands, altered sebaceous gland activity, altered fur lipid abnormalities and impaired water repulsion and defective thermoregulation after water immersion as compared to normal animals. In most embodiments the subject animal is characterized as having abnormal DGAT activity, such as an increase or decrease in DGAT activity relative to a normal animal of the same species. Such animals find use in a variety of applications, including the screening methods described below.

Screening Assays

[0128] The invention provides methods of screening a candidate agent for sebaceous gland modulatory activity, e.g. stimulators or inhibitors of sebaceous gland activity. These screening assays typically provide for qualitative/quantitative measurements of a phenomenon associated with sebaceous glands in the presence of a particular candidate agent. The screening methods be performed in vivo, ex vivo, in vitro or in a cell free system, which are readily developed by those of skill in the art. Test agents that have a desirable effect in any subject screening assay method find use in a variety of applications, including modulating sebaceous gland activity in a host or treating a sebaceous gland disorder.

[0129] Using the above screening methods, a variety of different agents may be identified. Such agents may target the DGAT enzyme itself, or an expression regulatory factor thereof Such agents may be inhibitors or promoters of DGAT activity, where inhibitors are those agents that result in at least a reduction of DGAT activity as compared to a control and enhancers result in at least an increase in DGAT activity as compared to a control. Such agents may alternatively target leptin itself, or an expression regulatory factor thereof. Such agents may be inhibitors or promoters of leptin activity, where inhibitors are those agents that result in at least a reduction of leptin activity as compared to a control and enhancers result in at least an increase in leptin activity as compared to a control.

[0130] Specific screening assay methods are described below.

[0131] In Vivo Assays

[0132] The invention provides in vivo methods of screening a candidate agent for sebaceous gland modulatory activity. In general, the method involves administering a candidate agent to a subject transgenic animal and determining the effect of the candidate agent on the activity of sebaceous glands of the transgenic animal in order to assess the candidate agent's sebaceous gland modulatory activity.

[0133] In many embodiments the determining step of the in vivo assay method involves measuring a phenomenon associated with sebaceous glands, including DGAT activity, DGAT expression, lipid (e.g. TAG) biosynthesis, deposition or secretion and the like, performing visual examination of sebaceous glands for visual indications, such a change in sebaceous gland size, shape, color, inflammation, the formation of comidones, or determining the effect of water repulsion, hair sheen, thermoregulation or body weight after water immersion, or hair drying, hair dryness and the like.

[0134] In vivo assays of the invention include controls, where suitable controls include a sample in the absence of the test agent. Generally a plurality of assay mixtures is run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e. at zero concentration or below the level of detection.

[0135] A candidate agent of interest is one that modulates, i.e., reduces or increases, DGAT activity, DGAT expression, lipid (e.g. TAG) biosynthesis, deposition or secretion, hair sheen, hair lipids sebaceous gland size, water repulsion, or thermoregulation, etc., by at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 80%, at least about 90%, or more, when compared to a control in the absence of the test agent. In general, a candidate agent will cause a subject animal to be more similar to an equivalent animal that is not altered in DGAT activity.

[0136] Ex Vivo Assays

[0137] The invention provides ex vivo methods of screening a candidate agent for sebaceous gland modulatory activity. In general, the methods involve contacting a candidate agent with an isolated tissue having abnormal DGAT activity and determining the, effect of the candidate agent on a phenomenon associated with sebaceous glands in order to assess the candidate agent's sebaceous gland modulatory activity.

[0138] In many embodiments, a tissue with abnormal DGAT activity, particularly a skin tissue, is isolated from an animal. Methods of culturing isolated skin tissue ex vivo are known in the art (e.g. Companjen et al., Arch Dermatol Res. 2001 293:184-90; Calabrese et al., Drugs Exp Clin Res. 1999 25:43-9). In many embodiments the subject tissue is a tissue from a subject model animal.

[0139] In may embodiments, the test agent is applied to culture media, or directly applied, usually topically, to the ex vivo cultured tissue.

[0140] In many embodiments the determining step of the in vitro assay method involves measuring a phenomenon associated with sebaceous glands, including measureing DGAT activity, DGAT expression, lipid (e.g. TAG) biosynthesis, deposition or secretion and the like, or performing visual examination of sebaceous glands for visual indications, such a change in sebaceous gland size, shape, color, inflammation, or the formation of comidones. Hair characteristics, such as hair lipid compositions, sheen and dryness may also be determined.

[0141] Ex vivo assays of the invention include controls, where suitable controls include a sample in the absence of the test agent. Generally a plurality of assay mixtures is run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e. at zero concentration or below the level of detection.

[0142] A candidate agent of interest is one that modulates, i.e., reduces or increases, DGAT activity, DGAT expression, lipid (e.g. TAG) biosynthesis, deposition or secretion, hair sheen, hair lipids sebaceous gland size etc., by at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 80%, at least about 90%, or more, when compared to a control in the absence of the test agent. In general, a candidate agent will cause a subject tissue to be more similar to an equivalent tissue that is not altered in DGAT activity.

[0143] In Vitro Assays

[0144] The invention provides in vitro methods of screening a candidate agent for sebaceous gland modulatory activity. In general, the methods involve contacting a cell with abnormal DGAT activity with a candidate agent and determining the effect of the agent on the cell in order to assess the candidate agent's sebaceous gland modulatory activity.

[0145] In many embodiments, the cell with abnormal DGAT activity is an in which DGAT gene expression has been modified as compared to an unaltered cell. Methods for altering gene expression in a cell are well known to one of skill in the art (discussed in Ausubel, et al, Short Protocols in Molecular Biology, 3rd ed., Wiley & Sons, 1995; Sambrook, et al., Molecular Cloning. A Laboratory Manual, Second Edition, (1989) Cold Spring Harbor, N.Y.). These methods may involve DGAT overexpression via introduction of a genetic construct designed to express DGAT coding sequences, or may involve downregulating DGAT expression via knockout strategies (described in U.S. Pat. Nos. 5,487,992; 5,627,059; 5,631,153; and 6,204,061), or by other methods e.g. antisense, inhibitory RNA (RNAi), ribozyme or co-supression technologies, as is known in the art (e.g. Hannon et al., Nature 418:244-51, 2002; Ueda, J Neurogenet. 15:193-204, 2001; Review. Lindenbach et al., Mol Cell. 9:925-7, 2002; Brantl, Biochim Biophys Acta. 1575:15-25, 2002; Zhang et al., Ann NY Acad Sci. 923:210-33, 2000).

[0146] In embodiments where DGAT is overexpressed in a cell, DGAT expression is increased more than about 1.5-fold, more than about 2-fold, more than about 3-fold, more than about 5-fold, more than about 10-fold or even more than about 100-fold in the cell, as compared to an cell in which DGAT is not increased.

[0147] In embodiments where DGAT expression is decreased in a cell, DGAT expression is decreased by more than about 30%, more than about 50%, more than about 70%, more than about 90%, more than about 95% or even more than about 98%, about 99% or 99.5% in the, as compared to a cell in which DGAT is not decreased.

[0148] In many embodiments the subject cell is a cell from a subject model animal. In these embodiments, a cell, particularly a skin cell, from a subject animal model is isolated and may be cultured to produce a cell that has altered DGAT activity. In certain embodiments the subject skin cell is a sebocyte cell, isolation and culture methods for which are known in the art (Rosenfield et al., In Vitro Cell Dev Biol Anim 2002 38:54-7; Rosenfield et al., J Invest Dermatol. 1999 112:226-32).

[0149] In many embodiments the determining step of the in vitro assay method involves measuring a phenomenon associated with sebaceous glands, including DGAT activity, DGAT expression, lipid (e.g. TAG) biosynthesis, deposition or secretion and the like,

[0150] In vitro assays of the invention include controls, where suitable controls include a sample in the absence of the test agent. Generally a plurality of assay mixtures is run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e. at zero concentration or below the level of detection.

[0151] A test agent of interest is one that modulates, i.e., reduces or increases, DGAT activity, DGAT expression, lipid (e.g. TAG) biosynthesis, deposition or secretion and the like, by at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 80%, at least about 90%, or more, when compared to a control in the absence of the test agent. In general, a test agent will cause a subject cell to be more similar to an equivalent cell that is not altered in DGAT activity.

[0152] Cell Free Assays

[0153] The invention provides cell free methods of screening a candidate agent for sebaceous gland modulatory activity. In general, the methods involve admixing an extract of a cell (or a synthetic mimetic thereof) with abnormal DGAT activity with a candidate agent and determining the effect of the agent on the extract in order to assess the candidate agent's sebaceous gland modulatory activity. In many embodiments the assay methods involve measuring DGAT activity, lipid (e.g. TAG) biosynthesis, or and the like,

[0154] Cell free assays of the invention include controls, where suitable controls include a sample in the absence of the candidate agent. Generally a plurality of assay mixtures is run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, i.e. at zero concentration or below the level of detection.

[0155] A test agent of interest is one that modulates, i.e., reduces or increases, DGAT activity, lipid biosynthesis or the like, by at least about 10%, at least about 20%, at least about 25%, at least about 30%, at least about 35%, at least about 40%, at least about 45%, at least about 50%, at least about 55%, at least about 60%, at least about 65%, at least about 70%, at least about 80%, at least about 90%, or more, when compared to a control in the absence of the test agent. In general, a candidate agent will cause a subject extract to be more similar to an equivalent extract from a cell that is not altered in DGAT activity.

[0156] A variety of other reagents may be included ini the screening assay. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc that are used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Reagents that improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc. may be used.

[0157] Candidate Agents

[0158] The terms “candidate agent,” “test agent,” “agent”, “substance” and “compound” are used interchangeably herein and describe a variety of agents that may be screened using the above methods.

[0159] Candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 50 and less than about 2,500 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof.

[0160] Candidate agents include those found in large libraries of synthetic or natural compounds. For example, synthetic compound libraries are commercially available from Maybridge Chemical Co. (Trevillet, Cornwall, UK), ComGenex (South San Francisco, Calif.), and MicroSource (New Milford, Conn.). A rare chemical library is available from Aldrich (Milwaukee, Wis.). Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available from Pan Labs (Bothell, Wash.) or are readily producible. Additionally, natural or synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means, and may be used to produce combinatorial libraries. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs. New potential therapeutic agents may also be created using methods such as rational drug design or computer modeling. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides and oligopeptides.

[0161] Screening may be directed to known pharmacologically active compounds and chemical analogs thereof, or to new agents with unknown properties such as those created through rational drug design.

[0162] A variety of other reagents may be included in screening assays. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc that are used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Reagents that improve the efficiency of the assay, such as protease inhibitors, anti-microbial agents, etc. may be used. The mixture of components is added in any order that, provides for the requisite binding. Incubations are performed at any suitable temperature, typically between 4 and 40° C. Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high-throughput screening. Typically between 0.1 and 1 hour will be sufficient.

[0163] Candidate agents may also include biopolymers, including nucleic acids (e.g. DNA, RNA, cDNA, plasmids and this like), for example those encoding DGAT1 or DGAT2, leptin, leptin receptor, antisense DGAT1 or DGAT2, leptin, leptin receptor nucleic acids and the like), carbohydrates, lipids (e.g. lipids that inhibit the activity of DGAT) and proteins and polypeptides, (such as DGAT1 or DGAT2, leptin, leptin receptor or an antibody specific for DGAT1 or DGAT2, leptin, leptin receptor, etc.).

[0164] In particular embodiments, the candidate agent may be niacin, or other agents known in the art, e.g. those described in Lesnik et al. (Arch Dermatol Res 1992;284(2):100-5).

[0165] Agents that have an effect in an assay method of the invention may be further tested for cytotoxicity, bioavailability, and the like, using well known assays. Agents that have an effect in an assay method of the invention may be subjected to directed or random and/or directed chemical modifications, such as acylation, alkylation, esterification, amidification, etc. to produce structural analogs. Such structural analogs include those that increase bioavailability, and/or reduced cytotoxicity. Those skilled in the art can readily envision and generate a wide variety of structural analogs, and test them for desired properties such as increased bioavailability and/or reduced cytotoxicity and/or ability to cross the blood-brain barrier.

[0166] The following examples are presented for purposes of illustration only, and are not to be construed as limiting on the scope of the invention in any way.

EXPERIMENTAL

[0167] Materials and Methods

[0168] Mice: Dgat^(−/−) mice in C57BL/6 background were generated and genotyped as described (Smith, et al.(2000) Nat. Genet. 25:87-90). Wild-type (Dgat^(+/+)), ob/+, and Agouti yellow (A^(Y)/a) mice (all in C57BL/6 background) were from The Jackson Laboratory (Bar Harbor, Me., USA). DGAT1 deficiency was introduced into ob/ob and A^(Y)/a mice through breeding. Ob/ob mice lack leptin and, as a result, are obese and diabetic. A^(Y)/a mice are obese because of the ectopic production of agouti-signaling protein, which antagonizes the effects of melanocyte-stimulating hormone in the hypothalamus. A^(Y)/a mice have a functional leptin pathway, although they are leptin-resistant. Mice were housed in a pathogen-free barrier facility (12-hour light/dark cycle) and fed rodent chow (Ralston Purina Co., St. Louis, Mo., USA).

[0169] Water repulsion and temperature measurements: Mice were immersed in 37° C. water for 3 minutes and placed on a paper towel for about 5 seconds to absorb excess water. The mice were then exposed to ambient temperature (about 20° C.), and their weights and temperatures were recorded for 30-60 minutes. Core body temperature was measured rectally with a digital thermometer (model 4600; Yellow Springs Instruments Co., Yellow Springs, Ohio, USA).

[0170] Leptin infusion and testosterone administration: For peripheral (subcutaneous) infusion, a micro-osmotic pump (DURECT Corp., Cupertino, Calif., USA) was implanted in the interscapular region. The pump delivered recombinant human leptin (a gift from F. Chehab, University of California, San Francisco) at 250 ng/h for 14 days. This dose restores a normal plasma leptin level in mice with leptin deficiency resulting from lipodystrophy. For central (intracerebroventricular) infusion, a cannula (Brain Infusion Kit II, DURECT Corp.) was attached to the implanted micro-osmotic pump, and the needle was inserted 0.5 mm caudal and 1 mm lateral to the bregma. Leptin (10 ng/h) was infused for 14 days. This infusion rate does not affect plasma leptin concentrations. Testosterone propionate (Sigma Chemical Co., St. Louis, Mo., USA) was dissolved in vegetable oil and injected subcutaneously.

[0171] In situ hybridization: In situ hybridization was performed as described (Meiner, V. et al.(1997). J. Lipid Res. 38:1928-1933). Briefly, skin sections from wild-type mice were deparaffinized and fixed in 4% paraformaldehyde. After proteinase K digestion, the sections were hybridized at 55° C. for 12 hours with ³⁵S-labeled antisense or sense DGAT1 RNA probes. The sections were washed for 20 minutes in 2×SSC, 10 mM β-mercaptoethanol, and 1 mM EDTA, treated with RNase A (20 μg/ml), and washed at high stringency (0.1×SSC, 10 mM β-mercaptoethanol, and 1 mM EDTA) for 2 hours at 60° C. The sections were dehydrated, dipped in photographic emulsion NTB₂ (Eastman Kodak Co. Scientific Imaging Systems, Rochester, N.Y., USA), and stored at 4° C. After 8 weeks of exposure, the sections were developed and counterstained with hematoxylin and eosin.

[0172] Histology: Skin samples were fixed overnight in buffered formalin and embedded in paraffin. Sections were stained with hematoxylin and eosin.

[0173] Extraction and analysis of fur lipids: Hair lipids were extracted as follows. Briefly, about 150 mg of fur was clipped from the back of the mouse and treated twice with 20 ml of acetone for 15 minutes. Lipid extracts were filtered, dried under N₂, and resuspended in chloroform. Samples (150 μg of the dried lipids) were loaded on a TLC plate (Silica Gel 60; Sigma-Aldrich, St. Louis, Mo., USA) and resolved with hexane/ethyl ether/acetic acid (80:20:1 vol/vol/vol) or hexane/benzene (55:45 vol/vol). The latter system allowed a better separation of nonpolar lipids. For transesterification, the lipid was scraped from the TLC plate, incubated with methanolic acid/toluene (4:1 vol/vol) at 37° C. for 12 hours, and extracted twice with hexane (1.5 ml). For visualization of lipids, the TLC plate was either exposed to iodine vapor or sprayed with cupric sulfate (3%)/phosphoric acid (8%) and charred at 150° C. for color development. For 1,2-diol staining, the plate was sprayed with 1% lead tetraacetate (dissolved in benzene), followed by 0.05% pararosaniline (dissolved in acetic acid/acetone, 1:9 vol/vol).

[0174] Real-time PCR: Skin was homogenized, and total RNA was extracted (RNA STAT; Tel-Test Inc., Friendswood, Tex., USA). Primer and probe sequences (actin forward 5′-CATCTTGGCCTCACTGTCCA-3′ (SEQ ID NO: 19), reverse primer: 5′-GGGCCGGACTCATCGTACT-3′ (SEQ ID NO: 20), probe: 5′-CTTCCAGCAGATGTGGATCAGCAAGC-3′ (SEQ ID NO: 21); DGAT2 forward primer: 5′-AGTGGCAATGCTATCATCATCGT-3′ (SEQ ID NO: 22), reverse primer: 5′-AAGGAATAAGTGGGAACCCAGATCA-3′ (SEQ ID NO: 23), probe: 5′-CCTGG-CAAGAACGCAGTCACCCTG-3′ (SEQ ID NO: 24)) were selected with Primer Express software (Perkin-Elmer Applied Biosystems, Foster City, Calif., USA). RNA (1 μg) was reverse-transcribed in a 20-μl reaction containing oligo (dT)₁₂₋₁₈ primer and Superscript II enzyme (Invitrogen Corp., Carlsbad, Calif., USA). Each PCR (50 μl) contained 1 μl of cDNA, 1×gold buffer II, 4 mM MgCl₂, 500 μM dNTP, primers (200 nM), 100 nM probe (labeled with 6-carboxyfluorescein), and 1.25 U AmpliTaq Gold DNA polymerase (Perkin-Elmer Applied Biosystems). Real-time PCR was performed and analyzed with the ABI Prism 7700 Sequence Detection System (Perkin-Elmer Applied Biosystems). Relative expression levels were calculated by the comparative C_(T) (cycle of threshold detection) method as outlined in the manufacturer's technical bulletin; β-actin expression was used as control.

[0175] Statistical analysis: Data are expressed as mean±SD. Differences in weight and temperature curves were compared by ANOVA followed by the Tukey-Kramer test, as appropriate.

EXAMPLE I Preparation and Characterization of DGAT Knockout Mice

[0176] DGAT knockout mice were generated using standard techniques of gene targeting. A mouse P1 clone containing the mouse DGAT gene was isolated from a genomic 129/Sv library. Short and long arms of homologous sequences were amplified by PCR from this clone and subcloned intopNTKLoxP to generate a gene targeting vector. The vector contained a neomycin resistance gene for positive selection and a thymidine kinase gene for negative selection. Upon homologous recombination, the vector was designed to interrupt the DGAT coding sequences at amino acid 360 of the 498-amino acid murine protein. The entire C-terminus, including a highly conserved region common to all ACAT gene family members is deleted. The gene targeting vector was electroporated into RF8 embryonic stem cells by electroporation, and several targeted clones were identified by Southern blotting (targeting frequency of˜1 in 300).

[0177] One of these targeted clones was injected into C57BL/6 blastocysts and chimeras were generated; male chimeras subsequently passed the DGAT knockout mutation through the germline to their offspring. The resultant mice, which were heterozygous for the DGAT gene disruption, were intercrossed to generate mice that were homozygotes.

[0178] Inactivation of the DGAT gene in the homozygote knockouts was verified by examining DGAT mRNA which was found to be absent in the knockout mice. In activation of the DGAT gene was also verified by studying DGAT activity in tissues using an assay that measures the incorporation of [14C]oleoyl CoA into triglycerides. The results from the activity assays show that DGAT activity is virtually gone from every nearly every tissue tested.

EXAMPLE II Fur Abnormalities and Impaired Water Repulsion in Dgat^(31 /−) Mice

[0179] Dgat^(−/−) mice had normal fur appearance at weaning. After puberty (age 6-8 weeks), however, the fur of Dgat^(−/−) mice appeared drier and displayed a less prominent sheen than that of Dgat^(+/+) mice (FIG. 1a). Hair loss also occurred thereafter (FIG. 1a), beginning on the dorsal surface of the neck and proceeding caudally. Hair loss was more prominent in male mice than in female mice. Heterozygous (Dgat^(+/−)) mice appeared normal.

[0180] Because of their fur abnormalities, we tested the ability of Dgat^(−/−) mice to repel water and maintain normal body temperature when wet. Five minutes after water immersion, Dgat^(−/−) mice appeared wetter than Dgat^(+/+) mice, which were nearly dry (FIG. 1b). The delayed drying in Dgat^(−/−) mice resulted from increased water absorption during water immersion (FIG. 1c). Dgat^(−/−) mice became lethargic and exhibited little grooming behavior after water immersion, most likely because of hypothermia, which persisted for more than 60 minutes (FIG. 1d). Dry Dgat^(−/−) mice had no thermoregulatory defects. They had core body temperatures comparable to those of Dgat^(+/+) mice, both at room temperature (about 20° C.) and during prolonged cold exposure (24 hours at 4° C., not shown).

EXAMPLE III Fur Abnormalities in DGAT1 -Deficient A^(Y)/a but not ob/ob Mice

[0181] In a separate study to examine the metabolic effects of DGAT1 deficiency, we had introduced DGAT1 deficiency into two strains of genetically obese mice, ob/ob and A^(Y)/a. DGAT1 deficiency was associated with dry fur and hair loss in A^(Y)/a mice but had little impact on the fur of ob/ob mice. In addition, A^(Y)/a mice with DGAT1 deficiency (Dgat^(−/−) A^(Y)/a) retained more water than did wild-type (Dgat^(+/+)) A^(Y)/a mice (FIG. 2a) and developed hypothermia (FIG. 2b) after water immersion. In contrast, DGAT1 deficiency in ob/ob mice did not affect water repulsion (FIG. 2c) or thermoregulation (FIG. 2d).

[0182] To further explore whether the effects of DGAT1 deficiency on fur required leptin, we administered leptin to ob/ob mice with or without DGAT1 (Dgat^(+/+)ob/ob or Dgat^(−/−) ob/ob). After 2 weeks of continuous peripheral leptin infusion, Dgat^(−/−) ob/ob mice exhibited impaired water repulsion (FIG. 2e) and developed mild hypothermia (FIG. 2f) after water immersion. These findings were again absent 2 weeks after the cessation of leptin infusion (FIGS. 2, g and h).

EXAMPLE IV Sebaceous Gland Atrophy in Dgat^(−/−) Mice

[0183] To investigate the function of DGAT1 in the skin, we examined DGAT1 expression by in situ hybridization, which revealed high DGAT1 mRNA levels in the sebaceous glands (FIG. 3). We therefore examined sebaceous gland morphology in Dgat^(−/−) mice. The sebaceous glands and hair follicles of young (6-week-old) Dgat^(−/−) mice appeared normal (FIGS. 4, a and b). In contrast, the skin of older (3-month-old) Dgat^(−/−) mice had atrophic sebaceous glands on both the ventral and the dorsal surfaces (FIGS. 4, c and d). For many hair follicles, no associated sebaceous glands could be identified.

EXAMPLE V Atrophic Sebaceous Glands in DGAT1-Deficient A^(Y)/a Mice and Leptin-Treated ob/ob Mice

[0184] Similar to the situation for fur abnormalities, the sebaceous gland atrophy associated with DGAT1 deficiency was present in A^(Y)/a mice (FIGS. 5, a and b) but not in ob/ob mice (FIGS. 5, c and d). Dgat^(+/+) ob/ob mice, however, had larger sebaceous glands than did Dgat^(−/−) obob mice. Two weeks of peripheral or central leptin infusion decreased the size of sebaceous glands in Dgat^(+/+) ob/ob mice (FIGS. 5, e and g) but caused marked atrophy of sebaceous glands in Dgat^(−/−) ob/ob mice (FIGS. 5, f and h). These histological changes reverted to pretreatment states 2 weeks after the cessation of leptin administration (FIGS. 5, i and j).

EXAMPLE VI Abnormal Fur Lipids in Dgat^(−/−) Mice

[0185] We analyzed the effects of DGAT1 deficiency on the composition of fur lipids, which are produced by sebaceous glands. In both Dgat^(+/+) and Dgat^(−/−) mice, the fur lipids contained sterol esters, free cholesterol, and triglycerides. In addition, the fur of adult Dgat^(+/+) mice contained several lipids that were lacking in the fur of adult Dgat^(−/−) mice (FIG. 6a). The most prominent of these missing lipids was slightly more polar than sterol esters. After transesterification, this lipid yielded two products—one migrated similarly to a fatty acid methyl ester standard, and the other contained a 1,2-diol group (not shown). Based on this result, as well as the migration and quantity of the lipid on TLC, it is most likely a type II wax diester, the most abundant component in murine fur lipids. This difference in fur lipid content was age-dependent: it was less striking in younger (6-week-old) mice (FIG. 6b, lanes 1 and 2) and more pronounced in adult (3-month-old) mice (FIG. 6b, lanes 3 and 4).

EXAMPLE VII Abnormal Fur Lipids in DGAT1-Deficient A^(Y)/a Mice and Leptin-Treated ob/ob Mice

[0186] The fur of Dgat^(−/−) A^(Y)/a mice also contained little, if any, of the wax diester (FIG. 6b, lanes 5 and 6). In contrast, both Dgat^(+/+) ob/ob and Dgat^(−/−) ob/ob mice produced this fur lipid, although the quantity was slightly decreased in the fur of Dgat^(−/−) ob/ob mice (FIG. 6b, lanes 7 and 8). Two weeks of peripheral or central leptin administration had a minimal effect on the abundance of this fur lipid in Dgat^(+/+) ob/ob mice but caused a severe reduction in Dga^(−/−) ob/ob mice (FIG. 6b, lanes 9-12). Two weeks after the withdrawal of leptin, the fur of Dgat^(−/−) ob/ob mice contained this lipid again (FIG. 6b, lanes 13 and 14).

EXAMPLE VIII Effects of Androgens on Fur Lipids in Dgat^(−/−) Mice

[0187] Because the effects of DGAT1 deficiency on the skin were most noticeable in postpubertal male mice, we investigated the role of androgens in mediating these effects. Because ob/ob mice have a defective hypothalamic-pituitary-gonadal axis, they do not undergo puberty and have decreased serum testosterone levels. This lack of normal testosterone production may ameliorate the effects of DGAT1 deficiency in ob/ob mice. To test this hypothesis, we injected both Dgat^(+/+) ob/ob and Dgat^(−/−) ob/ob male mice with a replacement dose of testosterone (5 μg/g body weight/day) and assessed its effects on fur lipid content. Two weeks of testosterone treatment did not eliminate the presence of wax diesters in the fur of Dgat^(−/−) ob/ob mice (FIG. 7, lanes 1-4). Testosterone replacement also did not cause atrophy of sebaceous glands in these mice (not shown).

[0188] To further explore whether androgens mediated the effects of DGAT1 deficiency in the skin, we castrated postpubertal Dgat^(−/−) male mice. Castration did not restore the normal production of fur lipids in Dgat^(−/−) male mice; rather, it completely eliminated the presence of wax diesters in their fur (FIG. 7, lanes 5 and 6). Castration also did not reverse the atrophy of sebaceous glands in these mice (not shown).

EXAMPLE IX Upregulation of DGAT2 Expression in the Skin of DGAT1-Deficient ob/ob Mice

[0189] One possible mechanism by which the skin of Dgat^(−/−) ob/ob mice was largely protected from the effects of DGAT1 deficiency could be a compensatory increase in the expression of another DGAT enzyme. We therefore measured the mRNA expression of the recently identified DGAT2 to determine whether its expression was increased in the skin of Dgat^(−/−) ob/ob mice. In wild-type mice, DGAT2 mRNA was expressed highly in the skin (not shown). DGAT2 expression was not increased in Dgat^(−/−) mice and in fact was lower than in Dgat^(+/+) mice (FIG. 8a). However, leptin-deficient Dgat^(−/−) and Dgat^(+/+) mice had similarly increased levels of DGAT2 expression (FIG. 8a). Leptin deficiency, therefore, was associated with a greater upregulation of DGAT2 in the skin of Dgat^(−/−) mice than in that of Dgat^(+/+) mice (FIG. 8b).

[0190] It is evident from the above results and discussion that the subject invention provides an important new animal model for the treatment of sebaceous gland disorders, methods for treating sebaceous gland disorders and several sebaceous gland-related assay systems. As such, the subject methods and systems find use in a variety of different applications, including research, industry, and medicine. Accordingly, the present invention represents a significant contribution to the art.

[0191] All publications and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference. The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

[0192] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it is readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.

1 24 1 1497 DNA Mus musculus CDS (1)...(1497) Mouse DGAT1 coding sequence 1 atg ggc gac cgc gga ggc gcg gga agc tct cgg cgt cgg agg acc ggc 48 Met Gly Asp Arg Gly Gly Ala Gly Ser Ser Arg Arg Arg Arg Thr Gly 1 5 10 15 tcg cgg gtt tcc gtc cag ggt ggt agt ggg ccc aag gta gaa gag gac 96 Ser Arg Val Ser Val Gln Gly Gly Ser Gly Pro Lys Val Glu Glu Asp 20 25 30 gag gtg cga gac gcg gct gtg agc ccc gac ttg ggc gcc ggg ggt gac 144 Glu Val Arg Asp Ala Ala Val Ser Pro Asp Leu Gly Ala Gly Gly Asp 35 40 45 gcg ccg gct ccg gct ccg gct cca gcc cat acc cgg gac aaa gac ggg 192 Ala Pro Ala Pro Ala Pro Ala Pro Ala His Thr Arg Asp Lys Asp Gly 50 55 60 cgg acc agc gtg ggc gac ggc tac tgg gat ctg agg tgc cat cgt ctg 240 Arg Thr Ser Val Gly Asp Gly Tyr Trp Asp Leu Arg Cys His Arg Leu 65 70 75 80 caa gat tct ttg ttc agc tca gac agt ggt ttc agc aat tat cgt ggt 288 Gln Asp Ser Leu Phe Ser Ser Asp Ser Gly Phe Ser Asn Tyr Arg Gly 85 90 95 atc ctg aat tgg tgt gtg gtg atg ctg atc ctg agt aat gca agg tta 336 Ile Leu Asn Trp Cys Val Val Met Leu Ile Leu Ser Asn Ala Arg Leu 100 105 110 ttt tta gag aac ctt atc aag tat ggc atc ctg gtg gat cct atc cag 384 Phe Leu Glu Asn Leu Ile Lys Tyr Gly Ile Leu Val Asp Pro Ile Gln 115 120 125 gtg gtg tct ctg ttt ttg aag gac ccc tac agc tgg cct gcc cca tgc 432 Val Val Ser Leu Phe Leu Lys Asp Pro Tyr Ser Trp Pro Ala Pro Cys 130 135 140 gtg att att gca tcc aat att ttt gtt gtg gct gca ttt cag att gag 480 Val Ile Ile Ala Ser Asn Ile Phe Val Val Ala Ala Phe Gln Ile Glu 145 150 155 160 aag cgc ctg gca gtg ggt gcc ctg aca gag cag atg ggg ctg ctg cta 528 Lys Arg Leu Ala Val Gly Ala Leu Thr Glu Gln Met Gly Leu Leu Leu 165 170 175 cat gtg gtt aac ctg gcc aca atc att tgc ttc cca gca gct gtg gcc 576 His Val Val Asn Leu Ala Thr Ile Ile Cys Phe Pro Ala Ala Val Ala 180 185 190 tta ctg gtt gag tct atc act cca gtg ggt tcc gtg ttt gct ctg gca 624 Leu Leu Val Glu Ser Ile Thr Pro Val Gly Ser Val Phe Ala Leu Ala 195 200 205 tca tac tcc atc atg ttc ctc aag ctt tat tcc tac cgg gat gtc aac 672 Ser Tyr Ser Ile Met Phe Leu Lys Leu Tyr Ser Tyr Arg Asp Val Asn 210 215 220 ctg tgg tgc cgc cag cga agg gtc aag gcc aaa gct gtc tct aca ggg 720 Leu Trp Cys Arg Gln Arg Arg Val Lys Ala Lys Ala Val Ser Thr Gly 225 230 235 240 aag aag gtc agt ggg gct gct gcc cag caa gct gtg agc tat cca gac 768 Lys Lys Val Ser Gly Ala Ala Ala Gln Gln Ala Val Ser Tyr Pro Asp 245 250 255 aac ctg acc tac cga gat ctc tat tac ttc atc ttt gct cct act ttg 816 Asn Leu Thr Tyr Arg Asp Leu Tyr Tyr Phe Ile Phe Ala Pro Thr Leu 260 265 270 tgt tat gaa ctc aac ttt cct cgg tcc ccc cga ata cga aag cgc ttt 864 Cys Tyr Glu Leu Asn Phe Pro Arg Ser Pro Arg Ile Arg Lys Arg Phe 275 280 285 ctg cta cga cga gtt ctt gag atg ctc ttt ttt acc cag ctt caa gtg 912 Leu Leu Arg Arg Val Leu Glu Met Leu Phe Phe Thr Gln Leu Gln Val 290 295 300 ggg ctg atc caa cag tgg atg gtc cct act atc cag aac tcc atg aag 960 Gly Leu Ile Gln Gln Trp Met Val Pro Thr Ile Gln Asn Ser Met Lys 305 310 315 320 ccc ttc aag gat atg gac tat tca cgg atc att gag cgt ctc tta aag 1008 Pro Phe Lys Asp Met Asp Tyr Ser Arg Ile Ile Glu Arg Leu Leu Lys 325 330 335 ctg gcg gtc ccc aac cat ctg atc tgg ctt atc ttc ttc tat tgg ttt 1056 Leu Ala Val Pro Asn His Leu Ile Trp Leu Ile Phe Phe Tyr Trp Phe 340 345 350 ttc cac tcc tgt ctc aat gct gtg gca gag ctt ctg cag ttt gga gac 1104 Phe His Ser Cys Leu Asn Ala Val Ala Glu Leu Leu Gln Phe Gly Asp 355 360 365 cgc gag ttc tac aga gat tgg tgg aat gct gag tct gtc acc tac ttt 1152 Arg Glu Phe Tyr Arg Asp Trp Trp Asn Ala Glu Ser Val Thr Tyr Phe 370 375 380 tgg cag aac tgg aat atc ccc gtg cac aag tgg tgc atc aga cac ttc 1200 Trp Gln Asn Trp Asn Ile Pro Val His Lys Trp Cys Ile Arg His Phe 385 390 395 400 tac aag cct atg ctc aga cat ggc agc agc aaa tgg gtg gcc agg aca 1248 Tyr Lys Pro Met Leu Arg His Gly Ser Ser Lys Trp Val Ala Arg Thr 405 410 415 gga gta ttt ttg acc tca gcc ttc ttc cat gag tac cta gtg agc gtt 1296 Gly Val Phe Leu Thr Ser Ala Phe Phe His Glu Tyr Leu Val Ser Val 420 425 430 ccc ctg cgg atg ttc cgc ctc tgg gca ttc aca gcc atg atg gct cag 1344 Pro Leu Arg Met Phe Arg Leu Trp Ala Phe Thr Ala Met Met Ala Gln 435 440 445 gtc cca ctg gcc tgg att gtg ggc cga ttc ttc caa ggg aac tat ggc 1392 Val Pro Leu Ala Trp Ile Val Gly Arg Phe Phe Gln Gly Asn Tyr Gly 450 455 460 aat gca gct gtg tgg gtg aca ctc atc att ggg caa ccg gtg gct gtg 1440 Asn Ala Ala Val Trp Val Thr Leu Ile Ile Gly Gln Pro Val Ala Val 465 470 475 480 ctc atg tat gtc cac gac tac tac gtg ctc aac tac gat gcc cca gtg 1488 Leu Met Tyr Val His Asp Tyr Tyr Val Leu Asn Tyr Asp Ala Pro Val 485 490 495 ggg gta tga 1497 Gly Val * 2 1467 DNA Homo sapiens CDS (1)...(1467) Homo sapiens diacylglycerol O-acyltransferase homolog 1 2 atg ggc gac cgc ggc agc tcc cgg cgc cgg agg aca ggg tcg cgg ccc 48 Met Gly Asp Arg Gly Ser Ser Arg Arg Arg Arg Thr Gly Ser Arg Pro 1 5 10 15 tcg agc cac ggc ggc ggc ggg cct gcg gcg gcg gaa gag gag gtg cgg 96 Ser Ser His Gly Gly Gly Gly Pro Ala Ala Ala Glu Glu Glu Val Arg 20 25 30 gac gcc gct gcg ggc ccc gac gtg gga gcc gcg ggg gac gcg cca gcc 144 Asp Ala Ala Ala Gly Pro Asp Val Gly Ala Ala Gly Asp Ala Pro Ala 35 40 45 ccg gcc ccc aac aag gac gga gac gcc ggc gtg ggc agc ggc cac tgg 192 Pro Ala Pro Asn Lys Asp Gly Asp Ala Gly Val Gly Ser Gly His Trp 50 55 60 gag ctg agg tgc cat cgc ctg cag gat tct tta ttc agc tct gac agt 240 Glu Leu Arg Cys His Arg Leu Gln Asp Ser Leu Phe Ser Ser Asp Ser 65 70 75 80 ggc ttc agc aac tac cgt ggc atc ctg aac tgg tgt gtg gtg atg ctg 288 Gly Phe Ser Asn Tyr Arg Gly Ile Leu Asn Trp Cys Val Val Met Leu 85 90 95 atc ttg agc aat gcc cgg tta ttt ctg gag aac ctc atc aag tat ggc 336 Ile Leu Ser Asn Ala Arg Leu Phe Leu Glu Asn Leu Ile Lys Tyr Gly 100 105 110 atc ctg gtg gac ccc atc cag gtg gtt tct ctg ttc ctg aag gat ccc 384 Ile Leu Val Asp Pro Ile Gln Val Val Ser Leu Phe Leu Lys Asp Pro 115 120 125 tat agc tgg ccc gcc cca tgc ctg gtt att gcg gcc aat gtc ttt gct 432 Tyr Ser Trp Pro Ala Pro Cys Leu Val Ile Ala Ala Asn Val Phe Ala 130 135 140 gtg gct gca ttc cag gtt gag aag cgc ctg gcg gtg ggt gcc ctg acg 480 Val Ala Ala Phe Gln Val Glu Lys Arg Leu Ala Val Gly Ala Leu Thr 145 150 155 160 gag cag gcg gga ctg ctg ctg cac gtg gcc aac ctg gcc acc att ctg 528 Glu Gln Ala Gly Leu Leu Leu His Val Ala Asn Leu Ala Thr Ile Leu 165 170 175 tgt ttc cca gcg gct gtg gtc tta ctg gtt gag tct atc act cca gtg 576 Cys Phe Pro Ala Ala Val Val Leu Leu Val Glu Ser Ile Thr Pro Val 180 185 190 ggc tcc ctg ctg gcg ctg atg gcg cac acc atc ctc ttc ctc aag ctc 624 Gly Ser Leu Leu Ala Leu Met Ala His Thr Ile Leu Phe Leu Lys Leu 195 200 205 ttc tcc tac cgc gac gtc aac tca tgg tgc cgc agg gcc agg gcc aag 672 Phe Ser Tyr Arg Asp Val Asn Ser Trp Cys Arg Arg Ala Arg Ala Lys 210 215 220 gct gcc tct gca ggg aag aag gcc agc agt gct gct gcc ccg cac acc 720 Ala Ala Ser Ala Gly Lys Lys Ala Ser Ser Ala Ala Ala Pro His Thr 225 230 235 240 gtg agc tac ccg gac aat ctg acc tac cgc gat ctc tac tac ttc ctc 768 Val Ser Tyr Pro Asp Asn Leu Thr Tyr Arg Asp Leu Tyr Tyr Phe Leu 245 250 255 ttc gcc ccc acc ttg tgc tac gag ctc aac ttt ccc cgc tct ccc cgc 816 Phe Ala Pro Thr Leu Cys Tyr Glu Leu Asn Phe Pro Arg Ser Pro Arg 260 265 270 atc cgg aag cgc ttt ctg ctg cga cgg atc ctt gag atg ctg ttc ttc 864 Ile Arg Lys Arg Phe Leu Leu Arg Arg Ile Leu Glu Met Leu Phe Phe 275 280 285 acc cag ctc cag gtg ggg ctg atc cag cag tgg atg gtc ccc acc atc 912 Thr Gln Leu Gln Val Gly Leu Ile Gln Gln Trp Met Val Pro Thr Ile 290 295 300 cag aac tcc atg aag ccc ttc aag gac atg gac tac tca cgc atc atc 960 Gln Asn Ser Met Lys Pro Phe Lys Asp Met Asp Tyr Ser Arg Ile Ile 305 310 315 320 gag cgc ctc ctg aag ctg gcg gtc ccc aat cac ctc atc tgg ctc atc 1008 Glu Arg Leu Leu Lys Leu Ala Val Pro Asn His Leu Ile Trp Leu Ile 325 330 335 ttc ttc tac tgg ctc ttc cac tcc tgc ctg aat gcc gtg gct gag ctc 1056 Phe Phe Tyr Trp Leu Phe His Ser Cys Leu Asn Ala Val Ala Glu Leu 340 345 350 atg cag ttt gga gac cgg gag ttc tac cgg gac tgg tgg aac tcc gag 1104 Met Gln Phe Gly Asp Arg Glu Phe Tyr Arg Asp Trp Trp Asn Ser Glu 355 360 365 tct gtc acc tac ttc tgg cag aac tgg aac atc cct gtg cac aag tgg 1152 Ser Val Thr Tyr Phe Trp Gln Asn Trp Asn Ile Pro Val His Lys Trp 370 375 380 tgc atc aga cac ttc tac aag ccc atg ctt cga cgg ggc agc agc aag 1200 Cys Ile Arg His Phe Tyr Lys Pro Met Leu Arg Arg Gly Ser Ser Lys 385 390 395 400 tgg atg gcc agg aca ggg gtg ttc ctg gcc tcg gcc ttc ttc cac gag 1248 Trp Met Ala Arg Thr Gly Val Phe Leu Ala Ser Ala Phe Phe His Glu 405 410 415 tac ctg gtg agc gtc cct ctg cga atg ttc cgc ctc tgg gcg ttc acg 1296 Tyr Leu Val Ser Val Pro Leu Arg Met Phe Arg Leu Trp Ala Phe Thr 420 425 430 ggc atg atg gct cag atc cca ctg gcc tgg ttc gtg ggc cgc ttt ttc 1344 Gly Met Met Ala Gln Ile Pro Leu Ala Trp Phe Val Gly Arg Phe Phe 435 440 445 cag ggc aac tat ggc aac gca gct gtg tgg ctg tcg ctc atc atc gga 1392 Gln Gly Asn Tyr Gly Asn Ala Ala Val Trp Leu Ser Leu Ile Ile Gly 450 455 460 cag cca ata gcc gtc ctc atg tac gtc cac gac tac tac gtg ctc aac 1440 Gln Pro Ile Ala Val Leu Met Tyr Val His Asp Tyr Tyr Val Leu Asn 465 470 475 480 tat gag gcc cca gcg gca gag gcc tga 1467 Tyr Glu Ala Pro Ala Ala Glu Ala * 485 3 1497 DNA Rattus norvegicus CDS (1)...(1497) s norvegicus diacylglycerol O-acyltransferase 1 coding sequence 3 atg ggc gac cgc gga ggc gcg gga agc tct cgg cgt cgc agg acc ggc 48 Met Gly Asp Arg Gly Gly Ala Gly Ser Ser Arg Arg Arg Arg Thr Gly 1 5 10 15 tcg cgg gtt tcc gtc cag gga ggt agt ggg ccc aag gta gaa gag gac 96 Ser Arg Val Ser Val Gln Gly Gly Ser Gly Pro Lys Val Glu Glu Asp 20 25 30 gag gtg cga gaa gcg gct gtg agc ccc gac ttg ggc gcc ggg ggt gac 144 Glu Val Arg Glu Ala Ala Val Ser Pro Asp Leu Gly Ala Gly Gly Asp 35 40 45 gcg ccg gct ccg gct ccg gct cca gcc cat acc cgg gac aaa gac cgg 192 Ala Pro Ala Pro Ala Pro Ala Pro Ala His Thr Arg Asp Lys Asp Arg 50 55 60 cag acc agc gtg ggc gac ggc cac tgg gag ctg agg tgc cat cgt ctg 240 Gln Thr Ser Val Gly Asp Gly His Trp Glu Leu Arg Cys His Arg Leu 65 70 75 80 caa gac tct ttg ttc agc tca gac agc ggt ttc agc aat tac cgt ggt 288 Gln Asp Ser Leu Phe Ser Ser Asp Ser Gly Phe Ser Asn Tyr Arg Gly 85 90 95 atc ctg aat tgg tgc gtg gtg atg ctg atc ctg agt aat gca agg tta 336 Ile Leu Asn Trp Cys Val Val Met Leu Ile Leu Ser Asn Ala Arg Leu 100 105 110 tct tta gag aat ctt atc aag tat ggc atc ctg gtg gat ccc atc cag 384 Ser Leu Glu Asn Leu Ile Lys Tyr Gly Ile Leu Val Asp Pro Ile Gln 115 120 125 gtg gtg tct ctg ttt ctg aag gac ccc tac agc tgg cct gcc cca tgc 432 Val Val Ser Leu Phe Leu Lys Asp Pro Tyr Ser Trp Pro Ala Pro Cys 130 135 140 ttg atc att gca tcc aat atc ttt att gtg gct aca ttt cag att gag 480 Leu Ile Ile Ala Ser Asn Ile Phe Ile Val Ala Thr Phe Gln Ile Glu 145 150 155 160 aag cgc ctg tca gtg ggt gcc ctg aca gag cag atg ggg ctg ctg cta 528 Lys Arg Leu Ser Val Gly Ala Leu Thr Glu Gln Met Gly Leu Leu Leu 165 170 175 cat gtg gtt aac ctg gcc aca att atc tgc ttc cca gca gct gtg gcc 576 His Val Val Asn Leu Ala Thr Ile Ile Cys Phe Pro Ala Ala Val Ala 180 185 190 tta ctg gtt gag tct atc act cca gtg ggt tcc ctg ttt gct ctg gca 624 Leu Leu Val Glu Ser Ile Thr Pro Val Gly Ser Leu Phe Ala Leu Ala 195 200 205 tca tac tcc atc atc ttc ctc aag ctt tct tcc tac cgg gat gtc aat 672 Ser Tyr Ser Ile Ile Phe Leu Lys Leu Ser Ser Tyr Arg Asp Val Asn 210 215 220 ctg tgg tgc cgc cag cga agg gtc aag gcc aaa gct gtg tct gca ggg 720 Leu Trp Cys Arg Gln Arg Arg Val Lys Ala Lys Ala Val Ser Ala Gly 225 230 235 240 aag aag gtc agt ggg gct gct gcc cag aac act gta agc tat ccg gac 768 Lys Lys Val Ser Gly Ala Ala Ala Gln Asn Thr Val Ser Tyr Pro Asp 245 250 255 aac ctg acc tac cga gat ctc tat tac ttc atc ttt gct cct act ttg 816 Asn Leu Thr Tyr Arg Asp Leu Tyr Tyr Phe Ile Phe Ala Pro Thr Leu 260 265 270 tgt tat gaa ctc aac ttt cct cga tcc ccc cga ata cga aag cgc ttt 864 Cys Tyr Glu Leu Asn Phe Pro Arg Ser Pro Arg Ile Arg Lys Arg Phe 275 280 285 ctg cta cgg cgg gtt ctt gag atg ctc ttt ttc acc cag ctt caa gtg 912 Leu Leu Arg Arg Val Leu Glu Met Leu Phe Phe Thr Gln Leu Gln Val 290 295 300 ggg ctg atc cag cag tgg atg gtc cct act atc cag aac tcc atg aag 960 Gly Leu Ile Gln Gln Trp Met Val Pro Thr Ile Gln Asn Ser Met Lys 305 310 315 320 ccc ttc aag gac atg gac tat tca cga atc att gag cgt ctc tta aag 1008 Pro Phe Lys Asp Met Asp Tyr Ser Arg Ile Ile Glu Arg Leu Leu Lys 325 330 335 ctg gcg gtc ccc aac cat ctg ata tgg ctc atc ttc ttc tat tgg ctt 1056 Leu Ala Val Pro Asn His Leu Ile Trp Leu Ile Phe Phe Tyr Trp Leu 340 345 350 ttc cac tca tgt ctc aat gct gtg gca gag ctc ctg cag ttt gga gac 1104 Phe His Ser Cys Leu Asn Ala Val Ala Glu Leu Leu Gln Phe Gly Asp 355 360 365 cgc gag ttc tac agg gac tgg tgg aat gct gag tct gtc acc tac ttt 1152 Arg Glu Phe Tyr Arg Asp Trp Trp Asn Ala Glu Ser Val Thr Tyr Phe 370 375 380 tgg cag aac tgg aat atc ccc gtg cac aag tgg tgc atc aga cac ttt 1200 Trp Gln Asn Trp Asn Ile Pro Val His Lys Trp Cys Ile Arg His Phe 385 390 395 400 tac aag cct atg ctc aga ctg ggc agc aac aaa tgg atg gcc agg act 1248 Tyr Lys Pro Met Leu Arg Leu Gly Ser Asn Lys Trp Met Ala Arg Thr 405 410 415 ggg gtc ttt tgg gcg tca gct ttc ttt cat gag tac cta gtg agc att 1296 Gly Val Phe Trp Ala Ser Ala Phe Phe His Glu Tyr Leu Val Ser Ile 420 425 430 ccc ctg agg atg ttc cgc ctt tgg gca ttc aca gca atg atg gct cag 1344 Pro Leu Arg Met Phe Arg Leu Trp Ala Phe Thr Ala Met Met Ala Gln 435 440 445 gtc cca ctg gcc tgg att gtg aac cgc ttc ttc caa ggg aac tat ggc 1392 Val Pro Leu Ala Trp Ile Val Asn Arg Phe Phe Gln Gly Asn Tyr Gly 450 455 460 aat gca gct gtg tgg gtg aca ctc atc att ggg caa ccg gtg gct gtg 1440 Asn Ala Ala Val Trp Val Thr Leu Ile Ile Gly Gln Pro Val Ala Val 465 470 475 480 ctc atg tat gtc cac gac tac tac gtg ctc aac tat gat gcc cca gtg 1488 Leu Met Tyr Val His Asp Tyr Tyr Val Leu Asn Tyr Asp Ala Pro Val 485 490 495 ggg gca tga 1497 Gly Ala * 4 1470 DNA Bos taurus CDS (1)...(1470) Bos taurus dgat coding sequence 4 atg ggc gac cgc ggc ggc gcg ggc ggc tcc cgg cgc cgg agg acg ggg 48 Met Gly Asp Arg Gly Gly Ala Gly Gly Ser Arg Arg Arg Arg Thr Gly 1 5 10 15 tcg cgg cct tcg atc cag ggc ggc agt ggg ccc gcg gca gcg gaa gag 96 Ser Arg Pro Ser Ile Gln Gly Gly Ser Gly Pro Ala Ala Ala Glu Glu 20 25 30 gag gtg cgg gat gtg ggc gcc gga ggg gac gcg ccg gtc cgg gac aca 144 Glu Val Arg Asp Val Gly Ala Gly Gly Asp Ala Pro Val Arg Asp Thr 35 40 45 gac aag gac gga gac gta gac gtg ggc agc ggc cac tgg gac ctg agg 192 Asp Lys Asp Gly Asp Val Asp Val Gly Ser Gly His Trp Asp Leu Arg 50 55 60 tgt cac cgc ctg cag gat tcc ctg ttc agt tct gac agt ggc ttc agc 240 Cys His Arg Leu Gln Asp Ser Leu Phe Ser Ser Asp Ser Gly Phe Ser 65 70 75 80 aac tac cgt ggc atc ctg aat tgg tgt gtg gtg atg ctg atc tta agc 288 Asn Tyr Arg Gly Ile Leu Asn Trp Cys Val Val Met Leu Ile Leu Ser 85 90 95 aac gca cgg tta ttt cta gag aac ctc atc aag tat ggc atc ctg gtg 336 Asn Ala Arg Leu Phe Leu Glu Asn Leu Ile Lys Tyr Gly Ile Leu Val 100 105 110 gac ccc atc cag gtg gtg tct ctg ttc ctg aag gac ccc tac agc tgg 384 Asp Pro Ile Gln Val Val Ser Leu Phe Leu Lys Asp Pro Tyr Ser Trp 115 120 125 cca gct ctg tgc ctg gtc att gtg gcc aat atc ttt gcc gtg gct gcg 432 Pro Ala Leu Cys Leu Val Ile Val Ala Asn Ile Phe Ala Val Ala Ala 130 135 140 ttc cag gtg gag aag cgc ctg gcc gtg gga gct ctg acg gag cag gcg 480 Phe Gln Val Glu Lys Arg Leu Ala Val Gly Ala Leu Thr Glu Gln Ala 145 150 155 160 ggg ctg ctg ctg cac ggg gtc aac ctg gcc acc att ctc tgc ttc cca 528 Gly Leu Leu Leu His Gly Val Asn Leu Ala Thr Ile Leu Cys Phe Pro 165 170 175 gcg gcc gtg gcc ttt ctc ctc gag tct atc act cca gtg ggc tcc gtg 576 Ala Ala Val Ala Phe Leu Leu Glu Ser Ile Thr Pro Val Gly Ser Val 180 185 190 ctg gcc ctg atg gtc tac acc atc ctc ttc ctc aag ctg ttc tcc tac 624 Leu Ala Leu Met Val Tyr Thr Ile Leu Phe Leu Lys Leu Phe Ser Tyr 195 200 205 cgg gac gtc aac ctc tgg tgc cga gag cgc agg gct ggg gcc aag gcc 672 Arg Asp Val Asn Leu Trp Cys Arg Glu Arg Arg Ala Gly Ala Lys Ala 210 215 220 aag gct gct ttg gca ggt aag gcg gcc aac ggg gga gct gcc cag cgc 720 Lys Ala Ala Leu Ala Gly Lys Ala Ala Asn Gly Gly Ala Ala Gln Arg 225 230 235 240 acc gtg agc tac ccc gac aac ctg acc tac cgc gat ctc tac tac ttc 768 Thr Val Ser Tyr Pro Asp Asn Leu Thr Tyr Arg Asp Leu Tyr Tyr Phe 245 250 255 ctc ttc gcc ccc acc ctg tgc tac gag ctc aac ttc ccc cgc tcc ccc 816 Leu Phe Ala Pro Thr Leu Cys Tyr Glu Leu Asn Phe Pro Arg Ser Pro 260 265 270 cgc atc cga aag cgc ttc ctg ctg cgg cga ctc ctg gag atg ctg ttc 864 Arg Ile Arg Lys Arg Phe Leu Leu Arg Arg Leu Leu Glu Met Leu Phe 275 280 285 ctc acc cag ctc cag gtg ggg ctg atc cag cag tgg atg gtc ccg gcc 912 Leu Thr Gln Leu Gln Val Gly Leu Ile Gln Gln Trp Met Val Pro Ala 290 295 300 atc cag aac tcc atg aag ccc ttc aag gac atg gac tac tcc cgc atc 960 Ile Gln Asn Ser Met Lys Pro Phe Lys Asp Met Asp Tyr Ser Arg Ile 305 310 315 320 gtg gag cgc ctc ctg aag ctg gcg gtc ccc aac cac ctc atc tgg ctc 1008 Val Glu Arg Leu Leu Lys Leu Ala Val Pro Asn His Leu Ile Trp Leu 325 330 335 atc ttc ttc tac tgg ctc ttc cac tcc tgc ctg aac gcc gtg gct gag 1056 Ile Phe Phe Tyr Trp Leu Phe His Ser Cys Leu Asn Ala Val Ala Glu 340 345 350 ctc atg cag ttt gga gac cgc gag ttc tac cgg gac tgg tgg aac tcc 1104 Leu Met Gln Phe Gly Asp Arg Glu Phe Tyr Arg Asp Trp Trp Asn Ser 355 360 365 gag tcc atc acc tac ttc tgg cag aac tgg aac atc cct gtt cac aag 1152 Glu Ser Ile Thr Tyr Phe Trp Gln Asn Trp Asn Ile Pro Val His Lys 370 375 380 tgg tgc atc aga cac ttc tac aag ccc atg ctc cgg cgg ggc agc agc 1200 Trp Cys Ile Arg His Phe Tyr Lys Pro Met Leu Arg Arg Gly Ser Ser 385 390 395 400 aag tgg gca gcc agg acg gca gtg ttt ctg gcc tcc gcc ttc ttc cac 1248 Lys Trp Ala Ala Arg Thr Ala Val Phe Leu Ala Ser Ala Phe Phe His 405 410 415 gag tac ctg gtg agc atc ccc ctg gga atg ttc cgc ctc tgg gcc ttc 1296 Glu Tyr Leu Val Ser Ile Pro Leu Gly Met Phe Arg Leu Trp Ala Phe 420 425 430 acc ggc atg atg gcg cag atc ccg ctg gcc tgg ata gtg ggc cgc ttc 1344 Thr Gly Met Met Ala Gln Ile Pro Leu Ala Trp Ile Val Gly Arg Phe 435 440 445 ttc cgc ggc aac tac ggc aac gcg gcc gtg tgg ctg tca ctc atc atc 1392 Phe Arg Gly Asn Tyr Gly Asn Ala Ala Val Trp Leu Ser Leu Ile Ile 450 455 460 ggg cag ccg gtg gcc gtc ctg atg tac gtc cac gac tac tac gtg ctc 1440 Gly Gln Pro Val Ala Val Leu Met Tyr Val His Asp Tyr Tyr Val Leu 465 470 475 480 aac cgt gag gcg ccg gca gcc ggc acc tga 1470 Asn Arg Glu Ala Pro Ala Ala Gly Thr * 485 5 1497 DNA Caenorhabditis elegans CDS (1)...(1497) Caenorhabditis elegans diacylglycerol acyltransferase coding sequence 5 atg caa atg cgt caa caa acg gga cga cgg cgg cgt cag cct tcg gaa 48 Met Gln Met Arg Gln Gln Thr Gly Arg Arg Arg Arg Gln Pro Ser Glu 1 5 10 15 aca tct aat ggt tct ttg gct tcc agt aga cgc tcc tca ttt gca caa 96 Thr Ser Asn Gly Ser Leu Ala Ser Ser Arg Arg Ser Ser Phe Ala Gln 20 25 30 aat ggt aat tcg tca agg aaa agt tca gaa atg aga ggg cct tgc gag 144 Asn Gly Asn Ser Ser Arg Lys Ser Ser Glu Met Arg Gly Pro Cys Glu 35 40 45 aaa gtg gta cat act gct caa gat tca ttg ttt tcg acg agt tct gga 192 Lys Val Val His Thr Ala Gln Asp Ser Leu Phe Ser Thr Ser Ser Gly 50 55 60 tgg aca aat ttc cgt gga ttc ttc aat ttg tct att tta ctt ttg gta 240 Trp Thr Asn Phe Arg Gly Phe Phe Asn Leu Ser Ile Leu Leu Leu Val 65 70 75 80 ctt tca aat gga cgc gtg gca ctt gaa aat gtg atc aaa tat ggt att 288 Leu Ser Asn Gly Arg Val Ala Leu Glu Asn Val Ile Lys Tyr Gly Ile 85 90 95 ttg ata aca ccc ctt cag tgg atc tca acg ttt gtt gag cat cac tac 336 Leu Ile Thr Pro Leu Gln Trp Ile Ser Thr Phe Val Glu His His Tyr 100 105 110 tca att tgg agc tgg cca aat ctt gct ctc atc cta tgc tca aat att 384 Ser Ile Trp Ser Trp Pro Asn Leu Ala Leu Ile Leu Cys Ser Asn Ile 115 120 125 cag att ctc tcg gtt ttt gga atg gaa aaa att ctt gaa cgt gga tgg 432 Gln Ile Leu Ser Val Phe Gly Met Glu Lys Ile Leu Glu Arg Gly Trp 130 135 140 ctt gga aac gga ttc gct gca gtg ttc tac acc tcg ctt gtg att gca 480 Leu Gly Asn Gly Phe Ala Ala Val Phe Tyr Thr Ser Leu Val Ile Ala 145 150 155 160 cat ctg aca att cca gtt gtg gtc act ctt acc cac aaa tgg aag aat 528 His Leu Thr Ile Pro Val Val Val Thr Leu Thr His Lys Trp Lys Asn 165 170 175 cct ttg tgg tca gtc gta atg atg ggt gtt tat gtt att gaa gct ctc 576 Pro Leu Trp Ser Val Val Met Met Gly Val Tyr Val Ile Glu Ala Leu 180 185 190 aaa ttc atc tca tat ggc cac gtc aac tac tgg gct cgt gat gct cgg 624 Lys Phe Ile Ser Tyr Gly His Val Asn Tyr Trp Ala Arg Asp Ala Arg 195 200 205 cga aaa atc aca gag ctc aaa aca caa gtc acc gat ttg gca aag aaa 672 Arg Lys Ile Thr Glu Leu Lys Thr Gln Val Thr Asp Leu Ala Lys Lys 210 215 220 aca tgt gat ccg aaa caa ttt tgg gat ttg aaa gat gaa tta tca atg 720 Thr Cys Asp Pro Lys Gln Phe Trp Asp Leu Lys Asp Glu Leu Ser Met 225 230 235 240 cat cag atg gct gct caa tat cct gcc aat ttg aca ctt tcc aat atc 768 His Gln Met Ala Ala Gln Tyr Pro Ala Asn Leu Thr Leu Ser Asn Ile 245 250 255 tac tac ttc atg gct gca cca aca ttg tgc tac gaa ttc aaa ttt cca 816 Tyr Tyr Phe Met Ala Ala Pro Thr Leu Cys Tyr Glu Phe Lys Phe Pro 260 265 270 aga ttg ttg cga att cgg aag cac ttt ttg att aaa aga acc gtg gag 864 Arg Leu Leu Arg Ile Arg Lys His Phe Leu Ile Lys Arg Thr Val Glu 275 280 285 ctt atc ttt cta tcg ttt ttg ata gct gca ctt gtt caa caa tgg gtt 912 Leu Ile Phe Leu Ser Phe Leu Ile Ala Ala Leu Val Gln Gln Trp Val 290 295 300 gtt ccg act gtc cga aat agt atg aaa cct tta agt gaa atg gaa tac 960 Val Pro Thr Val Arg Asn Ser Met Lys Pro Leu Ser Glu Met Glu Tyr 305 310 315 320 tct aga tgt ttg gaa cga ctc ttg aaa ctt gca att cca aat cat ctc 1008 Ser Arg Cys Leu Glu Arg Leu Leu Lys Leu Ala Ile Pro Asn His Leu 325 330 335 atc tgg ctt cta ttc ttc tac aca ttc ttc cat tca ttt ttg aac ttg 1056 Ile Trp Leu Leu Phe Phe Tyr Thr Phe Phe His Ser Phe Leu Asn Leu 340 345 350 atc gcc gag ctg ctt cga ttt gcc gat cgt gag ttc tac aga gac ttt 1104 Ile Ala Glu Leu Leu Arg Phe Ala Asp Arg Glu Phe Tyr Arg Asp Phe 355 360 365 tgg aat gca gag acg ata gga tat ttc tgg aaa tca tgg aac atc cca 1152 Trp Asn Ala Glu Thr Ile Gly Tyr Phe Trp Lys Ser Trp Asn Ile Pro 370 375 380 gtt cac cga ttt gct gtt cgc cac atc tac agt cca atg atg cgt aac 1200 Val His Arg Phe Ala Val Arg His Ile Tyr Ser Pro Met Met Arg Asn 385 390 395 400 aat ttc tca aaa atg agc gca ttc ttc gtt gtg ttc ttc gtg tcg gca 1248 Asn Phe Ser Lys Met Ser Ala Phe Phe Val Val Phe Phe Val Ser Ala 405 410 415 ttc ttc cat gaa tat ctg gtt tct gtg cca tta aag att ttc cga ttg 1296 Phe Phe His Glu Tyr Leu Val Ser Val Pro Leu Lys Ile Phe Arg Leu 420 425 430 tgg tcc tac tat gga atg atg gga caa att cct cta tcc att atc act 1344 Trp Ser Tyr Tyr Gly Met Met Gly Gln Ile Pro Leu Ser Ile Ile Thr 435 440 445 gat aaa gtg gtg aga ggt gga cgt aca gga aac atc atc gtc tgg ctc 1392 Asp Lys Val Val Arg Gly Gly Arg Thr Gly Asn Ile Ile Val Trp Leu 450 455 460 tca ctg att gtt ggc caa cct ctt gca att ctc atg tac gga cat gat 1440 Ser Leu Ile Val Gly Gln Pro Leu Ala Ile Leu Met Tyr Gly His Asp 465 470 475 480 tgg tac att ttg aac ttt ggt gtt tca gca gtt caa aac caa acc gtt 1488 Trp Tyr Ile Leu Asn Phe Gly Val Ser Ala Val Gln Asn Gln Thr Val 485 490 495 ggt att tga 1497 Gly Ile * 6 1698 DNA Drosophila melanogaster CDS (1)...(1698) Drosophila melanogaster clone 12 acyl coenzyme Adiacylglycerol acyltransferase coding sequence 6 atg act acc aat aag gat ccc caa gat aag gag ccc ggg aaa gca gaa 48 Met Thr Thr Asn Lys Asp Pro Gln Asp Lys Glu Pro Gly Lys Ala Glu 1 5 10 15 caa ccg acc aag aat agc gga tcc agc gga gtg ggt atc atg aag cgc 96 Gln Pro Thr Lys Asn Ser Gly Ser Ser Gly Val Gly Ile Met Lys Arg 20 25 30 ttg aga aga tcg gcg tcc gcc aca gag cat aat ctt agc agt ctg cga 144 Leu Arg Arg Ser Ala Ser Ala Thr Glu His Asn Leu Ser Ser Leu Arg 35 40 45 aac cgc aag tca aca caa aat cta ttc gat cag cac ggg aat ccc ata 192 Asn Arg Lys Ser Thr Gln Asn Leu Phe Asp Gln His Gly Asn Pro Ile 50 55 60 gat ctg cga cag tat cgt aaa gtt ttg gat aag gat gaa aat ggt aat 240 Asp Leu Arg Gln Tyr Arg Lys Val Leu Asp Lys Asp Glu Asn Gly Asn 65 70 75 80 gga acc aac gga tcc gag aag aag ctt aga tac agg aga aca caa agt 288 Gly Thr Asn Gly Ser Glu Lys Lys Leu Arg Tyr Arg Arg Thr Gln Ser 85 90 95 gtg act cgt gct gag gag att tcc aat aaa gag gag aag cag aga aga 336 Val Thr Arg Ala Glu Glu Ile Ser Asn Lys Glu Glu Lys Gln Arg Arg 100 105 110 gct cag cct ggc aga cca atc cat cgg cca aga gat tct ctg ttt tct 384 Ala Gln Pro Gly Arg Pro Ile His Arg Pro Arg Asp Ser Leu Phe Ser 115 120 125 tgg agc tct gga ttt acc aat ttt tct gga ctg gtg aac tgg gga ttt 432 Trp Ser Ser Gly Phe Thr Asn Phe Ser Gly Leu Val Asn Trp Gly Phe 130 135 140 cta ctg ctc tgc att gga ggt ctg cgt ttg ggc ttg gag aat ctc cta 480 Leu Leu Leu Cys Ile Gly Gly Leu Arg Leu Gly Leu Glu Asn Leu Leu 145 150 155 160 aag tat ggc att cgc atc aat cca ctg gat tgg ttc ttc ttc ata agc 528 Lys Tyr Gly Ile Arg Ile Asn Pro Leu Asp Trp Phe Phe Phe Ile Ser 165 170 175 gga cac aac gaa ggc gaa gga cat aac gcc cta atc ctg agc att tac 576 Gly His Asn Glu Gly Glu Gly His Asn Ala Leu Ile Leu Ser Ile Tyr 180 185 190 tct tta gtg cat atc tcg ctc tgt ttg gct gtg gag aag ggt cta gcc 624 Ser Leu Val His Ile Ser Leu Cys Leu Ala Val Glu Lys Gly Leu Ala 195 200 205 atg gaa ata att gca gag ggc ttg ggc ttg ttc atc cag ata gtg aac 672 Met Glu Ile Ile Ala Glu Gly Leu Gly Leu Phe Ile Gln Ile Val Asn 210 215 220 att gtt gtc ttg gtt tgc cta ccg gtg gta aca att cac cta aaa gga 720 Ile Val Val Leu Val Cys Leu Pro Val Val Thr Ile His Leu Lys Gly 225 230 235 240 cat gct ttt agt ttg atg ggc gct tca aca gtt tgc ttc ttt tac tct 768 His Ala Phe Ser Leu Met Gly Ala Ser Thr Val Cys Phe Phe Tyr Ser 245 250 255 gtg ttg ttc cta aaa cta tgg tcc tat gtg cag acg aat atg tgg tgc 816 Val Leu Phe Leu Lys Leu Trp Ser Tyr Val Gln Thr Asn Met Trp Cys 260 265 270 cgt cag act tat tat caa aag aat ccg cgg gag cgt cga cca agc ata 864 Arg Gln Thr Tyr Tyr Gln Lys Asn Pro Arg Glu Arg Arg Pro Ser Ile 275 280 285 act ttg gcg gaa cta aaa aaa gga gtt ttg aat gga ggt gaa gaa gac 912 Thr Leu Ala Glu Leu Lys Lys Gly Val Leu Asn Gly Gly Glu Glu Asp 290 295 300 gag gac gtt tcc aag ctg gtg caa tat cct gat aat ctc aca tac aat 960 Glu Asp Val Ser Lys Leu Val Gln Tyr Pro Asp Asn Leu Thr Tyr Asn 305 310 315 320 gat ctc ctg tac ttc ctt tgc gcg ccc act ctc tgc tat gag ttg aat 1008 Asp Leu Leu Tyr Phe Leu Cys Ala Pro Thr Leu Cys Tyr Glu Leu Asn 325 330 335 ttc ccg cga act tct cgc gtg cgc aaa cgc ttt ttg ctg aag cgt tta 1056 Phe Pro Arg Thr Ser Arg Val Arg Lys Arg Phe Leu Leu Lys Arg Leu 340 345 350 ttg gag gtg gtg att gga gtg aat gtg gtt atg gcc ttg ttt caa caa 1104 Leu Glu Val Val Ile Gly Val Asn Val Val Met Ala Leu Phe Gln Gln 355 360 365 tgg atc att cca tcg gtt cgg aac tcc ctg att ccg ttc tcc aat atg 1152 Trp Ile Ile Pro Ser Val Arg Asn Ser Leu Ile Pro Phe Ser Asn Met 370 375 380 gac gtg gcc tta gcc act gag cga ctt ctt aaa ctt gcg cta ccc aat 1200 Asp Val Ala Leu Ala Thr Glu Arg Leu Leu Lys Leu Ala Leu Pro Asn 385 390 395 400 cat ctt tgc tgg ctc tgc ttt ttc tat cta atg ttc cac tct ttt ctt 1248 His Leu Cys Trp Leu Cys Phe Phe Tyr Leu Met Phe His Ser Phe Leu 405 410 415 aat gcg gtc ggc gaa ctg ctg aac ttt gca gat cgc aat ttt tat tgt 1296 Asn Ala Val Gly Glu Leu Leu Asn Phe Ala Asp Arg Asn Phe Tyr Cys 420 425 430 gat tgg tgg aat gcg aat aac att gac acc ttc tgg cgt aca tgg aac 1344 Asp Trp Trp Asn Ala Asn Asn Ile Asp Thr Phe Trp Arg Thr Trp Asn 435 440 445 atg cca gtt cat agg tgg tgc gtg cgt cat ctc tac atc cct gtg gtc 1392 Met Pro Val His Arg Trp Cys Val Arg His Leu Tyr Ile Pro Val Val 450 455 460 caa atg gga tat tcc tca aga cag gcc tct act att gtc ttt ctt ttc 1440 Gln Met Gly Tyr Ser Ser Arg Gln Ala Ser Thr Ile Val Phe Leu Phe 465 470 475 480 agt gcc gtc ttc cat gaa tat ttg gtt tca gtt cct ttg caa ata tac 1488 Ser Ala Val Phe His Glu Tyr Leu Val Ser Val Pro Leu Gln Ile Tyr 485 490 495 aag atc tgg gca ttt atg ggc atg atg ggt cag att ccc cta tcg gcc 1536 Lys Ile Trp Ala Phe Met Gly Met Met Gly Gln Ile Pro Leu Ser Ala 500 505 510 ata tcc aaa tcc att gaa aag aaa ctg ggt ccc cga atg ggc aat ata 1584 Ile Ser Lys Ser Ile Glu Lys Lys Leu Gly Pro Arg Met Gly Asn Ile 515 520 525 atc gtg tgg gct tcc att att ctt ggt cag cct ctg tgc ata atg gcc 1632 Ile Val Trp Ala Ser Ile Ile Leu Gly Gln Pro Leu Cys Ile Met Ala 530 535 540 tat tat cac gat tat gtc gtc cag cat ttc aaa aac tcg ctc aac ggc 1680 Tyr Tyr His Asp Tyr Val Val Gln His Phe Lys Asn Ser Leu Asn Gly 545 550 555 560 acc gac tac agt agt tag 1698 Thr Asp Tyr Ser Ser * 565 7 1470 DNA Sus scrofa CDS (1)...(1470) Sus scrofa diacylglycerol acyltransferase (DGAT) coding sequence 7 atg ggt gac cgc agc ggc gcg ggc ggc tcc cgg cgc cgg agg acg ggg 48 Met Gly Asp Arg Ser Gly Ala Gly Gly Ser Arg Arg Arg Arg Thr Gly 1 5 10 15 tcg cgg ccc tcc agc cag agc ggc agc ggg ttc gcg gcc gca gaa gag 96 Ser Arg Pro Ser Ser Gln Ser Gly Ser Gly Phe Ala Ala Ala Glu Glu 20 25 30 gag gtg cgg gac gta ggc gcc ggg ggg gac gca ccg acg ccg gac aag 144 Glu Val Arg Asp Val Gly Ala Gly Gly Asp Ala Pro Thr Pro Asp Lys 35 40 45 gac aag gac gga cac gac gat gtg agc agc ggc cac tgg gat ctg agg 192 Asp Lys Asp Gly His Asp Asp Val Ser Ser Gly His Trp Asp Leu Arg 50 55 60 tgc cac cgc ctg cag gat tct ttg ttc agt tca gac agt ggt ttc agc 240 Cys His Arg Leu Gln Asp Ser Leu Phe Ser Ser Asp Ser Gly Phe Ser 65 70 75 80 aac tac cgt ggc atc ctg aat tgg tgt gtg gtc atg ctg gtc ttg agc 288 Asn Tyr Arg Gly Ile Leu Asn Trp Cys Val Val Met Leu Val Leu Ser 85 90 95 aat gca cgg ctg ttt cta gag aac ctc atc aag tac ggc atc ctg gta 336 Asn Ala Arg Leu Phe Leu Glu Asn Leu Ile Lys Tyr Gly Ile Leu Val 100 105 110 gac ccc atc cag gtg gtg tct ctg ttc ctg aag gac ccc tat agc tgg 384 Asp Pro Ile Gln Val Val Ser Leu Phe Leu Lys Asp Pro Tyr Ser Trp 115 120 125 cct gcc ctg tgc ctg gtt att gtg gcc aat gtc ttt gct gtg act gcg 432 Pro Ala Leu Cys Leu Val Ile Val Ala Asn Val Phe Ala Val Thr Ala 130 135 140 ttc cag gtg gag aag cgc ctg gcc gtg ggt gcc ctg acc gag cag gcg 480 Phe Gln Val Glu Lys Arg Leu Ala Val Gly Ala Leu Thr Glu Gln Ala 145 150 155 160 ggg ctg ctg atc cac gtg gcc aac ctg gcc acc atc ctc tgc ttc cca 528 Gly Leu Leu Ile His Val Ala Asn Leu Ala Thr Ile Leu Cys Phe Pro 165 170 175 gcg gcc gtg gct ttc ctg ctg gag tcc atc act cca gtg ggc tcc ctg 576 Ala Ala Val Ala Phe Leu Leu Glu Ser Ile Thr Pro Val Gly Ser Leu 180 185 190 ctg gct ctg atg gtc tac gcc atc ctc ttc ctc aag ctg ttc tcc tac 624 Leu Ala Leu Met Val Tyr Ala Ile Leu Phe Leu Lys Leu Phe Ser Tyr 195 200 205 cgg gac gtc aac ctg tgg tgc cga gag cgc agg gct act gcc aag gcc 672 Arg Asp Val Asn Leu Trp Cys Arg Glu Arg Arg Ala Thr Ala Lys Ala 210 215 220 aag gcc gct tct gca ggt aag aag gcc aac ggg ggc gcc gcc cag cac 720 Lys Ala Ala Ser Ala Gly Lys Lys Ala Asn Gly Gly Ala Ala Gln His 225 230 235 240 agc gtg agc tac ccc gac aac ctg acc tac cgc gat ctc tac tac ttc 768 Ser Val Ser Tyr Pro Asp Asn Leu Thr Tyr Arg Asp Leu Tyr Tyr Phe 245 250 255 ctc ctg gcc ccg act ctg tgc tac gag ctc aac ttt tcc cgc ttc ccg 816 Leu Leu Ala Pro Thr Leu Cys Tyr Glu Leu Asn Phe Ser Arg Phe Pro 260 265 270 cgc atc cga aag cgc ttc ctg ctg cgg cgg ctc ctg gag atg ctg ttc 864 Arg Ile Arg Lys Arg Phe Leu Leu Arg Arg Leu Leu Glu Met Leu Phe 275 280 285 ctc atc cag ctg cag gtg ggg ctg atc cag cag tgg atg gtc ccc acc 912 Leu Ile Gln Leu Gln Val Gly Leu Ile Gln Gln Trp Met Val Pro Thr 290 295 300 atc cag aac tcc atg aag ccc ttc aag gac atg gac tac tca cgc atc 960 Ile Gln Asn Ser Met Lys Pro Phe Lys Asp Met Asp Tyr Ser Arg Ile 305 310 315 320 atc gag cgc ctc ctg aag ctg gcg gtg ccc aac cac ctc atc tgg ctc 1008 Ile Glu Arg Leu Leu Lys Leu Ala Val Pro Asn His Leu Ile Trp Leu 325 330 335 atc ttc ttc tac tgg ctc ttc cac tcc tgc ctg aac gct gtg gct gag 1056 Ile Phe Phe Tyr Trp Leu Phe His Ser Cys Leu Asn Ala Val Ala Glu 340 345 350 ctc atg cag ttt gga gac cgg gag ttc tac cgg gac tgg tgg aac tcg 1104 Leu Met Gln Phe Gly Asp Arg Glu Phe Tyr Arg Asp Trp Trp Asn Ser 355 360 365 gag tct gtc acc tac ttc tgg cag aac tgg aac atc cct gta cac aag 1152 Glu Ser Val Thr Tyr Phe Trp Gln Asn Trp Asn Ile Pro Val His Lys 370 375 380 tgg tgc ctc aga cac ttc tac aag ccc atg ctc cgg cgg ggc agc agc 1200 Trp Cys Leu Arg His Phe Tyr Lys Pro Met Leu Arg Arg Gly Ser Ser 385 390 395 400 aag tgg gta gcc agg atg ggg gtg ttc ctg gct tca gcc ttc ttc cac 1248 Lys Trp Val Ala Arg Met Gly Val Phe Leu Ala Ser Ala Phe Phe His 405 410 415 gag tac ctg gtg agc atc cct ctg cgc atg ttc cgc ctc tgg gcc ttc 1296 Glu Tyr Leu Val Ser Ile Pro Leu Arg Met Phe Arg Leu Trp Ala Phe 420 425 430 acg ggc atg atg gct cag atc ccg ctg gct tgg ata gtg ggc cgc ttc 1344 Thr Gly Met Met Ala Gln Ile Pro Leu Ala Trp Ile Val Gly Arg Phe 435 440 445 ttc cgt ggc aac tac ggc aac gcg gct gtg tgg ctg tcg ctc atc atc 1392 Phe Arg Gly Asn Tyr Gly Asn Ala Ala Val Trp Leu Ser Leu Ile Ile 450 455 460 ggg cag ccg gtg gcc gtg ctc atg tac gtc cat gac tac tac gtg ctc 1440 Gly Gln Pro Val Ala Val Leu Met Tyr Val His Asp Tyr Tyr Val Leu 465 470 475 480 cac cac gag gcc ccg aca gcg ggg gcc tga 1470 His His Glu Ala Pro Thr Ala Gly Ala * 485 8 1167 DNA Homo sapiens CDS (1)...(1167) Homo sapiens DGAT 2 coding sequence 8 atg aag acc ctc ata gcc gcc tac tcc ggg gtc ctg cgc ggc gag cgt 48 Met Lys Thr Leu Ile Ala Ala Tyr Ser Gly Val Leu Arg Gly Glu Arg 1 5 10 15 cag gcc gag gct gac cgg agc cag cgc tct cac gga gga cct gcg ctg 96 Gln Ala Glu Ala Asp Arg Ser Gln Arg Ser His Gly Gly Pro Ala Leu 20 25 30 tcg cgc gag ggg tct ggg aga tgg ggc act gga tcc agc atc ctc tcc 144 Ser Arg Glu Gly Ser Gly Arg Trp Gly Thr Gly Ser Ser Ile Leu Ser 35 40 45 gcc ctc cag gac ctc ttc tct gtc acc tgg ctc aat agg tcc aag gtg 192 Ala Leu Gln Asp Leu Phe Ser Val Thr Trp Leu Asn Arg Ser Lys Val 50 55 60 gaa aag cag cta cag gtc atc tca gtg ctc cag tgg gtc ctg tcc ttc 240 Glu Lys Gln Leu Gln Val Ile Ser Val Leu Gln Trp Val Leu Ser Phe 65 70 75 80 ctt gta ctg gga gtg gcc tgc agt gcc atc ctc atg tac ata ttc tgc 288 Leu Val Leu Gly Val Ala Cys Ser Ala Ile Leu Met Tyr Ile Phe Cys 85 90 95 act gat tgc tgg ctc atc gct gtg ctc tac ttc act tgg ctg gtg ttt 336 Thr Asp Cys Trp Leu Ile Ala Val Leu Tyr Phe Thr Trp Leu Val Phe 100 105 110 gac tgg aac aca ccc aag aaa ggt ggc agg agg tca cag tgg gtc cga 384 Asp Trp Asn Thr Pro Lys Lys Gly Gly Arg Arg Ser Gln Trp Val Arg 115 120 125 aac tgg gct gtg tgg cgc tac ttt cga gac tac ttt ccc atc cag ctg 432 Asn Trp Ala Val Trp Arg Tyr Phe Arg Asp Tyr Phe Pro Ile Gln Leu 130 135 140 gtg aag aca cac aac ctg ctg acc acc agg aac tat atc ttt gga tac 480 Val Lys Thr His Asn Leu Leu Thr Thr Arg Asn Tyr Ile Phe Gly Tyr 145 150 155 160 cac ccc cat ggt atc atg ggc ctg ggt gcc ttc tgc aac ttc agc aca 528 His Pro His Gly Ile Met Gly Leu Gly Ala Phe Cys Asn Phe Ser Thr 165 170 175 gag gcc aca gaa gtg agc aag aag ttc cca ggc ata cgg cct tac ctg 576 Glu Ala Thr Glu Val Ser Lys Lys Phe Pro Gly Ile Arg Pro Tyr Leu 180 185 190 gct aca ctg gca ggc aac ttc cga atg cct gtg ttg agg gag tac ctg 624 Ala Thr Leu Ala Gly Asn Phe Arg Met Pro Val Leu Arg Glu Tyr Leu 195 200 205 atg tct gga ggt atc tgc cct gtc agc cgg gac acc ata gac tat ttg 672 Met Ser Gly Gly Ile Cys Pro Val Ser Arg Asp Thr Ile Asp Tyr Leu 210 215 220 ctt tca aag aat ggg agt ggc aat gct atc atc atc gtg gtc ggg ggt 720 Leu Ser Lys Asn Gly Ser Gly Asn Ala Ile Ile Ile Val Val Gly Gly 225 230 235 240 gcg gct gag tct ctg agc tcc atg cct ggc aag aat gca gtc acc ctg 768 Ala Ala Glu Ser Leu Ser Ser Met Pro Gly Lys Asn Ala Val Thr Leu 245 250 255 cgg aac cgc aag ggc ttt gtg aaa ctg gcc ctg cgt cat gga gct gac 816 Arg Asn Arg Lys Gly Phe Val Lys Leu Ala Leu Arg His Gly Ala Asp 260 265 270 ctg gtt ccc atc tac tcc ttt gga gag aat gaa gtg tac aag cag gtg 864 Leu Val Pro Ile Tyr Ser Phe Gly Glu Asn Glu Val Tyr Lys Gln Val 275 280 285 atc ttc gag gag ggc tcc tgg ggc cga tgg gtc cag aag aag ttc cag 912 Ile Phe Glu Glu Gly Ser Trp Gly Arg Trp Val Gln Lys Lys Phe Gln 290 295 300 aaa tac att ggt ttc gcc cca tgc atc ttc cat ggt cga ggc ctc ttc 960 Lys Tyr Ile Gly Phe Ala Pro Cys Ile Phe His Gly Arg Gly Leu Phe 305 310 315 320 tcc tcc gac acc tgg ggg ctg gtg ccc tac tcc aag ccc atc acc act 1008 Ser Ser Asp Thr Trp Gly Leu Val Pro Tyr Ser Lys Pro Ile Thr Thr 325 330 335 gtt gtg gga gag ccc atc acc atc ccc aag ctg gag cac cca acc cag 1056 Val Val Gly Glu Pro Ile Thr Ile Pro Lys Leu Glu His Pro Thr Gln 340 345 350 caa gac atc gac ctg tac cac acc atg tac atg gag gcc ctg gtg aag 1104 Gln Asp Ile Asp Leu Tyr His Thr Met Tyr Met Glu Ala Leu Val Lys 355 360 365 ctc ttc gac aag cac aag acc aag ttc ggc ctc ccg gag act gag gtc 1152 Leu Phe Asp Lys His Lys Thr Lys Phe Gly Leu Pro Glu Thr Glu Val 370 375 380 ctg gag gtg aac tga 1167 Leu Glu Val Asn * 385 9 1467 DNA Homo sapiens CDS (1)...(1467) Homo sapiens diacylglycerol O-acyltransferase homolog 1 (DGAT1), coding sequence 9 atg ggc gac cgc ggc agc tcc cgg cgc cgg agg aca ggg tcg cgg ccc 48 Met Gly Asp Arg Gly Ser Ser Arg Arg Arg Arg Thr Gly Ser Arg Pro 1 5 10 15 tcg agc cac ggc ggc ggc ggg cct gcg gcg gcg gaa gaa gag gtg cgg 96 Ser Ser His Gly Gly Gly Gly Pro Ala Ala Ala Glu Glu Glu Val Arg 20 25 30 gac gcc gct gcg ggc ccc gac gtg gga gcc gcg ggg gac gcg cca gcc 144 Asp Ala Ala Ala Gly Pro Asp Val Gly Ala Ala Gly Asp Ala Pro Ala 35 40 45 ccg gcc ccc aac aag gac gga gac gcc ggc gtg ggc agc ggc cac tgg 192 Pro Ala Pro Asn Lys Asp Gly Asp Ala Gly Val Gly Ser Gly His Trp 50 55 60 gag ctg agg tgc cat cgc ctg cag gat tct tta ttc agc tct gac agt 240 Glu Leu Arg Cys His Arg Leu Gln Asp Ser Leu Phe Ser Ser Asp Ser 65 70 75 80 ggc ttc agc aac tac cgt ggc atc ctg aac tgg tgt gtg gtg atg ctg 288 Gly Phe Ser Asn Tyr Arg Gly Ile Leu Asn Trp Cys Val Val Met Leu 85 90 95 atc ttg agc aat gcc cgg tta ttt ctg gag aac ctc atc aag tat ggc 336 Ile Leu Ser Asn Ala Arg Leu Phe Leu Glu Asn Leu Ile Lys Tyr Gly 100 105 110 atc ctg gtg gac ccc atc cag gtg gtt tct ctg ttc ctg aag gat ccc 384 Ile Leu Val Asp Pro Ile Gln Val Val Ser Leu Phe Leu Lys Asp Pro 115 120 125 cat agc tgg ccc gcc cca tgc ctg gtt att gcg gcc aat gtc ttt gct 432 His Ser Trp Pro Ala Pro Cys Leu Val Ile Ala Ala Asn Val Phe Ala 130 135 140 gtg gct gca ttc cag gtt gag aag cgc ctg gcg gtg ggt gcc ctg acg 480 Val Ala Ala Phe Gln Val Glu Lys Arg Leu Ala Val Gly Ala Leu Thr 145 150 155 160 gag cag gcg gga ctg ctg ctg cac gta gcc aac ctg gcc acc att ctg 528 Glu Gln Ala Gly Leu Leu Leu His Val Ala Asn Leu Ala Thr Ile Leu 165 170 175 tgt ttc cca gcg gct gtg gtc tta ctg gtt gag tct atc act cca gtg 576 Cys Phe Pro Ala Ala Val Val Leu Leu Val Glu Ser Ile Thr Pro Val 180 185 190 ggc tcc ctg ctg gcg ctg atg gcg cac acc atc ctc ttc ctc aag ctc 624 Gly Ser Leu Leu Ala Leu Met Ala His Thr Ile Leu Phe Leu Lys Leu 195 200 205 ttc tcc tac cgc gac gtc aac tca tgg tgc cgc agg gcc agg gcc aag 672 Phe Ser Tyr Arg Asp Val Asn Ser Trp Cys Arg Arg Ala Arg Ala Lys 210 215 220 gct gcc tct gca ggg aag aag gcc agc agt gct gct gcc ccg cac acc 720 Ala Ala Ser Ala Gly Lys Lys Ala Ser Ser Ala Ala Ala Pro His Thr 225 230 235 240 gtg agc tac ccg gac aat ctg acc tac cgc gat ctc tac tac ttc ctc 768 Val Ser Tyr Pro Asp Asn Leu Thr Tyr Arg Asp Leu Tyr Tyr Phe Leu 245 250 255 ttc gcc ccc acc ttg tgc tac gag ctc aac ttt ccc cgc tct ccc cgc 816 Phe Ala Pro Thr Leu Cys Tyr Glu Leu Asn Phe Pro Arg Ser Pro Arg 260 265 270 atc cgg aag cgc ttt ctg ctg cga cgg atc ctt gag atg ctg ttc ttc 864 Ile Arg Lys Arg Phe Leu Leu Arg Arg Ile Leu Glu Met Leu Phe Phe 275 280 285 acc cag ctc cag gtg ggg ctg atc cag cag tgg atg gtc ccc acc atc 912 Thr Gln Leu Gln Val Gly Leu Ile Gln Gln Trp Met Val Pro Thr Ile 290 295 300 cag aac tcc atg aag ccc ttc aag gac atg gac tac tca cgc atc atc 960 Gln Asn Ser Met Lys Pro Phe Lys Asp Met Asp Tyr Ser Arg Ile Ile 305 310 315 320 gag cgc ctc ctg aag ctg gcg gtc ccc aat cac ctc atc tgg ctc atc 1008 Glu Arg Leu Leu Lys Leu Ala Val Pro Asn His Leu Ile Trp Leu Ile 325 330 335 ttc ttc tac tgg ctc ttc cac tcc tgc ctg aat gcc gtg gct gag ctc 1056 Phe Phe Tyr Trp Leu Phe His Ser Cys Leu Asn Ala Val Ala Glu Leu 340 345 350 atg cag ttt gga gac cgg gag ttc tac cgg gac tgg tgg aac tcc gag 1104 Met Gln Phe Gly Asp Arg Glu Phe Tyr Arg Asp Trp Trp Asn Ser Glu 355 360 365 tct gtc acc tac ttc tgg cag aac tgg aac atc cct gtg cac aag tgg 1152 Ser Val Thr Tyr Phe Trp Gln Asn Trp Asn Ile Pro Val His Lys Trp 370 375 380 tgc atc aga cac ttc tac aag ccc atg ctt cga cgg ggc agc agc aag 1200 Cys Ile Arg His Phe Tyr Lys Pro Met Leu Arg Arg Gly Ser Ser Lys 385 390 395 400 tgg atg gcc agg aca ggg gtg ttc ctg gcc tcg gct ttc ttc cac gag 1248 Trp Met Ala Arg Thr Gly Val Phe Leu Ala Ser Ala Phe Phe His Glu 405 410 415 tac ctg gtg agc gtc cct ctg cga atg ttc cgc ctc tgg gct ttc acg 1296 Tyr Leu Val Ser Val Pro Leu Arg Met Phe Arg Leu Trp Ala Phe Thr 420 425 430 ggc atg atg gct cag atc cca ctg gcc tgg ttc gtg ggc cgc ttt ttc 1344 Gly Met Met Ala Gln Ile Pro Leu Ala Trp Phe Val Gly Arg Phe Phe 435 440 445 cag ggc aac tat ggc aac gca gct gtg tgg ctg tcg ctc atc atc gga 1392 Gln Gly Asn Tyr Gly Asn Ala Ala Val Trp Leu Ser Leu Ile Ile Gly 450 455 460 cag cca ata gcc gtc ctc atg tac gtc cac gac tac tac gtg ctc aac 1440 Gln Pro Ile Ala Val Leu Met Tyr Val His Asp Tyr Tyr Val Leu Asn 465 470 475 480 tat gag gcc cca gcg gca gag gcc tga 1467 Tyr Glu Ala Pro Ala Ala Glu Ala * 485 10 1005 DNA Homo sapiens CDS (1)...(1005) Homo sapiens diacylglycerol acyltransferase 2-like protein coding sequence 10 atg aag gta gag ttt gca ccg ctc aac atc cag ctg gcg cgg cgg ctg 48 Met Lys Val Glu Phe Ala Pro Leu Asn Ile Gln Leu Ala Arg Arg Leu 1 5 10 15 cag acg gtg gcc gtg ctg cag tgg gtc ctt tct ttt ctt aca ggg ccg 96 Gln Thr Val Ala Val Leu Gln Trp Val Leu Ser Phe Leu Thr Gly Pro 20 25 30 atg tcc att gga atc act gtg atg ctg atc ata cac aac tat ttg ttc 144 Met Ser Ile Gly Ile Thr Val Met Leu Ile Ile His Asn Tyr Leu Phe 35 40 45 ctt tac atc cct tat ttg atg tgg ctt tac ttt gac tgg cat acc cca 192 Leu Tyr Ile Pro Tyr Leu Met Trp Leu Tyr Phe Asp Trp His Thr Pro 50 55 60 gag cga gga ggc agg aga tcc agc tgg atc aaa aat tgg act ctt tgg 240 Glu Arg Gly Gly Arg Arg Ser Ser Trp Ile Lys Asn Trp Thr Leu Trp 65 70 75 80 aaa cac ttt aag gac tat ttt cca att cat ctt atc aaa act caa gat 288 Lys His Phe Lys Asp Tyr Phe Pro Ile His Leu Ile Lys Thr Gln Asp 85 90 95 ttg gat cca agt cac aac tat ata ttt ggg ttt cac ccc cat gga ata 336 Leu Asp Pro Ser His Asn Tyr Ile Phe Gly Phe His Pro His Gly Ile 100 105 110 atg gca gtt gga gcc ttt ggg aat ttt tct gta aat tat tct gac ttc 384 Met Ala Val Gly Ala Phe Gly Asn Phe Ser Val Asn Tyr Ser Asp Phe 115 120 125 aag gac ctg ttt cct ggc ttt act tca tat ctt cac gtg ctg cca ctt 432 Lys Asp Leu Phe Pro Gly Phe Thr Ser Tyr Leu His Val Leu Pro Leu 130 135 140 tgg ttc tgg tgt cct gtc ttt cga gaa tat gtg atg agt gtt ggg ctg 480 Trp Phe Trp Cys Pro Val Phe Arg Glu Tyr Val Met Ser Val Gly Leu 145 150 155 160 gtt tca gtt tcc aag aaa agt gtg tcc tac atg gta agc aag gag gga 528 Val Ser Val Ser Lys Lys Ser Val Ser Tyr Met Val Ser Lys Glu Gly 165 170 175 ggt gga aac atc tct gtc att gtc ctt ggg ggt gca aaa gaa tca ctg 576 Gly Gly Asn Ile Ser Val Ile Val Leu Gly Gly Ala Lys Glu Ser Leu 180 185 190 gat gct cat cct gga aag ttc act ctg ttc atc cgc cag cgg aaa gga 624 Asp Ala His Pro Gly Lys Phe Thr Leu Phe Ile Arg Gln Arg Lys Gly 195 200 205 ttt gtt aaa att gct ttg acc cat ggc gcc tct ctg gtc cca gtg gtt 672 Phe Val Lys Ile Ala Leu Thr His Gly Ala Ser Leu Val Pro Val Val 210 215 220 tct ttt ggt gaa aat gaa ctg ttt aaa caa act gac aac cct gaa gga 720 Ser Phe Gly Glu Asn Glu Leu Phe Lys Gln Thr Asp Asn Pro Glu Gly 225 230 235 240 tca tgg att aga act gtt cag aat aaa ctg cag aag atc atg ggg ttt 768 Ser Trp Ile Arg Thr Val Gln Asn Lys Leu Gln Lys Ile Met Gly Phe 245 250 255 gct ttg ccc ctg ttt cat gcc agg gga gtt ttt cag tac aat ttt ggc 816 Ala Leu Pro Leu Phe His Ala Arg Gly Val Phe Gln Tyr Asn Phe Gly 260 265 270 cta atg acc tat agg aaa gcc atc cac act gtt gtt ggc cgc ccg atc 864 Leu Met Thr Tyr Arg Lys Ala Ile His Thr Val Val Gly Arg Pro Ile 275 280 285 cct gtt cgt cag act ctg aac ccg acc cag gag cag att gag gag tta 912 Pro Val Arg Gln Thr Leu Asn Pro Thr Gln Glu Gln Ile Glu Glu Leu 290 295 300 cat cag acc tat atg gag gaa ctt agg aaa ttg ttt gag gaa cac aaa 960 His Gln Thr Tyr Met Glu Glu Leu Arg Lys Leu Phe Glu Glu His Lys 305 310 315 320 gga aag tat ggc att cca gag cac gag act ctt gtt tta aaa tga 1005 Gly Lys Tyr Gly Ile Pro Glu His Glu Thr Leu Val Leu Lys * 325 330 11 1008 DNA Mus musculus CDS (1)...(1008) Mus musculus diacylglycerol acyltransferase 2-like protein coding sequence 11 atg atg gtc gag ttc gcg cca ctc aac acc ccg ctg gca cgg tgc cta 48 Met Met Val Glu Phe Ala Pro Leu Asn Thr Pro Leu Ala Arg Cys Leu 1 5 10 15 cag acc gct gcg gtg ctg cag tgg gtc ctg tcc ttc ctc ctg ctc gtg 96 Gln Thr Ala Ala Val Leu Gln Trp Val Leu Ser Phe Leu Leu Leu Val 20 25 30 cag gtg tgc att gga att atg gtg atg ctg gtc ctg tac aac tat tgg 144 Gln Val Cys Ile Gly Ile Met Val Met Leu Val Leu Tyr Asn Tyr Trp 35 40 45 ttc ctt tac atc cca tat ctg gtc tgg ttt tac tat gac tgg aga acc 192 Phe Leu Tyr Ile Pro Tyr Leu Val Trp Phe Tyr Tyr Asp Trp Arg Thr 50 55 60 cca gag caa gga ggc aga aga tgg aac tgg gtc caa agc tgg cct gtg 240 Pro Glu Gln Gly Gly Arg Arg Trp Asn Trp Val Gln Ser Trp Pro Val 65 70 75 80 tgg aag tat ttt aag gag tat ttt cca atc tgt ctt gtc aaa acg cag 288 Trp Lys Tyr Phe Lys Glu Tyr Phe Pro Ile Cys Leu Val Lys Thr Gln 85 90 95 gat ttg gat ccg ggt cac aat tat ata ttt ggg ttt cac cct cat gga 336 Asp Leu Asp Pro Gly His Asn Tyr Ile Phe Gly Phe His Pro His Gly 100 105 110 ata ttc gtg cct gga gcc ttt gga aat ttt tgt aca aaa tac tcg gac 384 Ile Phe Val Pro Gly Ala Phe Gly Asn Phe Cys Thr Lys Tyr Ser Asp 115 120 125 ttc aag aag cta ttt cct ggc ttt aca tcg tat ctc cac gtg gcc aag 432 Phe Lys Lys Leu Phe Pro Gly Phe Thr Ser Tyr Leu His Val Ala Lys 130 135 140 atc tgg ttc tgt ttc ccg ttg ttc cga gaa tat ctg atg agt aac ggg 480 Ile Trp Phe Cys Phe Pro Leu Phe Arg Glu Tyr Leu Met Ser Asn Gly 145 150 155 160 ccg gtt tca gtg tct aag gag agt ttg tct cat gtg ctg agc aag gat 528 Pro Val Ser Val Ser Lys Glu Ser Leu Ser His Val Leu Ser Lys Asp 165 170 175 gga ggt ggc aat gtc tca atc att gtc ctc gga ggt gca aag gag gcg 576 Gly Gly Gly Asn Val Ser Ile Ile Val Leu Gly Gly Ala Lys Glu Ala 180 185 190 ctg gag gct cac cca gga aca ttc acc ctg tgc atc cgc cag cgc aaa 624 Leu Glu Ala His Pro Gly Thr Phe Thr Leu Cys Ile Arg Gln Arg Lys 195 200 205 ggg ttt gtt aag atg gcc ttg acc cat ggt gcc agt ttg gtt cca gta 672 Gly Phe Val Lys Met Ala Leu Thr His Gly Ala Ser Leu Val Pro Val 210 215 220 ttt tct ttt ggt gaa aat gat cta tat aag caa att aac aac ccc aaa 720 Phe Ser Phe Gly Glu Asn Asp Leu Tyr Lys Gln Ile Asn Asn Pro Lys 225 230 235 240 ggc tcc tgg cta cga act ata caa gac gca atg tat gat tca atg gga 768 Gly Ser Trp Leu Arg Thr Ile Gln Asp Ala Met Tyr Asp Ser Met Gly 245 250 255 gta gcc ttg cca ctg ata tat gcc aga gga att ttc cag cac tac ttt 816 Val Ala Leu Pro Leu Ile Tyr Ala Arg Gly Ile Phe Gln His Tyr Phe 260 265 270 ggc ata atg ccc tat cgg aag ctg atc tac act gtt gtt ggc cgc cct 864 Gly Ile Met Pro Tyr Arg Lys Leu Ile Tyr Thr Val Val Gly Arg Pro 275 280 285 atc cct gtt cag cag att ctg aac ccg acc tca gag cag att gaa gag 912 Ile Pro Val Gln Gln Ile Leu Asn Pro Thr Ser Glu Gln Ile Glu Glu 290 295 300 ctg cat cag aca tac cta gag gag cta aag aaa cta ttc aat gaa cac 960 Leu His Gln Thr Tyr Leu Glu Glu Leu Lys Lys Leu Phe Asn Glu His 305 310 315 320 aaa ggg aaa tat ggg att ccg gag cac gaa act ctg gta ttt aaa taa 1008 Lys Gly Lys Tyr Gly Ile Pro Glu His Glu Thr Leu Val Phe Lys * 325 330 335 12 1497 DNA Mus musculus CDS (1)...(1497) Mus musculus diacylglycerol acyltransferase (Dgat) coding sequence 12 atg ggc gac cgc gga ggc gcg gga agc tct cgg cgt cgg agg acc ggc 48 Met Gly Asp Arg Gly Gly Ala Gly Ser Ser Arg Arg Arg Arg Thr Gly 1 5 10 15 tcg cgg gtt tcc gtc cag ggt ggt agt ggg ccc aag gta gaa gag gac 96 Ser Arg Val Ser Val Gln Gly Gly Ser Gly Pro Lys Val Glu Glu Asp 20 25 30 gag gtg cga gac gcg gct gtg agc ccc gac ttg ggc gcc ggg ggt gac 144 Glu Val Arg Asp Ala Ala Val Ser Pro Asp Leu Gly Ala Gly Gly Asp 35 40 45 gcg ccg gct ccg gct ccg gct cca gcc cat acc cgg gac aaa gac ggg 192 Ala Pro Ala Pro Ala Pro Ala Pro Ala His Thr Arg Asp Lys Asp Gly 50 55 60 cgg acc agc gtg ggc gac ggc tac tgg gat ctg agg tgc cat cgt ctg 240 Arg Thr Ser Val Gly Asp Gly Tyr Trp Asp Leu Arg Cys His Arg Leu 65 70 75 80 caa gat tct ttg ttc agc tca gac agt ggt ttc agc aat tat cgt ggt 288 Gln Asp Ser Leu Phe Ser Ser Asp Ser Gly Phe Ser Asn Tyr Arg Gly 85 90 95 atc ctg aat tgg tgt gtg gtg atg ctg atc ctg agt aat gca agg tta 336 Ile Leu Asn Trp Cys Val Val Met Leu Ile Leu Ser Asn Ala Arg Leu 100 105 110 ttt tta gag aac ctt atc aag tat ggc atc ctg gtg gat cct atc cag 384 Phe Leu Glu Asn Leu Ile Lys Tyr Gly Ile Leu Val Asp Pro Ile Gln 115 120 125 gtg gtg tct ctg ttt ttg aag gac ccc tac agc tgg cct gcc cca tgc 432 Val Val Ser Leu Phe Leu Lys Asp Pro Tyr Ser Trp Pro Ala Pro Cys 130 135 140 gtg att att gca tcc aat att ttt gtt gtg gct gca ttt cag att gag 480 Val Ile Ile Ala Ser Asn Ile Phe Val Val Ala Ala Phe Gln Ile Glu 145 150 155 160 aag cgc ctg gca gtg ggt gcc ctg aca gag cag atg ggg ctg ctg cta 528 Lys Arg Leu Ala Val Gly Ala Leu Thr Glu Gln Met Gly Leu Leu Leu 165 170 175 cat gtg gtt aac ctg gcc aca atc att tgc ttc cca gca gct gtg gcc 576 His Val Val Asn Leu Ala Thr Ile Ile Cys Phe Pro Ala Ala Val Ala 180 185 190 tta ctg gtt gag tct atc act cca gtg ggt tcc gtg ttt gct ctg gca 624 Leu Leu Val Glu Ser Ile Thr Pro Val Gly Ser Val Phe Ala Leu Ala 195 200 205 tca tac tcc atc atg ttc ctc aag ctt tat tcc tac cgg gat gtc aac 672 Ser Tyr Ser Ile Met Phe Leu Lys Leu Tyr Ser Tyr Arg Asp Val Asn 210 215 220 ctg tgg tgc cgc cag cga agg gtc aag gcc aaa gct gtc tct aca ggg 720 Leu Trp Cys Arg Gln Arg Arg Val Lys Ala Lys Ala Val Ser Thr Gly 225 230 235 240 aag aag gtc agt ggg gct gct gcc cag caa gct gtg agc tat cca gac 768 Lys Lys Val Ser Gly Ala Ala Ala Gln Gln Ala Val Ser Tyr Pro Asp 245 250 255 aac ctg acc tac cga gat ctc tat tac ttc atc ttt gct cct act ttg 816 Asn Leu Thr Tyr Arg Asp Leu Tyr Tyr Phe Ile Phe Ala Pro Thr Leu 260 265 270 tgt tat gaa ctc aac ttt cct cgg tcc ccc cga ata cga aag cgc ttt 864 Cys Tyr Glu Leu Asn Phe Pro Arg Ser Pro Arg Ile Arg Lys Arg Phe 275 280 285 ctg cta cga cga gtt ctt gag atg ctc ttt ttt acc cag ctt caa gtg 912 Leu Leu Arg Arg Val Leu Glu Met Leu Phe Phe Thr Gln Leu Gln Val 290 295 300 ggg ctg atc caa cag tgg atg gtc cct act atc cag aac tcc atg aag 960 Gly Leu Ile Gln Gln Trp Met Val Pro Thr Ile Gln Asn Ser Met Lys 305 310 315 320 ccc ttc aag gat atg gac tat tca cgg atc att gag cgt ctc tta aag 1008 Pro Phe Lys Asp Met Asp Tyr Ser Arg Ile Ile Glu Arg Leu Leu Lys 325 330 335 ctg gcg gtc ccc aac cat ctg atc tgg ctt atc ttc ttc tat tgg ttt 1056 Leu Ala Val Pro Asn His Leu Ile Trp Leu Ile Phe Phe Tyr Trp Phe 340 345 350 ttc cac tcc tgt ctc aat gct gtg gca gag ctt ctg cag ttt gga gac 1104 Phe His Ser Cys Leu Asn Ala Val Ala Glu Leu Leu Gln Phe Gly Asp 355 360 365 cgc gag ttc tac aga gat tgg tgg aat gct gag tct gtc acc tac ttt 1152 Arg Glu Phe Tyr Arg Asp Trp Trp Asn Ala Glu Ser Val Thr Tyr Phe 370 375 380 tgg cag aac tgg aat atc ccc gtg cac aag tgg tgc atc aga cac ttc 1200 Trp Gln Asn Trp Asn Ile Pro Val His Lys Trp Cys Ile Arg His Phe 385 390 395 400 tac aag cct atg ctc aga cat ggc agc agc aaa tgg gtg gcc agg aca 1248 Tyr Lys Pro Met Leu Arg His Gly Ser Ser Lys Trp Val Ala Arg Thr 405 410 415 gga gta ttt ttg acc tca gcc ttc ttc cat gag tac cta gtg agc gtt 1296 Gly Val Phe Leu Thr Ser Ala Phe Phe His Glu Tyr Leu Val Ser Val 420 425 430 ccc ctg cgg atg ttc cgc ctc tgg gca ttc aca gcc atg atg gct cag 1344 Pro Leu Arg Met Phe Arg Leu Trp Ala Phe Thr Ala Met Met Ala Gln 435 440 445 gtc cca ctg gcc tgg att gtg ggc cga ttc ttc caa ggg aac tat ggc 1392 Val Pro Leu Ala Trp Ile Val Gly Arg Phe Phe Gln Gly Asn Tyr Gly 450 455 460 aat gca gct gtg tgg gtg aca ctc atc att ggg caa ccg gtg gct gtg 1440 Asn Ala Ala Val Trp Val Thr Leu Ile Ile Gly Gln Pro Val Ala Val 465 470 475 480 ctc atg tat gtc cac gac tac tac gtg ctc aac tac gat gcc cca gtg 1488 Leu Met Tyr Val His Asp Tyr Tyr Val Leu Asn Tyr Asp Ala Pro Val 485 490 495 ggg gta tga 1497 Gly Val * 13 504 DNA Rattus norvegicus CDS (1)...(54) Rattus norvegicus leptin (Lep), coding sequence 13 atg tgc tgg aga ccc ctg tgc cgg ttc ctg tgg ctt tgg tcc tat ctg 48 Met Cys Trp Arg Pro Leu Cys Arg Phe Leu Trp Leu Trp Ser Tyr Leu 1 5 10 15 tcc tat gttcaagctg tgcctatcca caaagtccag gatgacacca aaaccctcat 104 Ser Tyr caagaccatt gtcaccagga tcaatgacat ttcacacacg cagtcggtat ccgccaggca 164 gagggtcacc ggtttggact tcattcccgg gcttcacccc attctgagtt tgtccaagat 224 ggaccagacc ctggcagtct atcaacagat cctcaccagc ttgccttccc aaaacgtgct 284 gcagatagct catgacctgg agaacctgcg agacctcctc catctgctgg ccttctccaa 344 gagctgctcc ctgccgcaga cccgtggcct gcagaagcca gagagcctgg atggcgtcct 404 ggaagcctcg ctctactcca cagaggtggt ggctctgagc aggctgcagg gctctctgca 464 ggacattctt caacagttgg accttagccc tgaatgctga 504 14 2679 DNA Mus musculus CDS (1)...(2679) Mus musculus leptin receptor (Lepr) coding sequence 14 atg atg tgt cag aaa ttc tat gtg gtt ttg tta cac tgg gaa ttt ctt 48 Met Met Cys Gln Lys Phe Tyr Val Val Leu Leu His Trp Glu Phe Leu 1 5 10 15 tat gtg ata gct gca ctt aac ctg gca tat cca atc tct ccc tgg aaa 96 Tyr Val Ile Ala Ala Leu Asn Leu Ala Tyr Pro Ile Ser Pro Trp Lys 20 25 30 ttt aag ttg ttt tgt gga cca ccg aac aca acc gat gac tcc ttt ctc 144 Phe Lys Leu Phe Cys Gly Pro Pro Asn Thr Thr Asp Asp Ser Phe Leu 35 40 45 tca cct gct gga gcc cca aac aat gcc tcg gct ttg aag ggg gct tct 192 Ser Pro Ala Gly Ala Pro Asn Asn Ala Ser Ala Leu Lys Gly Ala Ser 50 55 60 gaa gca att gtt gaa gct aaa ttt aat tca agt ggt atc tac gtt cct 240 Glu Ala Ile Val Glu Ala Lys Phe Asn Ser Ser Gly Ile Tyr Val Pro 65 70 75 80 gag tta tcc aaa aca gtc ttc cac tgt tgc ttt ggg aat gag caa ggt 288 Glu Leu Ser Lys Thr Val Phe His Cys Cys Phe Gly Asn Glu Gln Gly 85 90 95 caa aac tgc tct gca ctc aca gac aac act gaa ggg aag aca ctg gct 336 Gln Asn Cys Ser Ala Leu Thr Asp Asn Thr Glu Gly Lys Thr Leu Ala 100 105 110 tca gta gtg aag gct tca gtt ttt cgc cag cta ggt gta aac tgg gac 384 Ser Val Val Lys Ala Ser Val Phe Arg Gln Leu Gly Val Asn Trp Asp 115 120 125 ata gag tgc tgg atg aaa ggg gac ttg aca tta ttc atc tgt cat atg 432 Ile Glu Cys Trp Met Lys Gly Asp Leu Thr Leu Phe Ile Cys His Met 130 135 140 gag cca tta cct aag aac ccc ttc aag aat tat gac tct aag gtc cat 480 Glu Pro Leu Pro Lys Asn Pro Phe Lys Asn Tyr Asp Ser Lys Val His 145 150 155 160 ctt tta tat gat ctg cct gaa gtc ata gat gat tcg cct ctg ccc cca 528 Leu Leu Tyr Asp Leu Pro Glu Val Ile Asp Asp Ser Pro Leu Pro Pro 165 170 175 ctg aaa gac agc ttt cag act gtc caa tgc aac tgc agt ctt cgg ggt 576 Leu Lys Asp Ser Phe Gln Thr Val Gln Cys Asn Cys Ser Leu Arg Gly 180 185 190 tgt gaa tgt cat gtg ccg gta ccc aga gcc aaa ctc aac tac gct ctt 624 Cys Glu Cys His Val Pro Val Pro Arg Ala Lys Leu Asn Tyr Ala Leu 195 200 205 ctg atg tat ttg gaa atc aca tct gcc ggt gtg agt ttt cag tca cct 672 Leu Met Tyr Leu Glu Ile Thr Ser Ala Gly Val Ser Phe Gln Ser Pro 210 215 220 ctg atg tca ctg cag ccc atg ctt gtt gtg aaa ccc gat cca ccc tta 720 Leu Met Ser Leu Gln Pro Met Leu Val Val Lys Pro Asp Pro Pro Leu 225 230 235 240 ggt ttg cat atg gaa gtc aca gat gat ggt aat tta aag att tct tgg 768 Gly Leu His Met Glu Val Thr Asp Asp Gly Asn Leu Lys Ile Ser Trp 245 250 255 gac agc caa aca atg gca cca ttt ccg ctt caa tat cag gtg aaa tat 816 Asp Ser Gln Thr Met Ala Pro Phe Pro Leu Gln Tyr Gln Val Lys Tyr 260 265 270 tta gag aat tct aca att gta aga gag gct gct gaa att gtc tca gct 864 Leu Glu Asn Ser Thr Ile Val Arg Glu Ala Ala Glu Ile Val Ser Ala 275 280 285 aca tct ctg ctg gta gac agt gtg ctt cct gga tct tca tat gag gtc 912 Thr Ser Leu Leu Val Asp Ser Val Leu Pro Gly Ser Ser Tyr Glu Val 290 295 300 cag gtg agg agc aag aga ctg gat ggt tca gga gtc tgg agt gac tgg 960 Gln Val Arg Ser Lys Arg Leu Asp Gly Ser Gly Val Trp Ser Asp Trp 305 310 315 320 agt tca cct caa gtc ttt acc aca caa gat gtt gtg tat ttt cca ccc 1008 Ser Ser Pro Gln Val Phe Thr Thr Gln Asp Val Val Tyr Phe Pro Pro 325 330 335 aaa att ctg act agt gtt gga tcg aat gct tct ttt cat tgc atc tac 1056 Lys Ile Leu Thr Ser Val Gly Ser Asn Ala Ser Phe His Cys Ile Tyr 340 345 350 aaa aac gaa aac cag att atc tcc tca aaa cag ata gtt tgg tgg agg 1104 Lys Asn Glu Asn Gln Ile Ile Ser Ser Lys Gln Ile Val Trp Trp Arg 355 360 365 aat cta gct gag aaa atc cct gag ata cag tac agc att gtg agt gac 1152 Asn Leu Ala Glu Lys Ile Pro Glu Ile Gln Tyr Ser Ile Val Ser Asp 370 375 380 cga gtt agc aaa gtt acc ttc tcc aac ctg aaa gcc acc aga cct cga 1200 Arg Val Ser Lys Val Thr Phe Ser Asn Leu Lys Ala Thr Arg Pro Arg 385 390 395 400 ggg aag ttt acc tat gac gca gtg tac tgc tgc aat gag cag gcg tgc 1248 Gly Lys Phe Thr Tyr Asp Ala Val Tyr Cys Cys Asn Glu Gln Ala Cys 405 410 415 cat cac cgc tat gct gaa tta tac gtg atc gat gtc aat atc aat ata 1296 His His Arg Tyr Ala Glu Leu Tyr Val Ile Asp Val Asn Ile Asn Ile 420 425 430 tca tgt gaa act gac ggg tac tta act aaa atg act tgc aga tgg tca 1344 Ser Cys Glu Thr Asp Gly Tyr Leu Thr Lys Met Thr Cys Arg Trp Ser 435 440 445 ccc agc aca atc caa tca cta gtg gga agc act gtg cag ctg agg tat 1392 Pro Ser Thr Ile Gln Ser Leu Val Gly Ser Thr Val Gln Leu Arg Tyr 450 455 460 cac agg cgc agc ctg tat tgt cct gat agt cca tct att cat cct acg 1440 His Arg Arg Ser Leu Tyr Cys Pro Asp Ser Pro Ser Ile His Pro Thr 465 470 475 480 tct gag ccc aaa aac tgc gtc tta cag aga gac ggc ttt tat gaa tgt 1488 Ser Glu Pro Lys Asn Cys Val Leu Gln Arg Asp Gly Phe Tyr Glu Cys 485 490 495 gtt ttc cag cca atc ttt cta tta tct ggc tat aca atg tgg atc agg 1536 Val Phe Gln Pro Ile Phe Leu Leu Ser Gly Tyr Thr Met Trp Ile Arg 500 505 510 atc aac cat tct tta ggt tca ctt gac tcg cca cca acg tgt gtc ctt 1584 Ile Asn His Ser Leu Gly Ser Leu Asp Ser Pro Pro Thr Cys Val Leu 515 520 525 cct gac tcc gta gta aaa cca cta cct cca tct aac gta aaa gca gag 1632 Pro Asp Ser Val Val Lys Pro Leu Pro Pro Ser Asn Val Lys Ala Glu 530 535 540 att act gta aac act gga tta ttg aaa gta tct tgg gaa aag cca gtc 1680 Ile Thr Val Asn Thr Gly Leu Leu Lys Val Ser Trp Glu Lys Pro Val 545 550 555 560 ttt ccg gag aat aac ctt caa ttc cag att cga tat ggc tta agt gga 1728 Phe Pro Glu Asn Asn Leu Gln Phe Gln Ile Arg Tyr Gly Leu Ser Gly 565 570 575 aaa gaa ata caa tgg aag aca cat gag gta ttc gat gca aag tca aag 1776 Lys Glu Ile Gln Trp Lys Thr His Glu Val Phe Asp Ala Lys Ser Lys 580 585 590 tct gcc agc ctg ctg gtg tca gac ctc tgt gca gtc tat gtg gtc cag 1824 Ser Ala Ser Leu Leu Val Ser Asp Leu Cys Ala Val Tyr Val Val Gln 595 600 605 gtt cgc tgc cgg cgg ttg gat gga cta gga tat tgg agt aat tgg agc 1872 Val Arg Cys Arg Arg Leu Asp Gly Leu Gly Tyr Trp Ser Asn Trp Ser 610 615 620 agt cca gcc tat acg ctt gtc atg gat gta aaa gtt cct atg aga ggg 1920 Ser Pro Ala Tyr Thr Leu Val Met Asp Val Lys Val Pro Met Arg Gly 625 630 635 640 cct gaa ttt tgg aga aaa atg gat ggg gac gtt act aaa aag gag aga 1968 Pro Glu Phe Trp Arg Lys Met Asp Gly Asp Val Thr Lys Lys Glu Arg 645 650 655 aat gtc acc ttg ctt tgg aag ccc ctg acg aaa aat gac tca ctg tgt 2016 Asn Val Thr Leu Leu Trp Lys Pro Leu Thr Lys Asn Asp Ser Leu Cys 660 665 670 agt gtg agg agg tac gtg gtg aag cat cgt act gcc cac aat ggg acg 2064 Ser Val Arg Arg Tyr Val Val Lys His Arg Thr Ala His Asn Gly Thr 675 680 685 tgg tca gaa gat gtg gga aat cgg acc aat ctc act ttc ctg tgg aca 2112 Trp Ser Glu Asp Val Gly Asn Arg Thr Asn Leu Thr Phe Leu Trp Thr 690 695 700 gaa cca gcg cac act gtt aca gtt ctg gct gtc aat tcc ctc ggc gct 2160 Glu Pro Ala His Thr Val Thr Val Leu Ala Val Asn Ser Leu Gly Ala 705 710 715 720 tcc ctt gtg aat ttt aac ctt acc ttc tca tgg ccc atg agt aaa gtg 2208 Ser Leu Val Asn Phe Asn Leu Thr Phe Ser Trp Pro Met Ser Lys Val 725 730 735 agt gct gtg gag tca ctc agt gct tat ccc ctg agc agc agc tgt gtc 2256 Ser Ala Val Glu Ser Leu Ser Ala Tyr Pro Leu Ser Ser Ser Cys Val 740 745 750 atc ctt tcc tgg aca ctg tca cct gat gat tat agt ctg tta tat ctg 2304 Ile Leu Ser Trp Thr Leu Ser Pro Asp Asp Tyr Ser Leu Leu Tyr Leu 755 760 765 gtt att gaa tgg aag atc ctt aat gaa gat gat gga atg aag tgg ctt 2352 Val Ile Glu Trp Lys Ile Leu Asn Glu Asp Asp Gly Met Lys Trp Leu 770 775 780 aga att ccc tcg aat gtt aaa aag ttt tat atc cac gat aat ttt att 2400 Arg Ile Pro Ser Asn Val Lys Lys Phe Tyr Ile His Asp Asn Phe Ile 785 790 795 800 ccc atc gag aaa tat cag ttt agt ctt tac cca gta ttt atg gaa gga 2448 Pro Ile Glu Lys Tyr Gln Phe Ser Leu Tyr Pro Val Phe Met Glu Gly 805 810 815 gtt gga aaa cca aag ata att aat ggt ttc acc aaa gat gct atc gac 2496 Val Gly Lys Pro Lys Ile Ile Asn Gly Phe Thr Lys Asp Ala Ile Asp 820 825 830 aag cag cag aat gac gca ggg ctg tat gtc att gta ccc ata att att 2544 Lys Gln Gln Asn Asp Ala Gly Leu Tyr Val Ile Val Pro Ile Ile Ile 835 840 845 tcc tct tgt gtc cta ctg ctc gga aca ctg tta att tca cac cag aga 2592 Ser Ser Cys Val Leu Leu Leu Gly Thr Leu Leu Ile Ser His Gln Arg 850 855 860 atg aaa aag ttg ttt tgg gac gat gtt cca aac ccc aag aat tgt tcc 2640 Met Lys Lys Leu Phe Trp Asp Asp Val Pro Asn Pro Lys Asn Cys Ser 865 870 875 880 tgg gca caa gga ctg aat ttc caa aag gtc act gtt taa 2679 Trp Ala Gln Gly Leu Asn Phe Gln Lys Val Thr Val * 885 890 15 504 DNA Mus musculus CDS (1)...(504) Mus musculus leptin (Lep) 15 atg tgc tgg aga ccc ctg tgt cgg ttc ctg tgg ctt tgg tcc tat ctg 48 Met Cys Trp Arg Pro Leu Cys Arg Phe Leu Trp Leu Trp Ser Tyr Leu 1 5 10 15 tct tat gtt caa gca gtg cct atc cag aaa gtc cag gat gac acc aaa 96 Ser Tyr Val Gln Ala Val Pro Ile Gln Lys Val Gln Asp Asp Thr Lys 20 25 30 acc ctc atc aag acc att gtc acc agg atc aat gac att tca cac acg 144 Thr Leu Ile Lys Thr Ile Val Thr Arg Ile Asn Asp Ile Ser His Thr 35 40 45 cag tcg gta tcc gcc aag cag agg gtc act ggc ttg gac ttc att cct 192 Gln Ser Val Ser Ala Lys Gln Arg Val Thr Gly Leu Asp Phe Ile Pro 50 55 60 ggg ctt cac ccc att ctg agt ttg tcc aag atg gac cag act ctg gca 240 Gly Leu His Pro Ile Leu Ser Leu Ser Lys Met Asp Gln Thr Leu Ala 65 70 75 80 gtc tat caa cag gtc ctc acc agc ctg cct tcc caa aat gtg ctg cag 288 Val Tyr Gln Gln Val Leu Thr Ser Leu Pro Ser Gln Asn Val Leu Gln 85 90 95 ata gcc aat gac ctg gag aat ctc cga gac ctc ctc cat ctg ctg gcc 336 Ile Ala Asn Asp Leu Glu Asn Leu Arg Asp Leu Leu His Leu Leu Ala 100 105 110 ttc tcc aag agc tgc tcc ctg cct cag acc agt ggc ctg cag aag cca 384 Phe Ser Lys Ser Cys Ser Leu Pro Gln Thr Ser Gly Leu Gln Lys Pro 115 120 125 gag agc ctg gat ggc gtc ctg gaa gcc tca ctc tac tcc aca gag gtg 432 Glu Ser Leu Asp Gly Val Leu Glu Ala Ser Leu Tyr Ser Thr Glu Val 130 135 140 gtg gct ttg agc agg ctg cag ggc tct ctg cag gac att ctt caa cag 480 Val Ala Leu Ser Arg Leu Gln Gly Ser Leu Gln Asp Ile Leu Gln Gln 145 150 155 160 ttg gat gtt agc cct gaa tgc tga 504 Leu Asp Val Ser Pro Glu Cys * 165 16 363 DNA Bos taurus unsure (0)...(0) Bos taurus leptin receptor partial coding sequence 16 ctggaaattt aagttgtctt gcatgccatc aaatacaaca tatgacttcc tctttcctcc 60 tggaatctca aagaacactt caaatttgaa tggacgttat gaggcagttg ttgaaactaa 120 gcttaattca agtggtacct acttatctaa cttatcatcc agaacaactt tccactgttg 180 cttttggagc gcggaagata aaaactgctc tgtatataca gatgacattg aagggaaggc 240 atttgttaca acagtaaatt ctttagtttt tcagcaaaca ggtgcaaact ggaacataca 300 gtgctggatg aaagaggact tgaaattatt catctgtaat attgagtcat tatttaagaa 360 tcc 363 17 504 DNA Homo sapiens CDS (1)...(504) Homo sapiens leptin 17 atg cat tgg gga acc ctg tgc gga ttc ttg tgg ctt tgg ccc tat ctt 48 Met His Trp Gly Thr Leu Cys Gly Phe Leu Trp Leu Trp Pro Tyr Leu 1 5 10 15 ttc tat gtc caa gct gtg ccc atc caa aaa gtc caa gat gac acc aaa 96 Phe Tyr Val Gln Ala Val Pro Ile Gln Lys Val Gln Asp Asp Thr Lys 20 25 30 acc ctc atc aag aca att gtc acc agg atc aat gac att tca cac acg 144 Thr Leu Ile Lys Thr Ile Val Thr Arg Ile Asn Asp Ile Ser His Thr 35 40 45 cag tca gtc tcc tcc aaa cag aaa gtc acc ggt ttg gac ttc att cct 192 Gln Ser Val Ser Ser Lys Gln Lys Val Thr Gly Leu Asp Phe Ile Pro 50 55 60 ggg ctc cac ccc atc ctg acc tta tcc aag atg gac cag aca ctg gca 240 Gly Leu His Pro Ile Leu Thr Leu Ser Lys Met Asp Gln Thr Leu Ala 65 70 75 80 gtc tac caa cag atc ctc acc agt atg cct tcc aga aac gtg atc caa 288 Val Tyr Gln Gln Ile Leu Thr Ser Met Pro Ser Arg Asn Val Ile Gln 85 90 95 ata tcc aac gac ctg gag aac ctc cgg gat ctt ctt cac gtg ctg gcc 336 Ile Ser Asn Asp Leu Glu Asn Leu Arg Asp Leu Leu His Val Leu Ala 100 105 110 ttc tct aag agc tgc cac ttg ccc tgg gcc agt ggc ctg gag acc ttg 384 Phe Ser Lys Ser Cys His Leu Pro Trp Ala Ser Gly Leu Glu Thr Leu 115 120 125 gac agc ctg ggg ggt gtc ctg gaa gct tca ggc tac tcc aca gag gtg 432 Asp Ser Leu Gly Gly Val Leu Glu Ala Ser Gly Tyr Ser Thr Glu Val 130 135 140 gtg gcc ctg agc agg ctg cag ggg tct ctg cag gac atg ctg tgg cag 480 Val Ala Leu Ser Arg Leu Gln Gly Ser Leu Gln Asp Met Leu Trp Gln 145 150 155 160 ctg gac ctc agc cct ggg tgc tga 504 Leu Asp Leu Ser Pro Gly Cys * 165 18 3489 DNA Rattus norvegicus CDS (1)...(3489) Rattus norvegicus leptin receptor 18 atg acg tgt cag aaa ttc tat gtg gtt ttg tta cac tgg gaa ttt ctg 48 Met Thr Cys Gln Lys Phe Tyr Val Val Leu Leu His Trp Glu Phe Leu 1 5 10 15 tat gtg ata act gca ctt aac ctg gcc tat cca acc tct ccc tgg aga 96 Tyr Val Ile Thr Ala Leu Asn Leu Ala Tyr Pro Thr Ser Pro Trp Arg 20 25 30 ttt aag ctg ttt tgt gcg cca ccg agt aca act gat gac tcc ttt ctc 144 Phe Lys Leu Phe Cys Ala Pro Pro Ser Thr Thr Asp Asp Ser Phe Leu 35 40 45 tct cct gct gga gtc cca aac aat act tcg tct ttg aag ggg gct tct 192 Ser Pro Ala Gly Val Pro Asn Asn Thr Ser Ser Leu Lys Gly Ala Ser 50 55 60 gaa gca ctt gtt gaa gct aaa ttt aat tca act ggt atc tac gtt tct 240 Glu Ala Leu Val Glu Ala Lys Phe Asn Ser Thr Gly Ile Tyr Val Ser 65 70 75 80 gag tta tcc aaa acc att ttc cac tgt tgc ttt ggg aat gag caa ggt 288 Glu Leu Ser Lys Thr Ile Phe His Cys Cys Phe Gly Asn Glu Gln Gly 85 90 95 caa aac tgc tcc gca ctc aca ggc aac act gaa ggg aag acg ctg gct 336 Gln Asn Cys Ser Ala Leu Thr Gly Asn Thr Glu Gly Lys Thr Leu Ala 100 105 110 tca gtg gtg aag cct tta gtt ttc cgc caa cta ggt gta aac tgg gac 384 Ser Val Val Lys Pro Leu Val Phe Arg Gln Leu Gly Val Asn Trp Asp 115 120 125 ata gag tgc tgg atg aaa ggg gac ttg aca tta ttc atc tgt cat atg 432 Ile Glu Cys Trp Met Lys Gly Asp Leu Thr Leu Phe Ile Cys His Met 130 135 140 gaa cca tta ctt aag aac ccc ttc aag aat tat gac tct aag gtt cac 480 Glu Pro Leu Leu Lys Asn Pro Phe Lys Asn Tyr Asp Ser Lys Val His 145 150 155 160 ctt tta tat gat ctg cct gaa gtt ata gat gat ttg cct ctg ccc cca 528 Leu Leu Tyr Asp Leu Pro Glu Val Ile Asp Asp Leu Pro Leu Pro Pro 165 170 175 ctg aaa gac agc ttt cag act gtc cag tgc aac tgc agt gtt cgg gaa 576 Leu Lys Asp Ser Phe Gln Thr Val Gln Cys Asn Cys Ser Val Arg Glu 180 185 190 tgc gaa tgt cat gta cca gta ccc aga gcc aaa gtc aac tac gct ctt 624 Cys Glu Cys His Val Pro Val Pro Arg Ala Lys Val Asn Tyr Ala Leu 195 200 205 ctg atg tat tta gaa atc aca tct gct ggt gtg agt ttt cag tca cct 672 Leu Met Tyr Leu Glu Ile Thr Ser Ala Gly Val Ser Phe Gln Ser Pro 210 215 220 cta atg tca ctg cag ccc atg ctt gtt gtg aag ccc gat cca ccg ctg 720 Leu Met Ser Leu Gln Pro Met Leu Val Val Lys Pro Asp Pro Pro Leu 225 230 235 240 ggt ttg cgt atg gaa gtc aca gat gat ggt aat tta aag att tca tgg 768 Gly Leu Arg Met Glu Val Thr Asp Asp Gly Asn Leu Lys Ile Ser Trp 245 250 255 gac agc caa aca aaa gca cca ttt cca ctt caa tat cag gtg aaa tat 816 Asp Ser Gln Thr Lys Ala Pro Phe Pro Leu Gln Tyr Gln Val Lys Tyr 260 265 270 tta gag aat tct aca atc gta aga gag gct gct gaa atc gtc tcg gat 864 Leu Glu Asn Ser Thr Ile Val Arg Glu Ala Ala Glu Ile Val Ser Asp 275 280 285 aca tct ctg ctg gta gac agc gtg ctt cct ggg tct tca tac gag gtc 912 Thr Ser Leu Leu Val Asp Ser Val Leu Pro Gly Ser Ser Tyr Glu Val 290 295 300 cag gtg agg agc aag aga ctg gat ggc tca gga gtc tgg agt gac tgg 960 Gln Val Arg Ser Lys Arg Leu Asp Gly Ser Gly Val Trp Ser Asp Trp 305 310 315 320 agt tta cct caa ctc ttt acc aca caa gat gtc atg tat ttt cca ccc 1008 Ser Leu Pro Gln Leu Phe Thr Thr Gln Asp Val Met Tyr Phe Pro Pro 325 330 335 aaa att ctg acg agt gtt gga tcc aat gct tcc ttt tgc tgc atc tac 1056 Lys Ile Leu Thr Ser Val Gly Ser Asn Ala Ser Phe Cys Cys Ile Tyr 340 345 350 aaa aat gag aac cag act atc tcc tca aaa caa ata gtt tgg tgg atg 1104 Lys Asn Glu Asn Gln Thr Ile Ser Ser Lys Gln Ile Val Trp Trp Met 355 360 365 aat cta gcc gag aag atc ccc gag aca cag tac aac act gtg agt gac 1152 Asn Leu Ala Glu Lys Ile Pro Glu Thr Gln Tyr Asn Thr Val Ser Asp 370 375 380 cac att agc aaa gtc act ttc tcc aac ctg aaa gcc acc aga cct cga 1200 His Ile Ser Lys Val Thr Phe Ser Asn Leu Lys Ala Thr Arg Pro Arg 385 390 395 400 ggg aag ttt acc tat gat gca gtg tac tgc tgc aat gag cag gca tgc 1248 Gly Lys Phe Thr Tyr Asp Ala Val Tyr Cys Cys Asn Glu Gln Ala Cys 405 410 415 cat cac cgc tac gct gaa tta tat gtg atc gat gtc aat atc aat ata 1296 His His Arg Tyr Ala Glu Leu Tyr Val Ile Asp Val Asn Ile Asn Ile 420 425 430 tca tgt gaa act gac ggg tac tta act aaa atg act tgc aga tgg tca 1344 Ser Cys Glu Thr Asp Gly Tyr Leu Thr Lys Met Thr Cys Arg Trp Ser 435 440 445 ccc agc aca atc caa tca cta gtg gga agc act gtg cag ttg agg tat 1392 Pro Ser Thr Ile Gln Ser Leu Val Gly Ser Thr Val Gln Leu Arg Tyr 450 455 460 cac agg cgc agc ctg tac tgt ccc gat aat cca tct att cgt cct aca 1440 His Arg Arg Ser Leu Tyr Cys Pro Asp Asn Pro Ser Ile Arg Pro Thr 465 470 475 480 tca gag ctc aaa aac tgc gtc tta cag aca gat ggc ttt tat gaa tgt 1488 Ser Glu Leu Lys Asn Cys Val Leu Gln Thr Asp Gly Phe Tyr Glu Cys 485 490 495 gtt ttc cag cca atc ttt cta tta tct ggc tat aca atg tgg atc agg 1536 Val Phe Gln Pro Ile Phe Leu Leu Ser Gly Tyr Thr Met Trp Ile Arg 500 505 510 atc aac cat tct tta ggt tca ctt gac tct cca cca acg tgt gtc ctt 1584 Ile Asn His Ser Leu Gly Ser Leu Asp Ser Pro Pro Thr Cys Val Leu 515 520 525 cct gac tcc gta gta aaa cca cta cct cca tct aat gta aaa gca gag 1632 Pro Asp Ser Val Val Lys Pro Leu Pro Pro Ser Asn Val Lys Ala Glu 530 535 540 att act ata aac act gga tta ttg aaa gta tct tgg gaa aag cca gtc 1680 Ile Thr Ile Asn Thr Gly Leu Leu Lys Val Ser Trp Glu Lys Pro Val 545 550 555 560 ttt cca gag aat aac ctt cag ttc cag att cga tat ggc tta aat gga 1728 Phe Pro Glu Asn Asn Leu Gln Phe Gln Ile Arg Tyr Gly Leu Asn Gly 565 570 575 aaa gaa ata caa tgg aag aca cac gag gta ttc gat gca aaa tca aaa 1776 Lys Glu Ile Gln Trp Lys Thr His Glu Val Phe Asp Ala Lys Ser Lys 580 585 590 tcg gcc agc ctg cca gtg tca gat ctc tgt gcg gtc tat gtg gta cag 1824 Ser Ala Ser Leu Pro Val Ser Asp Leu Cys Ala Val Tyr Val Val Gln 595 600 605 gtt cgc tgc cgg cgg ttg gat gga cta ggg tat tgg agt aat tgg agc 1872 Val Arg Cys Arg Arg Leu Asp Gly Leu Gly Tyr Trp Ser Asn Trp Ser 610 615 620 agt cca gcc tac act ctt gtc atg gat gta aaa gtt cct atg aga ggg 1920 Ser Pro Ala Tyr Thr Leu Val Met Asp Val Lys Val Pro Met Arg Gly 625 630 635 640 cct gaa ttc tgg aga ata atg gat ggg gat att act aaa aag gag aga 1968 Pro Glu Phe Trp Arg Ile Met Asp Gly Asp Ile Thr Lys Lys Glu Arg 645 650 655 aat gtc acc ttg ctt tgg aag cca ctg atg aaa aat gac tca ctg tgt 2016 Asn Val Thr Leu Leu Trp Lys Pro Leu Met Lys Asn Asp Ser Leu Cys 660 665 670 agt gtg agg agg tat gtg gtg aag cat cgt act gcc cac aat ggg aca 2064 Ser Val Arg Arg Tyr Val Val Lys His Arg Thr Ala His Asn Gly Thr 675 680 685 tgg tca caa gat gtg gga aat cag acc aat ctc act ttc ctg tgg gca 2112 Trp Ser Gln Asp Val Gly Asn Gln Thr Asn Leu Thr Phe Leu Trp Ala 690 695 700 gaa tca gca cac act gtt aca gtt ctg gcc atc aat tcc atc ggt gcc 2160 Glu Ser Ala His Thr Val Thr Val Leu Ala Ile Asn Ser Ile Gly Ala 705 710 715 720 tcc ctt gtg aat ttt aac ctt acg ttc tca tgg ccc atg agt aaa gtg 2208 Ser Leu Val Asn Phe Asn Leu Thr Phe Ser Trp Pro Met Ser Lys Val 725 730 735 aat gct gtg cag tca ctc agt gct tat ccc ctg agc agc agc tgc gtc 2256 Asn Ala Val Gln Ser Leu Ser Ala Tyr Pro Leu Ser Ser Ser Cys Val 740 745 750 atc ctt tcc tgg aca ctg tca cct aat gat tat agt ctg tta tat ctg 2304 Ile Leu Ser Trp Thr Leu Ser Pro Asn Asp Tyr Ser Leu Leu Tyr Leu 755 760 765 gtt att gaa tgg aag aac ctt aat gat gat gat gga atg aag tgg ctt 2352 Val Ile Glu Trp Lys Asn Leu Asn Asp Asp Asp Gly Met Lys Trp Leu 770 775 780 aga atc cct tcg aat gtt aac aag tat tat atc cat gat aat ttt att 2400 Arg Ile Pro Ser Asn Val Asn Lys Tyr Tyr Ile His Asp Asn Phe Ile 785 790 795 800 cct atc gag aaa tat cag ttt agt ctt tac cca gta ttt atg gaa gga 2448 Pro Ile Glu Lys Tyr Gln Phe Ser Leu Tyr Pro Val Phe Met Glu Gly 805 810 815 gtt gga aaa cca aag ata att aat ggt ttc acc aaa gat gat atc gcc 2496 Val Gly Lys Pro Lys Ile Ile Asn Gly Phe Thr Lys Asp Asp Ile Ala 820 825 830 aaa cag caa aat gat gca ggg ctg tat gtc att gta ccg ata att att 2544 Lys Gln Gln Asn Asp Ala Gly Leu Tyr Val Ile Val Pro Ile Ile Ile 835 840 845 tcc tct tgt gtc ctg ctg ctc gga aca ctg tta att tca cac cag aga 2592 Ser Ser Cys Val Leu Leu Leu Gly Thr Leu Leu Ile Ser His Gln Arg 850 855 860 atg aaa aag ttg ttt tgg gac gat gtt cca aac ccc aag aat tgt tcc 2640 Met Lys Lys Leu Phe Trp Asp Asp Val Pro Asn Pro Lys Asn Cys Ser 865 870 875 880 tgg gca caa gga ctt aat ttc caa aag cct gaa aca ttt gag cat ctt 2688 Trp Ala Gln Gly Leu Asn Phe Gln Lys Pro Glu Thr Phe Glu His Leu 885 890 895 ttt acc aag cat gca gaa tca gtg ata ttt ggt cct ctt ctt ctg gag 2736 Phe Thr Lys His Ala Glu Ser Val Ile Phe Gly Pro Leu Leu Leu Glu 900 905 910 cct gaa cca gtt tca gaa gaa atc agt gtc gat aca gct tgg aaa aat 2784 Pro Glu Pro Val Ser Glu Glu Ile Ser Val Asp Thr Ala Trp Lys Asn 915 920 925 aaa gat gag atg gta cca gca gct atg gtc tca ctt ctt ttg acc act 2832 Lys Asp Glu Met Val Pro Ala Ala Met Val Ser Leu Leu Leu Thr Thr 930 935 940 cca gat tcc aca agg ggt tct att tgt atc agt gac cag tgt aac agt 2880 Pro Asp Ser Thr Arg Gly Ser Ile Cys Ile Ser Asp Gln Cys Asn Ser 945 950 955 960 gct aac ttc tct ggg gct cag agc acc cag gga acc tgt gag gat gag 2928 Ala Asn Phe Ser Gly Ala Gln Ser Thr Gln Gly Thr Cys Glu Asp Glu 965 970 975 tgt cag agt caa ccc tca gtt aaa tat gca acg ctg gtc agc aac gtg 2976 Cys Gln Ser Gln Pro Ser Val Lys Tyr Ala Thr Leu Val Ser Asn Val 980 985 990 aaa aca gtg gaa act gat gaa gag caa ggg gct ata cat agt tct gtc 3024 Lys Thr Val Glu Thr Asp Glu Glu Gln Gly Ala Ile His Ser Ser Val 995 1000 1005 agc cag tgc atc gcc agg aaa cat tcc cca ctg aga cag tct ttt tct 3072 Ser Gln Cys Ile Ala Arg Lys His Ser Pro Leu Arg Gln Ser Phe Ser 1010 1015 1020 agc aac tcc tgg gag ata gag gcc cag gca ttt ttc ctt tta tca gat 3120 Ser Asn Ser Trp Glu Ile Glu Ala Gln Ala Phe Phe Leu Leu Ser Asp 1025 1030 1035 1040 cat cca ccc aat gtg att tca cca caa ctt tca ttc tca ggg ttg gat 3168 His Pro Pro Asn Val Ile Ser Pro Gln Leu Ser Phe Ser Gly Leu Asp 1045 1050 1055 gag ctt ttg gaa ctg gag gga aat ttt cct gaa gaa aat cac ggg gaa 3216 Glu Leu Leu Glu Leu Glu Gly Asn Phe Pro Glu Glu Asn His Gly Glu 1060 1065 1070 aaa tct gtg tat tat cta gga gtc tcc tca gga aac aaa aga gag aat 3264 Lys Ser Val Tyr Tyr Leu Gly Val Ser Ser Gly Asn Lys Arg Glu Asn 1075 1080 1085 gat atg ctt ttg act gat gag gca ggg gta ttg tgc cca ttc cca gct 3312 Asp Met Leu Leu Thr Asp Glu Ala Gly Val Leu Cys Pro Phe Pro Ala 1090 1095 1100 cac tgt ctg ttc agt gac atc aga atc ctc cag gag agt tgt tca cac 3360 His Cys Leu Phe Ser Asp Ile Arg Ile Leu Gln Glu Ser Cys Ser His 1105 1110 1115 1120 ttt gta gaa aat aat ttg aat tta ggg acc tct ggt aag aac ttt gta 3408 Phe Val Glu Asn Asn Leu Asn Leu Gly Thr Ser Gly Lys Asn Phe Val 1125 1130 1135 cct tac atg ccc cag ttt caa tcc tgt tcc act cac agt cat aag ata 3456 Pro Tyr Met Pro Gln Phe Gln Ser Cys Ser Thr His Ser His Lys Ile 1140 1145 1150 ata gaa aat aag atg tgt gac tta act gtg taa 3489 Ile Glu Asn Lys Met Cys Asp Leu Thr Val * 1155 1160 19 20 DNA Artificial Sequence Synthetic oligonucleotide primer 19 catcttggcc tcactgtcca 20 20 19 DNA Artificial Sequence Synthetic oligonucleotide primer 20 gggccggact catcgtact 19 21 26 DNA Artificial Sequence Synthetic oligonucleotide primer 21 cttccagcag atgtggatca gcaagc 26 22 23 DNA Artificial Sequence Synthetic oligonucleotide primer 22 agtggcaatg ctatcatcat cgt 23 23 25 DNA Artificial Sequence Synthetic oligonucleotide primer 23 aaggaataag tgggaaccca gatca 25 24 19 DNA Artificial Sequence Synthetic oligonucleotide primer 24 caagaacgca gtcaccctg 19 

What is claimed is:
 1. A method of modulating sebaceous glands in a host, said method comprising: administering to said host an effective amount of a DGAT1 modulatory agent so that sebaceous glands in said host are modulated.
 2. The method according to claim 1, wherein said sebaceous gland modulation comprises altered sebum production.
 3. The method according to claim 1, wherein said sebaceous gland modulation comprises altered sebaceous gland size.
 4. The method according to claim 1, wherein said DGAT1 modulatory agent is a DGAT1 inhibitory agent and said sebaceous gland modulation comprises at least one of reducing sebum production and reducing sebaceous gland size.
 5. The method according to claim 1, wherein said host is a mammal.
 6. The method according to claim 5, wherein said mammal is a human.
 7. The method according to claim 1, wherein said DGAT1 modulatory agent is a DGAT1 activity enhancing agent and said sebaceous gland modulation comprises at least one of increasing sebum production and increasing sebaceous gland size.
 8. The method according to claim 7, wherein said method further comprises administering a leptin activity enhancing agent to said host.
 9. The method according to claim 1, wherein said agent is systemically administered to said host.
 10. The method according to claim 1, wherein said agent is topically administered to said host.
 11. A method of treating a host suffering from a sebaceous gland condition, said method comprising: administering to said host an effective amount of a DGAT1 modulatory agent to treat said host for said condition.
 12. The method according to claim 11, wherein said DGAT1 modulatory agent is a DGAT1 inhibitor.
 13. The method according to claim 11, wherein said sebaceous gland condition is characterized by at least one of enhanced sebum production and sebaceous gland size as compared to a control.
 14. The method according to claim 12, wherein said condition is chosen from acne, rosacea, perioral dermatitis, sebaceous cysts, seborrhea and alopecia.
 15. The method according to claim 11, wherein said DGAT1 modulatory agent is a DGAT1 activity enhancing agent.
 16. The method according to claim 15, wherein said method further comprises administering a leptin activity enhancing agent to said host.
 17. The method according to claim 11, wherein said host is mammal.
 18. The method according to claim 11, wherein said mammal is a human.
 19. The method according to claim 11, wherein said agent is systemically administered to said host.
 20. A pharmaceutical preparation comprising a DGAT1 activity modulatory agent in a pharmaceutically acceptable delivery vehicle.
 21. The pharmaceutical preparation according to claim 20, wherein said DGAT1 activity modulatory agent is a DGAT1 activity inhibitor.
 22. The pharmaceutical preparation according to claim 20, wherein said DGAT1 activity modulatory agent is a DGAT1 activity enhancer.
 23. The pharmaceutical preparation according to claim 20, wherein said preparation further comprises a leptin activity modulatory agent.
 24. The pharmaceutical preparation according to claim 20, wherein said preparation delivery vehicle is a systemic delivery vehicle.
 25. The pharmaceutical preparation according to claim 20, wherein said delivery vehicle is a local delivery vehicle.
 26. The pharmaceutical preparation according to claim 25, wherein said local delivery vehicle is a topical delivery vehicle.
 27. A kit comprising: (a) a pharmaceutical preparation comprising a DGAT1 activity modulatory agent in a pharmaceutically acceptable delivery vehicle; and (b) instructions for treating a host suffering from a sebaceous gland condition by administering to said host an effective amount of said pharmaceutical preparation.
 28. The kit according to claim 27, wherein said DGAT1 activity modulatory agent is a DGAT1 inhibitor.
 29. The kit according to claim 28, wherein said pharmaceutical preparation further comprises a leptin activity modulatory agent. 